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“I am among those who think that science has great beauty. A scientist 
in his laboratory is not only a technician: he is also a child placed before 
natural phenomena which impress him like a fairy tale.” 
Marie Curie (1867 - 1934) 
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3. ABSTRACT 
 
This thesis has focused on the discovery and characterization of novel 
diagnostic and prognostic markers in various cancer entities, with a special 
emphasis on colorectal cancer (CRC). 
In Switzerland the incidence of colorectal cancer ranks third in males and 
second in females, with about 4000 new patients diagnosed each year. 
Incidence trends over the last decades have remained constant in both sexes, 
whereas mortality rates have been decreasing. Decreasing mortality is thought 
to be related to improved treatment during the past years as well as 
generalisation of colorectal cancer screening in the Swiss population. About 
80% of colorectal cancers are thought to have occurred by chance (sporadic) 
with the remainder displaying either familial aggregation (about 15%) or 
mendelian inheritance (about 5%).  
In the first part of this work we identify and characterize a novel target gene 
locus for microsatellite instability (MSI) consisting of a mononucleotide (T/U)16 
tract, EWS16T, located in the 3’ UTR of the Ewing sarcoma break point region 
1 (EWSR1) gene in 319 patients with hereditary and sporadic CRC. We show 
that the EWS16T locus discriminates MMR proficient from deficient cancers 
with high diagnostic sensitivity (100%) and specificity (100%). It could thus 
substantially improve and facilitate MSI analysis in routine daily practice. In 
addition, biochemical analyses indicate that EWS16T contractions alter 
poly(A) site selection by promoting SFPQ-mediated distal poly(A) site usage in 
EWSR1 pre-mRNAs and result in decreased mRNA as well as EWS protein 
expression. Our findings thus directly implicate the RNA-/DNA-binding Ewing 
sarcoma protein in MSI-associated colorectal tumorigenesis. 
In the second part we characterize a new tumour suppressor gene designated 
SH2D4A located on the short arm of chromosome 8. We demonstrate that 
SH2D4A physically interacts with the EGFR/STAT3 pathway and controls cell 
proliferation. Upon EGF signaling, SH2D4A recruits the serine/threonine 
phosphatase PP1β to the receptor complex and represses activated STAT3 
via dephosphorylation. SH2D4A expression reduces anchorage-independent 
tumour cell growth and its loss promotes the expression of c-Myc, Cyclin D1 
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and Jun B. In addition we show that SH2D4A expression is partially lost in 
human colorectal cancers as a result of chromosomal instability, mutations 
and epigenetic changes. Finally, diminished SH2D4A protein expression was 
found to correlate with advanced disease stages and was associated with 
poor prognosis. 
In the third part we investigate HGMA1/HGM2 protein expression 210 and 
1202 patients with pancreatic and breast cancers, respectively. HMGA1 and 
HMGA2 over-expression was found in a significant number of breast and 
pancreatic carcinoma samples, and its over-expression positively correlated 
with grade and stage of the disease. Conversely, no HMGA1 and HMGA2 
expression was observed in cancer-free breast and pancreas tissues. Taken 
together, our findings show that high expression levels of HMGA1 and 
HMGA2 are related to an unfavorable histological type and a poor prognosis in 
both, pancreatic and breast cancer. Moreover, these findings further support 
the notion that these proteins represent appropriate targets for the therapy of 
human cancer, as suggested by numerous in vitro and in vivo studies. 
In the fourth part of the thesis we evaluate the potential role of the cancer 
stem cell (CSC) proteins EpCAM, CD44s, CD166 and CD133 in tumors of the 
ampulla of Vater. CSC expression was determined in 175 carcinoma, 111 
adenoma and 152 cancer free-mucosa specimens arranged on a tissue 
microarray format. The expression of all evaluated marker proteins differed 
significantly between cancer-free mucosa, adenoma and carcinoma samples. 
EpCAM expression was significantly correlated with better patient survival. In 
contrast, increased expression of CD44s, CD166 and CD133 from normal 
mucosa samples to adenoma and carcinoma was linked to tumor progression 
but no statistically significant correlation with survival observed. Our findings 
therefore indicate that in ampullary carcinomas loss of EpCAM expression 
may be associated with a more aggressive tumor phenotype. 
In the fifth part we develop a specific monoclonal antibody for the highly 
immunogenic member of the MAGE-A family of cancer/testis tumor-associated 
antigens (C/T TAAs). The antibody was used to stain a multi-tumor tissue 
microarray comprising more than 2,500 paraffin-embedded specimens of 
different histological origin. C/T TAA appears to be expressed in a high 
percentage (>50%) of cancer cells from different tumor types such as lung, 
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skin, gynecological, stomach and gall bladder cancers. The future 
characterization of MAGE-A10-specific antibodies might set the stage for the 
development of targeted active immunotherapy by clarifying potential 
indications and by allowing the selection of patients eligible for treatment and 
monitoring of its effectiveness. 
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4. GENERAL INTRODUCTION 
4.1 Cancer  
 
Cancer is a leading cause of death worldwide, according to the International 
Agency for Research on Cancer (IARC) data, there were 12.7 million new 
cancer cases in 2008 worldwide, of which 5.6 million occurred in economically 
developed countries and 7.1 million in economically developing countries. The 
corresponding estimates for total cancer deaths in 2008 were 7.6 million 
(about 21,000 cancer deaths a day), 2.8 million in economically developed 
countries and 4.8 million in economically developing countries [1].  
Cancer arises from a loss of normal growth control. In normal healthy tissue, 
the ratio between cell growth and cell death are in balance. In cancer, this 
balance is disrupted. This disturbance can result from uncontrolled cell growth 
or loss of a cell's ability to undergo apoptosis “cell suicide”. This is also 
referred to as programmed cell death and the mechanism by which old or 
damaged cells can be removed. Cancer being a genetic disease, the genetic 
material  (DNA) of a cell can get damaged, acquiring mutations that affect 
normal cell growth, division and apoptosis. When this occurs, cells may start 
to grow uncontrollably and eventually form a mass of tissue called a tumor [2]. 
Cancer is a disease in which cells display uncontrolled growth, invade and 
destroy adjacent tissues, and often metastasize to other regions of the body 
via the lymphatic system or through the bloodstream [2]. These properties 
discriminate benign from malignant tumors. There are more than 100 different 
types of cancer. The name of the tumors often comes from the organs or the 
type of cells affected and can be broadly grouped into the following categories 
[2]: 
a. Carcinoma - a malignant epithelial neoplasm that tends to invade 
surrounding tissue and to metastasize to distant regions of the body. 
Carcinomas develop most frequently in the skin, large intestine, lungs, 
stomach, prostate, cervix, or breast. The tumor is firm, irregular, and 
nodular, with a well-defined border.  
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b. Sarcoma - a tumor, often highly malignant, composed of cells derived from 
connective tissue such as bone, cartilage, muscle, blood vessel, or 
lymphoid tissue.  
Sarcomas usually develop rapidly and metastasize through the lymph 
channels. Different types are named for the specific tissue they affect: 
FIBROSARCOMA in fibrous connective tissue; LYMPHOSARCOMA in lymphoid 
tissues; OSTEOSARCOMA in bone; CHONDROSARCOMA in cartilage; 
RHABDOMYOSARCOMA in muscle; and LIPOSARCOMA in fat cells. 
c. Leukemia - a progressive, malignant neoplasm of the blood-forming 
organs, marked by diffuse replacement of the bone marrow leukocytes and 
their precursors in the blood and bone marrow, based on cell type can be 
divided in to myeloid (acute and chronic) and lymphoid (acute and chronic). 
It is accompanied by a reduced number of erythrocytes and blood 
platelets, resulting in anemia and increased susceptibility to infection and 
hemorrhage.  
d. Myeloma  - an osteolytic neoplasm consisting of a profusion of cells typical 
of the bone marrow that may develop in many sites and cause extensive 
destruction of the bone. The tumor occurs most frequently in the ribs, 
vertebrae, pelvic bones, and flat bones of the skull  
e. Lymphoma - Cancer that begins in cells of the immune system that affects 
lymph cells and tissues, including certain white blood cells (T and B cells), 
lymph nodes, bone marrow, and the spleen. There are two basic 
categories of lymphomas. One kind is Hodgkin lymphoma, which is marked 
by the presence of a type of cell called the Reed-Sternberg cell. The other 
category is non-Hodgkin lymphomas, which develop from lymphocytes — 
a type of white blood cell. Non-Hodgkin lymphomas can be further divided 
into cancers that have an indolent (slow-growing) course and those that 
have an aggressive (fast-growing) course. 
f. Central nervous system cancers - a neoplasm of the brain or spinal cord 
that characteristically does not spread beyond the cerebrospinal axis, 
although it may be highly invasive locally and have widespread effects on 
body functions. Intracranial neoplasms are about four times more common 
than those arising in the spinal cord. From 20% to 40% of brain tumors are 
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metastatic lesions from primary cancer elsewhere, such as in the breast, 
lung, GI tract, kidney, or a site of melanoma [2].  
Cancer can be treated by chemotherapy, surgery, radiation therapy, 
immunotherapy, monoclonal antibody therapy or other methods (experimental 
cancer treatments are also under development). The choice of therapy 
depends on the cancer type, the degree and location of the cancer and the 
patient's general medical condition [2]. 
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4.2 Cancer Genetics 
 
Cancers arise as consequence of accumulating multiple mutations in the 
genome. Mutations in genes controlling cell growth are responsible for many 
major human cancers. Two broad classes of genes have been defined:  proto-
oncogenes (Table 1) and tumor suppressor genes like Rb, VHL, APC, PTEN, 
TP53 CD95, ST5, YPEL3, ST7, and ST14 play a key role in cancer initiation 
and progression. These genes encode many kinds of proteins that help control 
cell growth and proliferation; mutations in these genes can thus contribute to 
the development of cancer. Under normal conditions the activities of these two 
gene classes are optimally balanced. In general, proto-oncogenes allow cell 
growth whereas tumor suppressor genes inhibit it. 
Proto-oncogenes are genes that encode proteins, which can be mutated into a 
cancer-promoting oncogenes, either by changing the protein-coding segment 
or by altering its expression. This activation results in a gain of function and 
drives cell multiplication and thus proliferation. 
In contrast tumor suppressor genes encode proteins directly or indirectly 
inhibiting initiation and/or progression through the cell cycle and other tumor 
related pathways (e.g. WNT) in which a loss-of-function mutation is oncogenic. 
A germline mutation in a tumor suppressor gene (e.g. RB, APC, and BRCA1) 
greatly increases the risk for developing certain types of (hereditary) cancer.  
There are also some genetic alterations in DNA that lead to cancer 
development such as chromosomal translocations and gene promoter (hyper- 
and hypo-) methylation. 
Translocations generate novel chromosomes. In a translocation, a segment 
from one chromosome is transferred to a nonhomologous chromosome or to a 
new site on the same chromosome. Translocation events may disrupt gene 
loci, cause (micro)deletions or result in genes fusion. Some examples are: 
Ewing's sarcoma, which is the result of a translocation between chromosomes 
11 and 22, which fuses the EWSR1 gene of chromosome 22 to the FLI1 gene 
of chromosome 11; chronic myelogenous leukemia (CML) which is the result 
of a reciprocal translocation between chromosome 9 and 22 (Philadelphia 
chromosome). 
DNA methylation is an important regulator of gene transcription, and its role in 
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carcinogenesis has been a topic of considerable interest in the last few years. 
Alterations in DNA methylation are common in a variety of tumors as well as in 
development. Of all epigenetic modifications, hypermethylation, which 
represses transcription of the promoter regions of tumor suppressor genes 
leading to gene silencing, has been most extensively studied [3]. 
DNA methylation mainly consists of a covalent chemical modification, resulting 
in the addition of a methyl (CH3) group at the carbon 5 position of the cytosine 
ring. Even though most cytosine methylation occurs in the sequence context 
5′CG3′ (also called the CpG dinucleotide), some involves CpA and CpT 
dinucleotides [4, 5]. Numerous genes have been found to undergo 
hypermethylation in cancer like genes involved in cell cycle regulation 
(p16INK4a, p15INK4a, Rb, p14ARF) genes associated with DNA repair (BRCA1, 
MLH1, MGMT), apoptosis (DAPK, TMS1), drug resistance, detoxification, 
differentiation, angiogenesis, and metastasis [5]. Although certain genes such 
as RASSF1A and p16 are commonly methylated in a variety of cancers, other 
genes are methylated in specific cancers. One example is the GSTP1 gene, 
which is hypermethylated in more than 90% of prostate cancers but is largely 
unmethylated in acute myeloid leukemia [5]. DNA hypomethylation, on the 
other hand, is observed in a wide variety of malignancies [6, 7]. It is common 
in solid tumors such as metastatic hepatocellular cancer and prostate tumors 
[8, 9]. 
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Table 1: Oncogenes commonly altered in human cancer. 
 
Common Oncogenes Altered in Human Cancers 
Oncogene Function Alteration in Cancer Neoplasm 
AKT1 Serine/threonine kinase Amplification Gastric carcinoma 
AKT2 Serine/threonine kinase Amplification Ovarian, breast, pancreas 
cancer 
BRAF Serine/threonine kinase Point mutation Melanoma, lung, colorectal 
cancer 
CTNNB1 Signal transduction Point mutation Colon, prostate, melanoma, 
skin, others 
FOS Transcription factor Overexpression Osteosarcoma 
ERBB2 Receptor tyrosine kinase Point mutation, amplification Breast, ovary, stomach, 
neuroblastoma 
JUN Transcription factor Overexpression Lung cancer 
MET Receptor tyrosine kinase Point mutation, 
rearrangement 
Osteocarcinoma, kidney, 
glioma 
MYB Transcription factor Amplification AML, CML, colon cancer, 
melanoma 
C-MYC Transcription factor Amplification Breast, colon, gastric, lung 
L-MYC Transcription factor Amplification Lung carcinoma, bladder 
N-MYC Transcription factor Amplification Neuroblastoma, lung cancer 
HRAS GTPase Point mutation Colon, lung, pancreas 
KRAS GTPase Point mutation Melanoma, colorectal cancer, 
AML 
NRAS GTPase Point mutation Various carcinomas, 
melanoma 
REL Transcription factor Rearrangement, amplification Lymphoma 
WNT1 Growth factor Point mutation Retinoblastoma 
 
Compilation of oncogenes commonly altered in human cancer, taken from [2]: 
AML, acute myelogenous leukemia; CML, chronic myelogenous leukemia. 
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4.2.1 Colorectal Cancer 
The colon is part of the digestive system, which is a series of bodily organs 
beginning at the mouth and ending with the anus, and it is responsible for the 
final stages of the digestive process (Figure 1). 
The colon's function is threefold: to absorb the remaining water and 
electrolytes from indigestible food matter; to accept and stores food remains 
that were not digested in the small intestine; and to eliminate solid waste 
(feces) from the body. The rectum is the segment from end of the colon to the 
anus. Together, they form a long, muscular tube called the large intestine 
(also known as the large bowel). Tumors of the colon and rectum are growths 
arising from the inner wall of the large intestine.  
Precursor lesions of the large intestine are called polyps and has been defined 
as a benign neoplastic growth with variable malignant potential, representing 
proliferation of epithelial tissue in the lumen of the sigmoid colon, rectum, or 
stomach, polyps do not invade nearby tissue or spread to other parts of the 
body. The majority of colorectal cancer (CRC) arises from malignant 
transformation of an adenomatous polyp (Figure 2). 
CRC is the fourth most common cancer in men and the third most common 
cancer in women worldwide [10, 11]. The American Cancer Society's most 
recent estimates for the number of colorectal cancer cases in the United 
States for 2011 are: 101,700 new cases of colon cancer and 39,510 of rectal 
cancers with 49,380 deaths.  
Risk factors according to the American Cancer Society for the development of 
CRC are:  
a. Age: peak incidence in the 6Th/7Th decade. 
b. Nutrition: a diet that is high in red meat, processed meats and not enough 
fruits and vegetables consumption is a colon cancer risk.  
c. A family history of colorectal cancer: A family history of colorectal 
cancer or adenomatous polyps increases the risk of colorectal cancer. That 
risk is even higher if the close relative was diagnosed at a young age or if 
more than one 1Th degree family member had colon cancer. 
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d. Member of certain racial or ethnic groups: African Americans get colon 
cancer more often than other racial groups in the U.S. and are nearly twice 
as likely to die from it. 
e. Inherited conditions such as familial adenomatous polyposis, which 
causes the development of 100-1000 of polyps in the colon, also raises the 
risk of colorectal cancer. 
f. Inflammatory bowel disease: ulcerative colitis and Crohn's disease are a 
bowel disease characterized by inflammation with ulcer formation in the 
lining of the colon (large intestine). People with either of these diseases 
can develop expansion of immature cells, with a corresponding decrease 
in the number and location of mature cells, this is called dysplasia, which 
may turn into cancer [2]. 
 
 
Figure 1: Anatomy of the colon. 
 
 
Depiction of colorectal anatomy, taken from [12].  
A: anatomy of the colon; B: anatomy of the rectum. 
CRC progresses through a series of clinical and histopathological stages 
ranging from single crypt lesions through small benign tumors (adenomatous 
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polyps) to malignant cancers (carcinomas) (Figure 2). Stages are usually 
defined by TNM classification, where T describes the size of the tumor and 
whether it has invaded nearby tissue, N describes regional lymph nodes that 
are involved, M describes distant metastasis (spread of cancer from one body 
part to another). The depth of tumor invasion defines the T stage and 
increases from T1 (invasion of the submucosa) to T4 (invasion into the serosa 
or adjacent structures) [13]. Another grading system is Dukes classification 
that considers the arrangement of the cells rather than the percentage of the 
differentiated cells. The initial Dukes approach has evolved into the three-
grade system. Grade 1 is the most differentiated, with well-formed tubules and 
the least nuclear polymorphisms and mitoses. Grade 3 is the least 
differentiated, with only occasional glandular structures, pleomorphic cells and 
a high incidence of mitoses. Grade 2 is intermediate between Grades 1 and 3 
[14].  
The development of colorectal cancer is a multistep process that involves an 
accumulation of mutations in tumor suppressor genes and oncogenes. The 
model of colorectal tumorigenesis includes several genetic changes that are 
required for cancer initiation and progression [15].  The earliest trigger genetic 
event is the inactivation of the APC (adenomatous polyposis coli) gene (WNT 
pathway). Mutations in other tumor suppressor genes like SMAD4 and TP53 
and oncogenes like KRAS and likely several other genes/pathways 
accompany transitions (in the pathology) of the lesions and drive tumors 
towards malignancy and metastasis [16]. Alongside with gene mutations, 
deregulated expression of oncogenes and/or tumor suppressor genes can 
also occur following epigenetic modifications of their promoters.  In chapter 6.2 
we describe SH2D4A gene as novel tumour suppressor in colorectal cancer, 
that physically interacts with the EGFR/STAT3 pathway and controls cell 
proliferation. Upon EGF signalling, Shoca-2 recruits the serine/threonine 
phosphatase PP1βto the receptor complexand represses activated STAT3 via 
dephosphorylation. Shoca-2 expression reduces anchorage-independent 
tumour cell growth and its loss promotes the expression of c-Myc, Cyclin D1 
and Jun B. Shoca-2 expression may be lost in human colorectal cancers as a 
result of chromosomal instability, mutations and epigenetic changes and 
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diminished Shoca-2 protein expression correlates with advanced disease 
stages and is associated with poor prognosis. 
 
Figure 2: Stages of colon cancer. 
 
The diagram, taken from [2], above illustrates the progression of polyp to a 
cancer and the cancer's subsequent progression if left untreated. 
 
 
 
 
 
4.3 Hereditary cancer syndromes 
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The majority of cancers occur without any predisposition, although genetic 
factors are believed to have an impact on the susceptibility of an individual to 
develop cancer [17]. Approximately 5-10% of all cancers are hereditary, which 
means that germline mutations in specific genes that are known to be related 
to cancer development can be passed on to offspring. Individuals who inherit 
one of these gene changes will have a higher likelihood of developing cancer 
within their lifetime. Inherited cancer syndromes with their genetic causes are 
listed in Table 2. 
 
Table 2: Examples of hereditary cancer syndromes. 
 
Syndrome Gene(s) Location(s) Tumor types 
Breast/Ovarian BRCA1 17q21 Breast, ovarian 
Breast/Ovarian BRCA2 13q12.3 Breast, ovarian, 
prostate 
Cowden syndrome PTEN 10q23.3 Pituitary, testicle, 
thyroid, breast 
Familial Adenomatous Polyposis APC 5q21 GI tract, thyroid 
Lynch syndrome MLH1, MSH2, MSH6, 
PMS2 
2p22-21, 3p21, 2p16, 
2q31-33, 7p22 
GI tract, ovary, 
endometrium 
Juvenile polyposis coli SMAD4, BMP1A 18q21.1, 10q23.2 GI tract 
Li-Fraumeni TP53 17p13 Breast, soft tissue, 
brain, leukaemia 
Neurofibromatosis 1 NF1 17q11 Nervous system, 
skin, muscle, 
leukaemia 
Neurofibromatosis 2 NF2 22q12 Schwann cells, 
spine skin 
Peutz-Jeghers STK1 19p13.3 Gastointestinal tract 
 
In hereditary cancer predisposing syndromes, the critical gene is mutated only 
on one allele but no on the second, “wild type” one. According to Knudson’s 
widely accepted “two hit theory” which was based on the epidemiological 
studies of retinoblastoma gene (Rb) [18], both of the alleles of a tumor 
suppressor gene need to be inactivated before tumorigenesis ensues. Thus, 
the germline mutation alone is not sufficient to give rise to tumor formation, but 
the functional wild type allele needs to be inactivated before neoplastic 
reactions may occur [19].  
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There are several known and proposed mechanisms, which can cause the 
inactivation of the wild type allele. It can occur for example by loss of 
heterozygosity (LOH), somatic deletion [20], or epigenetically by promoter 
methylation [21]. However, to explain the sometimes even 100% penetrance 
of hereditary cancer syndromes resulting from a heterozygous mutation in a 
tumor suppressor gene, it is nowadays believed that also “recessive” mutation 
have an effect on the tissue phenotype and thus result in a clonal expansion of 
mutated cells [22]. Dominantly functioning oncogenes can accelerate 
tumorigenesis also when heterozygous. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3.1 Lynch syndrome (aka HNPCC) 
 
Lynch syndrome (LS) represents the most common, autosomal dominantly 
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inherited cancer predisposition worldwide with incomplete penetrance, 
accounting for approximately 1-6% of all colorectal malignancies. It is 
characterized by an increased lifetime risk for colon cancer and cancers of the 
endometrium, ovary, stomach, small intestine, hepatobiliary tract, urinary tract, 
brain, and skin [23-25]. 
It is caused by a germline mutation in a mismatch repair gene (MLH1, MSH2, 
PMS2, and MSH6), MSH2 on chromosome 2p, and MLH1 on chromosome 3p 
account for the majority of genetically defined cases. 50-60% of families with 
the clinical diagnosis of Lynch syndrome are found to have mutations in these 
genes; the mutation prevalence depends on features of the family history [26, 
27].  
The number of polyps is modest without endoscopical differences compared 
to sporadic polyps but with an early onset (44 years), bigger size and 
frequency, and with more villous and dysplastic features as wells as a more 
rapid progression to cancer [28, 29]. Without intervention, patients with Lynch 
syndrome have an 80% lifetime risk of colorectal cancer [30] however the risk 
of cancer-related mortality remains considerable. Nevertheless, patients with 
Lynch syndrome-related colorectal cancer appear to have better survival rates 
when compared to patients with sporadic colorectal cancer [31]. Tumors in LS 
patients characteristically exhibit microsatellite instability (MSI). The diagnostic 
settings for LS diagnosis are based on Amsterdam criteria (constantly update) 
to identify the affected family and the Bethesda guidelines to define the tumors 
(Table 2) [32-37]. Essentially this guideline specifies that at least three 
relatives be affected with colorectal cancer, endometrial cancer (female 
patients), possibly other LS-related malignancies and MSI-H. Genetic testing 
is improving the approach to patients at risk for LS. The American 
Gastroenterological Association recommends a testing strategy beginning with 
MSI testing on tumor tissue from individuals satisfying the revised Bethesda 
criteria. In persons with MSI-high tumors, germline analysis of hMSH2, 
hMSH1 and hMSH6 should be assessed. For families in which tumor tissue is 
not available, germline testing is recommended if any of the first three 
Bethesda criteria are met (Table 2) [38]. Failure to detect a clearly pathogenic 
mutation in the proband doesn’t exclude Lynch syndrome. 
Immunohistochemistry (IHC) testing for the expression of mismatch related 
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proteins in tumor tissue is a complementary screening method [39], The MMR 
gene products work in eterodimers: MSH2 with MSH6 or MSH3 protein, and 
MLH1 with PMS2 or PMS1 protein. A germline mutation in MSH2 typically 
results in loss of expression of both proteins MSH2 and MSH6 and a germline 
mutation in MLH1 in loss of expression of the proteins MLH1 and PMS2. 
Germline mutations in MSH6 and PMS2 typically however do not result in loss 
of MSH2 or MLH1 expression because these proteins are still present in other 
pairings and therefore remain stable expressed [40].  
For patients with a definitive or suspected diagnosis of LS, interval 
surveillance is recommended encompassing: full colonoscopy every one to 
two years beginning between the ages of 20 and 25 and endometrial and 
ovarian cancer screening beginning between the of 25 and 35 (for female) [41, 
42].  
In appendix 8.2 analyzing 12 samples from 6 LS patients (CRC and matched 
cancer free mucosa) with Affymetrix Whole Genome 2.7M chip and validating 
the results in a large cohort of LS-related CRCs (50 patients), we describe 3 
new hotspot frequently deleted or duplicated in LS related colorectal cancers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Clinical criteria for LS.  
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Amsterdam 1. Three or more relatives with colorectal cancer, one of whom is a first-degree relative of 
the other two; 
2. Colorectal cancer involving at least two generations; 
3. One or more colorectal cancers diagnosed at age <50 years 
Amsterdam II 1. Three or more relatives with a HNPCC-associated cancer (colorectal, endometrial, small 
bowel, ureter, renal pelvis), one of whom is a first-degree relative of the other two; 
2. Colorectal cancer involving at least two generations; 
3. One or more colorectal cancers diagnosed at age <50 years 
Modified Amsterdam  1. Very small families which cannot be further expanded can be considered as HNPCC with 
only two colorectal cancers in first-degree relatives; colorectal cancer must involve at least 
two generations, and at least one colorectal cancer must be diagnosed at age <55 years 
2. In families with two first-degree relatives affected by colorectal cancer, the presence of a 
third relative with an unusual early-onset neoplasm or endometrial cancer is sufficient 
Young age at onset Proband diagnosed at age <40 years without a family history fulfilling Amsterdam or 
Modified Amsterdam criteria 
HNPCC-variant Family history suggestive of HNPCC, but not fulfilling Amsterdam, Modified Amsterdam, or 
young age at onset criteria 
Bethesda 1. Amsterdam criteria 
2. Two HNPCC-related cancers, including synchronous and metachronous colorectal 
cancers or associated extracolonic cancers 
3. Colorectal cancer and a first-degree relative with colorectal cancer and /or a HNPCC-
related extracolonic cancer and/or a colorectal adenoma; one of the cancers diagnosed at 
age <45 years, and the adenoma diagnosed age <40 years 
4. Colorectal cancer or endometrial cancer diagnosed at age <45 years 
5. Right-sided colorectal cancer with an undifferentiated pattern on histology diagnosed at 
age < 45 years 
6. Signet-ring cell-type colorectal cancer diagnosed at age <45 years 
7. Adenomas diagnosed at age <40 years 
Revised Bethesda 1. Colorectal cancer diagnosed at age <50 years 
2. Synchronous or metachrounous colorectal or other HNPCC-associated tumors 
regardless of age 
3. Colorectal cancer diagnosed at age <60 years with histologic findings of infiltrating 
lymphocytes, Crohn’s-like lymphocytic reaction, mucinous/signet ring differentiation or 
medullary growth pattern. 
4. Colorectal cancer in ‡1 first-degree relative(s) with an HNPCC-related tumor, with one of 
the cancers being diagnosed at age <50 years 
5. Colorectal cancer diagnosed in ‡2 first- or second-degree relatives with HNPCC-related 
tumors, regardless of age 
 
Table taken from [43] 
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4.3.1.1 Mismatch repair system  
 
The DNA Mismatch repair system has an important role in maintaining 
genomic stability during DNA replication by correcting mismatches and small 
insertion or deletion loops (IDLs) introduced through errors made by DNA 
polymerases. Components of the MMR system MutS, MutL, MutH and Uvr 
were identified in Escherichia coli through the genetic studies of mutants [44, 
45] and the system has been well conserved during the evolutionary process 
in all eukaryotic organisms (yeast, mouse and human), [46, 47].  
DNA mismatch repair (MMR) can be divided in three phases: initiation, 
excision and resynthesis (Figure 3). The three MutS homologs, MSH2, MSH3 
and MSH6 are involved in the initiation of MMR. The MutS homologs forming 
heterodimers, recognize DNA damage; the MSH2 and MSH6 dimer (the 
MutSα complex) recognizes mismatches base-base and single base loops 
while the MSH2 and MSH3 dimer (hMutSβ complex) identifies 
deletion/insertion loops of more than one base [48-50].  
After recognition of the DNA damage the heterodimer MutLα, formed by MLH1 
and PMS2, binds  MutSα and  mediates the interaction between the MutS 
proteins and enzymes involved in long-patch excision in postreplication 
mismatch repair [51]. 
Other proteins are involved in the excision of the damaged strand and 
resynthesis steps of MMR that are recruited subsequently. Proteins known to 
be involved are proliferating cell nuclear antigen (PCNA) that is known to work 
as a processivity factor for replicative polymerases [52], with interactions with 
MSH2 and MLH1 [53], and with MSH6 [54], as well as exonuclease ExoI, and 
DNA polymerase δ I [55, 56]. 
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Figure 3: The mismatch repair system (MMR).  
 
 
The mismatch repair system (MMR), taken from Helleman et al. [57].  
A. Initiation of MMR by recognizing the DNA damage by the MutSα or β 
complex and recruiting the MutLα complex. B. Excision of the damaged strand 
and resynthesis in which exonuclease ExoI, proliferating cell nuclear antigen 
(PCNA), DNA polymerase δ or ε and DNA helicase I are suggested to play a 
role. 
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4.3.1.2 Microsatellite instability 
 
The inactivation of the MMR system leads to widespread genomic instability, 
because the DNA-replication errors induced DNA polymerase slippage during 
replication of long repetitive DNA sequences. As a consequence, these 
tumors (MMR deficients) exhibit a specific phenotype called microsatellite 
instability (MSI), affecting mono-, di-, tri- and tetra nucleotide repetitive 
sequences [58, 59]. 
MSI in tumors can be initiated by genetic or epigenetic inactivation of MMR 
genes. Mouse knockout models have demonstrated that MLH1-/-, PMS2-/- 
MSH2-/- and MSH3-/-, exhibit a high frequency of MSI in tumors while MSH6-/-  
and PMS1-/- mice a had a low frequency [60].  
Five markers (two mononucleotide repeats: BAT25 and BAT26 and three 
dinucleotide repeats: D2S123, D5S346, and D17S250) have been 
recommended by the National Cancer Institute to screen for MSI in LS-related 
CRCs (often called Bethesda markers) [61]. Tumors with instability at two or 
more of these markers were defined as MSI-High (MSI-H), while those with 
instability at one repeat or display no instability were defined as MSI-Low 
(MSI-L) and those without as microsatellite stable (MSS) tumors, respectively 
[62]. They occur usually in the Lynch syndrome or sporadically in as many as 
10–15% of colorectal, gastric, and endometrial (20-30%) carcinomas [63-65]. 
Repetitive segments of DNA (dinucleotide, trinucleotide, tetranucleotide, 
pentanucleotide repeats), scattered throughout the genome in non-coding 
regions between genes or within genes (introns), often used as markers for 
linkage analysis because of the naturally occurring high variability in repeat 
number between individuals. These regions are inherently unstable and 
susceptible to mutation, Sporadically these repetitive sequences are located in 
the coding region of genes. The TGFβRII, BAX, IGFIIR, MSH3, and MSH6 
genes were the first described genes for instability in MSI-H cancers [66-69]. 
More recently, additional genes with similar mutations were described 
encompassing ACTRII, AIM2, APAF-1, AXIN-2, BCL-10, BLM, Caspase-5, 
CDX-2, CHK-1, FAS, GRB-14, cell cycle protein hG4-1, KIAA0977, MBD-4, 
hMLH3, NADH ubiquinone oxidoreductase, OGT, PTEN, RAD-50, RHAMM, 
RIZ, SEC63, SLC23AT, TCF-4, and WISP-3. MSI-H CRCs [59, 62, 70-84], 
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whether hereditary or sporadic (through somatic MLH1 promoter 
hypermethylation), are generally associated with a more favorable prognosis 
when compared to MSI-L and MSS ones [85]. Recent genome-wide gene 
expression data on (sporadic) MSS and MSI-H CRCs further demonstrate that 
tumor development in microsatellite unstable, MMR deficient cancers follows 
distinct pathogenetic alleys. 
In chapter 6.1 we identified a mononucleotide repeat tract (EWS16T) within 
the 3’UTR of the EWSR1 gene that is consistently mutated in cancers with 
microsatellite instability and thus represents a novel target gene locus in 
mismatch repair-deficient tumors. Our data indicate that contractions at this 
locus promote SFPQ-mediated distal poly(A) site usage in EWSR1 pre-
mRNAs resulting in decreased EWS expression that is accompanied by 
altered subcellular localization of the protein.  
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4.4 Other hereditary colorectal cancer syndromes 
4.4.1 Familial adenomatous polyposis 
 
Familial adenomatous polyposis (FAP) is a an autosomal dominantly inherited 
disorder with 100% penetrance by age 40 years characterized by the 
presence of more than hundreds/thousands of benign polyps (adenomas) 
some of which, inevitably progress to colorectal cancer in the third and fourth 
decade of life [86, 87]. In addition an extracolonic cancer spectrum may occur, 
including polyps of the upper gastrointestinal tract, desmoids, osteomas, 
fibromas, and congenital hypertrophy of the retinal pigment epithelium 
(CHRPE) [88]. It is thought to be responsible for about 0,5-1% of colorectal 
cancers diagnosed each year with an estimated prevalence of approximately 
1/10,000 [89]. It is caused by germline mutations in the APC (adenomatous 
polyposis coli) gene located on the long arm of chromosome 5 (5q21). The 
majority of mutations (>90%) are nonsense or frameshift mutations that lead 
to premature stop codons. The resulting protein is truncated and apparently 
nonfunctional. The bi-allelic inactivation (1stgermline and 2nd somatic hit) of the 
APC have a direct role to the disruption of Wnt signalling pathway. Indeed, it is 
well understood that APC acts as a down regulator of β-catenin; and the 
mutant APC protein would therefore lead to the accumulation of cytoplasmic 
β-catenin. This subsequently leads to an increased level of β-catenin/Tcf 
complex which alters the expression of genes such as c-myc and cyclin D, 
and then initiating uncontrollable cell growth.  
An APC gene mutation can be identified in 80–90% of kindreds with the 
classical disorder [90]. In addition somatic mutations of the APC gene are 
found in as many as 80% of sporadic tumors, and seems to be involved in 
initiating tumorigenesis [91]. 
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4.4.1.1 Familial adenomatous polyposis variants 
 
Attenuated Adenomatous Polyposis Coli (AAPC), Gardner syndrome and 
Turcot syndrome are the three variants of the FAP syndrome. Extraintestinal 
manifestations distinguish the first two of these variants. AAPC as the name 
implies, represents a less pronounced FAP. In addition, biallelic mutations in 
the MUTYH gene have been found in 30% of families with multiple adenomas 
(15–100) who do not exhibit an autosomal dominant inheritance pattern or a 
germline mutation in the APC gene [92]. Patients with attenuated 
adenomatous polyposis coli develop fewer (10-99) polyps than the typical FAP 
and at a later age. The polyps tend to be distributed more proximally, and the 
risk of colon adenocarcinoma, appear to be lower than iun a classical FAP[93]. 
Beside polyposis Gardner syndrome includes the development of benign 
extracolonic tumors, desmoid tumors, soft-tissue tumors, osteomas and dental 
abnormalities. Although extremely rare in the general population, desmoids 
occur in approximately 10% of patients with FAP, most often in the mesentery 
or abdominal wall following surgical trauma. Despite they do not metastasize, 
they are locally aggressive and a common cause of death in patients with 
FAP. The distinction between Gardner syndrome and FAP has become less 
clear with improved understanding of the genetic basis of these disorders. The 
same genetic abnormalities are found in patients with either syndrome and 
both syndromes can be seen within the same family [94].The additional 
feature of Turcot syndrome is the growth of central nervous system tumors like 
medulloblastomas, astrocytomas and ependymomas. In about  70-80% of 
classical FAP an APC gene mutation can be detected. Nevertheless, in few 
patients with Turcot syndrome, MLH1 and MSH2 genes mutation have been 
described [95].  
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4.4.2 Hamartomatous polyposis syndromes 
 
This group of disorders has in common the development of hamartomatous 
polyps in the GI tract, which may also confers an increased risk of cancer. 
These conditions include Juvenile Polyposis Syndrome (JPS), Peutz-Jeghers 
Syndrome (PJS), Bannayan-Riley-Ruvalcaba Syndrome (BRRS), Cowden 
Syndrome (CS), Cronkhite-Canada Syndrome (CCS), and Hereditary Mixed 
Polyposis Syndrome (HMPS). 
 
4.4.2.1 Juvenile polyposis 
 
JPS is characterized by multiple distinct juvenile polyps in the gastrointestinal 
tract and an increased risk of colorectal cancer. Clinically it is defined by the 
presence of five or more juvenile polyps in the colorectum, juvenile polyps 
throughout the gastrointestinal tract or any number of juvenile polyps, and a 
positive family history of juvenile polyposis [96, 97]. 
Juvenile polyposis syndrome (JPS) is a rare (2.8 per 100 000 in children under 
10 years of age) autosomal dominantly inherited disorder with germline 
mutations in the SMAD4 or BMPR1A gene in about 50%-60% of JPS patients 
[98, 99], and about 10% of JPS patients with a germline mutation in PTEN 
[100]. 
Patients present with bleeding, anemia, rectal prolapse of a polyp, diarrhea, 
abdominal pain and/or failure to thrive and in a small subset of patients 
congenital abnormalities, including cardiac, and bowel rotations have been 
shown. The most significant cause of mortality in patients with juvenile 
polyposis is colorectal cancer. In one large series, 18 of 87 patients (21%) 
developed colorectal cancer. These cancers tended to have early onset (mean 
age 34 years), were poorly differentiated and had a poor prognosis [96]. 
Overall, the risk of gastrointestinal malignancy may exceed 50% [101]. 
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4.4.2.2 Peutz–Jeghers syndrome 
 
Peutz–Jeghers syndrome (PJS)is a rare autosomal dominant condition (1 in 
150,000 persons), characterized by the development of hamartomatous 
polyps, benign polyps comprised of several types of typical epithelial cells 
supported by a thick band of smooth muscle. They are found throughout the 
gastrointestinal tract (particularly the small bowel) and may cause bleeding, 
intussusception, or obstruction [102]. Patients usually develop distinctive 
mucocutaneous pigmented lesion on lips, buccal mucosa, hands, and feet. 
The lifetime risk of colon cancer is about  39%, and 93% for stomach, small 
bowel, pancreas, breast, sex cord, uterine, cervical, and melanoma cancers 
[103-107]. 
PJS has been associated with germline mutations or deletions in LKB1 
(STK11), a serine–threonine kinase that regulates p53-mediated apoptosis 
and the mammalian target of rapamycin (mTOR) pathway; STK11 germline 
alterations can be identified in only 50%-60% of cases of suspected PJS [108-
110].  
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4.4.2.3 PTEN Hamartoma Tumor Syndrome  
 
The PTEN hamartoma tumor syndrome (PHTS) includes Cowden syndrome 
(CS), Bannayan-Riley-Ruvalcaba syndrome (BRRS), PTEN-related Proteus 
syndrome (PS), and Proteus-like syndrome are rare polyposis syndromes 
related to juvenile polyposis. 
CS is a multiple hamartoma syndrome with a high risk for benign and 
malignant tumors of the thyroid, breast, and endometrium [111]. Affected 
individuals usually have macrocephaly, trichilemmomas, and papillomatous 
papules and present by the late 20s. The lifetime risk of developing breast 
cancer is 25%-50%, with an average age of diagnosis between 38 and 46 
years. The lifetime risk for thyroid cancer (usually follicular, rarely papillary, but 
never medullary thyroid cancer) is approximately 10%. The risk for 
endometrial cancer, although not well defined, may approach 5%-10% [111]. 
BRRS is a congenital disorder characterized by hamartomatous polyps as well 
as unusual facies, macrocephaly, developmental delay, and pigmented 
papules on the penis [43].  
PS is a complex, highly variable disorder involving congenital malformations 
and hamartomatous overgrowth of multiple tissues, as well as connective 
tissue nevi, epidermal nevi, and hyperostoses [111].  
Proteus-like syndrome is undefined but refers to individuals with significant 
clinical features of PS who do not meet the diagnostic criteria for PS [111]. 
The diagnosis of PHTS is made only when a PTEN mutation is identified. Up 
to 85% of individuals who meet the diagnostic criteria for CS and 65% of 
individuals with a clinical diagnosis of BRRS have a detectable PTEN 
mutation. Preliminary data also suggest that up to 50% of individuals with a 
Proteus-like syndrome and up to 20% of individuals with Proteus syndrome 
have PTEN mutations [111].  
PTEN is a tumor suppressor gene. It acts as a dual-specificity protein 
phosphatase, dephosphorylating tyrosine-, serine- and threonine-
phosphorylated proteins. Also acts as a lipid phosphatase and this  activity is 
critical for its tumor suppressor function. Antagonizes the PI3K-AKT/PKB 
signaling pathway by dephosphorylating phosphoinositides and thereby 
modulating cell cycle progression and cell survival. The unphosphorylated 
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form cooperates with AIP1 to suppress AKT1 activation. Dephosphorylates 
tyrosine-phosphorylated focal adhesion kinase and inhibits cell migration and 
integrin-mediated cell spreading and focal adhesion formation. Plays a role as 
a key modulator of the AKT-mTOR signaling pathway [112]. 
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4.5 Diagnostic and prognostic genetic markers in cancer 
 
Tumor development starts through the accumulation of genetic and epigenetic 
alterations that allow cells to escape from the cellular control mechanisms that 
regulate the homeostatic equilibrium between cell proliferation and cell death 
[113]. 
To transform a primary cell into a malignant one in vitro requires alterations in 
the functionality of many processes by which cells control their growth, division 
and differentiation [114]. Studies on colorectal, breast, lung, pancreatic cancer 
tissues have demonstrated the view that acquisition of genetic alterations and 
epigenetic changes could determine the morphological changes that leads to 
cancer progression [15, 115]. Mutations in cancer cells comprises a large 
variety of DNA alterations including chromosome copy number, 
(micro)deletions/(micro)duplications or structural chromosomal alterations like 
translocations, deletions or amplifications, as well as changes at nucleotide 
level such as point mutations affecting a single nucleotide at a critical position 
in a cancer-related gene. It has been shown that these alterations often co-
exist in a single tumor [116]. Genetic and epigenetic events represent two 
complementary mechanisms that are involved in carcinogenesis 
initiation/progression/metastasis and sometimes coexisting [117]. 
Biomarkers can be defined as biological molecules found in blood, other body 
fluids, or tissues, which can indicate a normal or abnormal process, or directly 
a condition or disease. A biomarker may be further used to see how well the 
body responds to a treatment for a disease or condition [2, 118]. Biomarkers 
are an reliable indicators for a disease process and can be divided in five 
categories: diagnostic, early detection, prognostic and predictive [118]. Each 
marker should have different characteristics such as specificity, refers to the 
quantity of control subjects who test negative for the biomarker (patients 
without disease), and sensitivity refer to quantity of case subject who test 
positive for the biomarker (patients with confirmed disease). 
Some examples are: TP53 has been found mutated in many tumors and is 
used as biomarker in epidemiology and for early cancer detection [119-122]; 
EGFR is often mutated in lung adenocarcinomas of never smokers (with 
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additional mutation in KRAS) [123] and is used as biomarker for predicting the 
response of lung cancer patients to small molecule Tyrosine Kinase Inhibitors 
(TKIs) such as erlotinib or gefinitib [124-127]; de novo methylation of the 
p16INK4a promoter is one of the most frequent epigenetic alterations in human 
cancer and appears to be the earliest event in some cancer types [128, 129]; 
p16INKa, p15INK4b, RASSF1A, MLH1, GSTP1, CDH1, APC, and DAPK1 are 
frequently methylated in circulating DNA  and used as biomarkers in the clinic 
and risk assessment [130]; miR-141 in prostate cancer patients has been 
shown to be a marker that can distinguish, with significant specificity and 
sensitivity, patients with cancer from healthy controls [131]. 
Thus, the discovery of novel gene/pathway alterations could reveal new 
biomarkers for cancer detection, diagnosis and prognosis.  
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Tumor markers currently use in clinical practice.  
 
Tumor Marker Cancer Type Tissue Analyzed Usage 
ALK gene 
rearrangements 
Non-small cell lung 
cancer; anaplastic large 
cell lymphoma 
Tumor tissue To help determine treatment and prognosis 
Alpha-fetoprotein 
(AFP) 
Liver cancer; 
germ cell tumors 
Blood To help diagnose liver cancer and follow 
response to treatment; to assess stage, 
prognosis, and response to treatment of 
germ cell tumors 
Beta-2-microglobulin 
(B2M) 
 
Multiple myeloma; 
chronic lymphocytic 
leukemia; some 
lymphomas 
Blood, urine, or 
cerebrospinal fluid 
To determine prognosis and to follow 
response to treatment 
Beta-human chorionic 
gonadotropin (Beta-
hCG) 
 
Choriocarcinoma; 
testicular cancer 
Urine or blood To assess stage, prognosis, and response 
to treatment of testicular cancer 
BCR-ABL 
 
Chronic myeloid 
leukemia 
 
Blood and/or bone 
marrow 
 
To confirm diagnosis and monitor disease 
status 
 
BRAF mutation V600E 
 
Cutaneous melanoma; 
colorectal cancer 
 
Tumor tissue 
 
To predict response to targeted therapies 
CA15-3/CA27.29 
 
Breast cancer 
 
Blood 
 
To assess whether treatment is working or 
disease has recurred 
 
CA19-9 
  
 
Pancreatic cancer; 
gallbladder cancer; 
bile duct cancer; 
gastric cancer 
 
Blood 
 
To assess whether treatment is working 
 
CA-125 
 
Ovarian cancer 
 
Blood 
 
To help in diagnosis, assessment of 
response to treatment, and evaluation of 
recurrence 
 
Calcitonin 
 
Medullary thyroid cancer 
 
Blood 
 
To aid in diagnosis, to check whether 
treatment is working, and to assess 
recurrence 
 
Carcinoembryonic 
antigen (CEA) 
 
Colorectal cancer; breast 
cancer 
 
Blood 
Blood 
 
To check whether colorectal cancer has 
spread; to look for breast cancer 
recurrence and assess response to 
treatment 
 
CD20 
 
Non-Hodgkin lymphoma 
 
Blood 
 
To determine whether treatment with a 
targeted therapy is appropriate 
 
Chromogranin A 
(CgA) 
 
Neuroendocrine tumors 
 
Blood 
 
To help in diagnosis, assessment of 
treatment response, and evaluation of 
recurrence 
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Chromosomes 3, 7, 
17, and 9p21 
 
Bladder cancer 
 
Urine 
 
To help in monitoring for tumor recurrence 
 
Cytokeratin fragments 
21-1 
 
Lung cancer 
 
Blood 
 
To help in monitoring for recurrence 
 
EGFR mutation 
analysis 
 
Non-small cell lung 
cancer 
 
Tumor tissue 
 
To help determine treatment and prognosis 
 
Estrogen receptor 
(ER)/progesterone 
receptor (PR) 
 
Breast cancer 
 
Tumor tissue 
 
To determine whether treatment with anti-
hormonal therapy (such as tamoxifen) is 
appropriate 
 
Fibrin/fibrinogen 
 
Bladder cancer 
 
Urine 
 
To monitor progression and response to 
treatment 
 
HE4 
 
Ovarian cancer 
 
Blood 
 
To assess disease progression and monitor 
for recurrence 
 
HER2/neu 
 
Breast cancer; gastric 
cancer; esophageal 
cancer 
 
Tumor tissue 
 
To determine whether treatment with 
trastuzumab is appropriate 
 
Immunoglobulins 
 
Multiple myeloma; 
Waldenstrom 
macroglobulinemia 
 
Blood and urine 
 
To help diagnose disease, assess 
response to treatment, and look for 
recurrence 
 
KIT 
 
Gastrointestinal stromal 
tumor; mucosal 
melanoma 
 
Tumor tissue 
 
To help in diagnosis and determining 
treatment 
 
KRAS mutation 
analysis 
 
Colorectal cancer; 
non-small cell lung 
cancer 
 
Tumor tissue 
 
To determine whether treatment with a 
particular type of targeted therapy is 
appropriate 
 
Lactate 
dehydrogenase 
 
Germ cell tumors 
 
Blood 
 
To assess stage, prognosis, and response 
to treatment 
 
Nuclear matrix protein 
22 
 
Bladder cancer 
 
Urine 
 
To monitor response to treatment 
 
Prostate-specific 
antigen (PSA) 
 
Prostate cancer 
 
Blood 
 
To help in diagnosis, assess response to 
treatment, and  look for recurrence 
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Table taken from [2] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thyroglobulin 
 
Thyroid cancer 
 
Tumor tissue 
 
To evaluate response to treatment and to 
look for recurrence 
 
Urokinase 
plasminogen activator 
(uPA) and 
plasminogen activator 
inhibitor (PAI-1) 
 
Breast cancer 
 
Tumor tissue 
 
To determine aggressiveness of cancer 
(and guide treatment) 
 
70-Gene signature 
(Mammaprint) 
 
Breast cancer 
 
Tumor tissue 
 
To evaluate risk of recurrence 
 
21-Gene signature 
(Oncotype DX) 
 
Breast cancer 
 
Tumor tissue 
 
To evaluate risk of recurrence 
 
5-Protein signature 
(Ova1) 
 
Ovarian cancer 
 
Blood 
 
To pre-operatively assess pelvic mass for 
suspected ovarian cancer 
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4.6 MicroRNA: biogenesis, functions and targets 
 
MicroRNAs (miRNAs) represent a large family of small non-coding RNAs of 
about 25 nucleotides in length that serve as effector molecules of sequence-
specific gene silencing [132]. It is estimated that the number of miRNAs in the 
human genome range from about 450 to 1000 and that they control gene 
expression of about 30% of all protein-coding genes in mammals. The majority 
of identified miRNAs, are highly evolutionary conserved among many distantly 
related species, from worms to human, suggesting that miRNAs have roles in 
essential biological processes, including developmental timing, stem-cell 
differentiation, signal transduction.  
In the nucleus, miRNA genes are generally transcribed by RNA polymerase II 
or III to form large primary miRNA transcripts (pri-miRNAs). These are further 
processed by Drosha, an RNase III protein, into 70-nucleotide miRNA 
precursors (pre-miRNA). After transport into the cytoplasm, pre-miRNAs are 
further processed by another RNase III enzyme, Dicer, into miRNA duplexes, 
typically consisting of 19-25 nucleotides in length [133, 134]. Subsequently 
these duplexes can be loaded into the miRNA-associated multiprotein RNA-
induced silencing complex (miRISC) and the mature miRNA strand is 
preferentially retained. Once bound to the 3’ untranslated region (UTR) of 
target mRNAs, the mature miRNA induces cleavage, translational repression 
or deadenylation, depending on the degree of complementarity [135]. A single 
miRNA may bind to as many as 200 target genes encoding a broad range of 
proteins, such as transcription factors, receptors and transporters. In recent 
years, several approaches have been used to identify miRNA targets [136].  
For all known miRNA targets, perfect or near-perfect complementary sites of 
miRNAs have been conserved. This provides a powerful strategy for the 
prediction of miRNA targets through computational approaches, and several 
laboratories have developed different computational methods to achieve this 
using the available genome database; hundreds of miRNA targets for given 
miRNAs were predicted [137]. 
 
 
	
   35	
  
MicroRNA biogenesis  
 
 
 
 
The miRNA processing pathway, taken from Filipowicz et al. [132]: 
canonical maturation includes the production of the primary miRNA transcript 
(pri-miRNA) by RNA polymerase II or III and cleavage of the pri-miRNA by the 
microprocessor complex Drosha–DGCR8 (Pasha) in the nucleus. The 
resulting precursor hairpin, the pre-miRNA, is exported from the nucleus by 
Exportin-5–Ran-GTP. In the cytoplasm, the RNase Dicer in complex with the 
double-stranded RNA-binding protein TRBP cleaves the pre-miRNA hairpin to 
its mature length. The functional strand of the mature miRNA is loaded 
together with Argonaute (Ago2) proteins into the RNA-induced silencing 
complex (RISC), where it guides RISC to silence target mRNAs through 
mRNA cleavage, translational repression or deadenylation, whereas the 
passenger strand (black) is degraded. In this review we discuss the many 
branches, crossroads and detours in miRNA processing that lead to the 
conclusion that many different ways exist to generate a mature miRNA. 
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4.6.1 MicroRNA and cancer 
 
Early observations suggested a potential role of miRNAs in human 
carcinogenesis. miRNAs discovered in C. elegans and in Drosophila were 
shown to control cell proliferation and apoptosis [138, 139] and their 
deregulation can contribute to proliferative diseases like cancer. It has also 
been shown that malignant tumors and tumor cell lines have widespread 
deregulated miRNA expression compared to normal tissues [140, 141].  
One of the questions to be answered is if miRNA expression observed in 
cancer is cause or rather consequence of malignant transformation [142]. 
In the past 10 years many studies were performed in this direction, with the 
first direct evidence shown by Calin et al. They identified two miRNA, mir-15 
and mir-16, transcribed from genes located in a 30-kb deletion on 
chromosome 13, which is the most common chromosomal abnormality in 
chronic lymphocytic leukemia (CLL), consequently they found the two miRNAs 
absent or downregulated in the majority (68%) of cases compared to normal 
tissue. This finding suggested that these two miRNAs were causally involved 
in the pathogenesis of chronic lymphocytic leukemia [143].  
Other studies described specific activities of some microRNAs as oncogenes 
or tumor suppressors. He et al. showed the relationship between a miRNA 
cluster, mir-17-92 (oncomir-1) with the Myc oncogenic pathway [144, 145], 
using a mouse model of human B-cell lymphoma caused by Myc oncogene 
overexpression. They demonstrated that upregulation of the mir-17-92 cluster 
accelerated c-Myc-induced tumorigenesis in mice. The oncogenic role of the 
mir-17-92 cluster was confirmed by Matsubara et al. and Sylvestre et al. [146, 
147]. On the other hand, O’Donnell et al. identified the same cluster of 
miRNAs, mir-17-92, to be regulated by the transcription factor c-Myc which 
induces expression of a growth factor E2F1. The mir-17-92 cluster, which is 
also induced by c-Myc, in contrast, inhibits E2F1 expression, conferring a 
potential role as a tumor suppressor [144, 145]. 
MicroRNAs are also involved in the regulation of p53 that regulates part of the 
stress responses including response to the DNA damage. miR-34, is directly 
activated by p53 after DNA damage. Overexpression of miR-34 induces cell 
cycle arrest and promotes apoptosis [148, 149]. 
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It has been shown that expression of many miRNAs is significantly reduced in 
cancers compared to matched normal tissues. Furthermore, undifferentiated 
tumors had lower miRNA levels compared with more-differentiated tumors 
[141, 150], pointing to possible miRNAs functions in terminal differentiation 
and cell separation. Kumar et al. verified that reduction in miRNA levels 
promote tumorigenesis by knockdown of Drosha and Dicer in cell lines [151]. 
These cells with global miRNA downregulation showed enhanced cellular 
growth in vitro. When injected into nude mice, they generated faster growing 
and more invasive tumors compared to controls. To assess the effect of global 
miRNA dowregulation in vivo, the authors deleted Dicer in a mouse model of 
lung cancer. The enzyme lacking mutant mice developed an increased tumor 
burden, with a growth in tumor number and tumor size, as well as tumors that 
were less well differentiated compared to controls. These data suggest that 
global miRNA downregulation enhances tumorigenesis [151].  
Together, these data indicate that altered expression of miRNAs has a 
pleiotropic effect on tumor suppressors and oncogenes and represents a 
crucial step in tumorigenesis.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	
   38	
  
4.7 HMG proteins 
 
High Mobility Group (HMG) proteins, can be divided into three distinguishable 
families; (1) HMGA, (2) HMGB, and (3) HMGN. All three families share many 
biochemical features, but each has it own characteristic functional motifs and 
is expressed in distinctive ways in different cells and tissues [152].  
HMG protein families are classified as ‘architectural transcription factors 
according to their ability to positively and negatively regulate gene 
transcription by binding to DNA or chromatin in a structure-specific manner. 
HMG proteins have been implicated in a diverse array of additional nuclear 
processes like chromatin and nucleosome remodeling events, cell cycle-
related chromosomal changes, genetic recombination, DNA replication and 
repair, apoptosis, and molecular chaperoning [153-157].  
 
4.7.1 HMGA family 
 
The HMGA protein family consists of HMGA1 and HMGA2 genes that encode 
four proteins named HMGA1a, HMGA1b, HMGA1c (spliced isoforms of the 
HMGA1 gene; locus 6p21) and HMGA2. The HMGA1a, HMGA1b and HMGA2 
proteins are composed of 107, 96 and 108 amino acid residues, respectively. 
Each protein contains three basic domains, named AT-hooks and an acidic C-
terminal region, this motif bind the minor groove of a target DNA strand. 
The HMGA1a protein differs from HMGA1b in that it has an additional 
insertion of 11 amino acid residues between the first and the second AT-hook 
domains. The structure of HMGA2, very similar to that of HMGA1b, contained 
a short peptide of 12 amino acid residues between the third AT-hook and the 
acidic C-terminal [158].  
Until 2004 there were reports of over 50 different eukaryotic and viral genes 
regulated by HMGA proteins. The vast majority (>35) of these are positively 
regulated and their inducible expression is controlled by a variety of biological 
and environmental stimuli. The promoter regions of many of the positively 
regulated genes contain multiple stretches of AT-rich sequence (AT-hook 
binding site). Transcriptional activation of these types of promoter often 
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involves the formation of an “enhanceosome”, a stereo-specific, multi-protein 
complex that includes HMGA proteins and other transcription factors making 
specific protein-DNA and protein-protein contacts in intricate, but precise, 
ways. In the case where HMGA proteins act as negative regulators of gene 
transcription they often serve as inhibitors of enhanceosome formation, 
usually by sterically blocking the functional binding of other crucial 
transcription factors to their recognition sites in gene promoters [159]. Very 
recently, the down-regulation of the recombination activating gene (RAG2) by 
HMGA1 proteins has been described [160]. One of the best-studied 
mechanisms of gene regulation in which HMGA proteins are involved is that of 
the interferon-β gene (IFN- β). IFN- β expression is due to a multifactorial 
complex that assembles at the nucleosome-free enhancer region of the gene, 
formed by the factors NF-kB, IRF, ATF2/cJun, and the HMGA1a protein. 
HMGA1a plays a dual function in this context: (i) it induces allosteric changes 
in the DNA, thus increasing the affinity of the transcription factors for their 
binding sites and (ii) it establishes protein-protein interactions with the same 
factors. This new structure, called enhanceosome, is responsible for the 
modification and the remodeling of a nucleosome that masks the TATA-box; 
consequently, transcription can start. This remodeling is triggered by the 
recruitment from the “enhanceosome” of GCN5/PCAF that acetylates the 
nucleosome and also HMGA1a at K64, the latter modification resulting in the 
stabilization of the enhanceosome. Later, another acetyltransferase called 
CBP modifies HMGA1a at K70 destabilizing the enhanceosome and, 
consequently, repressing transcription [161]. 
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4.7.2 HMGA expression in normal and neoplastic tissues 
 
The HMGA2 gene is not expressed in human tissues except for CD34 positive 
hematopoietic stem cells. The HMGA1 gene is expressed at low levels in 
human tissues: a higher expression was observed in testis, skeletal muscle 
and thymus. Conversely, both genes are widely expressed during 
embryogenesis. HMGA1 and HMGA2 over-expression was first described in 
rat thyroid transformed cells and in experimental thyroid tumours. Over-
expression of the HMGA proteins was then found to be a common feature of 
experimental and human malignant neoplasias, including thyroid, prostate, 
uterus, breast, colorectum, ovary and pancreas carcinomas [158]. Recently, 
HMGA1 expression has been correlated with the histological grade of human 
glial tumors [162]. Moreover, the expression level of the HMGA proteins is 
significantly correlated with parameters of poor prognosis in patients with 
colorectal cancer. In all of these epithelial/endothelial cell-derived malignant 
tumors, the over-expressed proteins are full-length non-mutants forms. In 
contrast to the situation in carcinomas, benign tumors of mesenchymal origin 
(lipomas, leiomyomas, fibroadenomas, aggressive myxomas, pulmonary 
hamartomas and endometrial polyps) often contain chromosomal 
rearrangements that result in the creation of new hybrid genes that code for 
chimeric proteins in which the AT-hooks of the HMGA proteins are fused to 
ectopic peptidic sequences [163]. Over-expression of the HMGA proteins 
appears to be a necessary event in in vivo cell transformation. This was 
demonstrated by experiments in which HMGA expression was blocked by 
transfecting rat thyroid cells with antisense HMGA constructs. When these 
cells were infected by the myeloproliferative sarcoma virus and the Kirsten 
murine sarcoma virus carrying the v-mos and v-ras-Ki oncogenes, 
respectively, they did not acquire the typical markers of neoplastic 
transformation (ability to grow in soft agar and induce tumors after injection 
into athymic mice). Conversely, these markers were shown by the 
untransfected rat thyroid cells infected with the same murine retroviruses 
[164]. Over-expression of HMGA1 proteins is also essential in the 
development of cancer in humans. In fact, an adenovirus carrying the HMGA1 
gene in an antisense orientation induces programmed cell death in carcinoma 
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cell lines derived from human thyroid, lung, colon and breast cancers. 
Moreover, it has been reported that the overexpression of HMGA1a or 
HMGA2 leads to neoplastic transformation of both Rat-1a fibroblasts and 
CB33 cells, whereas the decrease of HMGA1a/b expression abrogates 
transformation in Burkitt’s lymphoma cells [165]. 
In chapter s 6.3 and 6.3.1 we characterized HMGA1, HMGA2, at protein level 
in different human neoplastic entities, correlating their overexpression with 
clinic-pathological features.  
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4.8 Cancer Stem Cell Markers 
 
Stem cells are defined as cells that have the ability to perpetuate themselves 
through selfrenewal and to generate mature cells of a particular tissue through 
differentiation [166] . 
Because normal stem cells and cancer cells share the ability to self-renew, it 
seems reasonable to propose that newly arising cancer cells appropriate the 
machinery for self-renewing cell division that is normally expressed in stem 
cells. Evidence shows that many pathways that are classically associated with 
cancer may also regulate normal stem cell development [167-169] 
In most tissues, stem cells are rare but it has been shown for solid cancers 
that these cell populations are phenotypically heterogeneous and that only a 
small proportion of cells are clonogenic. These observations led to the 
hypothesis that only a few cancer cells are actually tumorigenic and that these 
tumorigenic cells could be considered as cancer stem cells [166, 170-175]. 
The cancer stem cell hypothesis postulates that a small subpopulation of 
cancer cells possessing self-renewal characteristics is responsible for initiating 
and maintaining cancer growth. According to the CSC model the large 
populations found in a tumor might represent diverse stages of differentiation. 
The biological characteristics shared by normal stem cells (NSCs) and CSCs 
mainly involve self-renewal and differentiation potential, survival ability, niche-
specific microenvironment requirements and specific homing to injury sites 
and may have important implications in terms of new approaches to cancer. 
The identification of new therapeutic targets based on the CSC model 
represents a great challenge. 
In the chapter 6.4 in according to the CSC hypothesis, we evaluated a 
potential role of CSC proteins in tumors of the ampulla of Vater. Our findings 
indicate, that in ampullary carcinomas, loss of expression of EpCAM may be 
linked to a more aggressive tumor phenotype. 
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4.9 MAGE Gene Family 
 
The melanoma antigen gene (MAGE) family is divided in to two subfamilies: 
MAGE I and II. MAGE I consists of a large number of genes located on the X 
chromosome,  including: MAGE-A located on Xq28 [176, 177], MAGE –B 
cluster located on Xp21 [178, 179], and MAGE-C on  Xq26–27 [180]. MAGE-
A, -B, and –C is characterized by a large terminal exon encoding the entire 
protein. Most of them are relevant cancer/testis antigens (CTA) [181] and then 
silent in normal adult tissues except in male germ cells [182], and highly 
expressed in various forms of cancer [183]. Studies of MAGE I genes, aiming 
at quantifying mRNA expression in cancer (due to limited specificity of MAGE 
antibodies), have found the highest frequency of MAGE-I mRNA expression in 
different types of cancers like melanoma and lung cancer, particularly the 
squamous cell type. In contrast, hematopoietic malignancies, including 
lymphomas and leukemia as well as renal, colon, and pancreatic cancers, 
displayed notably low MAGE- I expression. For instance, MAGE-A3 mRNA 
expression has been observed in 85% of non-small-cell lung carcinoma [184], 
but only in 41% of multiple myeloma [185], 37% of bladder cancer [186] and 
10% of the breast cancers [187]. Most investigations showed high expression 
of MAGEs, except MAGE-A4 that was often associated with poor outcome 
[188]. Higher grade and metastatic tumors have also been found to have high 
MAGEs expression than the primary tumors [189, 190]. 
The MAGE-II family, which includes the MAGE-D group, differs from the 
previously described members since they are almost universally expressed in 
all tumor free tissues and not related to cancer. They also differ by their 
genomic structure, the open reading frame of hMAGE-D2 being split over 11 
exons. Importantly, MAGE-D1 was recently found to interact with the p75 
neurotrophin receptor and to facilitate nerve growth factor-dependent 
apoptosis [191]. MAGE-D1 was also recently reported to interact with 
members of the Dlx/Msx homeodomain family and to regulate the 
transcriptional function of Dlx5 [192].  
Encoding tumor-specific antigenic peptides directed against MAGE-I 
expressing cancer cells, MAGE-I protein-derived peptides are currently 
studied as targets for the development of cancer vaccines [193, 194] and 
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antitumor immunotherapy [195-197]. In addition, expression analysis in 
various malignancies could be of diagnostic and/or prognostic relevance.  
In chapter 6.5 we generated, a MAGE-A10 monoclonal antibodies (mAbs) to 
staining a multitumor tissue microarray. We described an overexpression of 
MAGE-A10 in cells from a number of malignancies, including lung, skin and 
urothelial tumors. 
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5. AIMS 
My thesis focuses on the discovery and characterization of new diagnostic and 
prognostic markers in various cancer entities, in particular in sporadic and 
hereditary colorectal cancer. The work can be divided in seven major parts 
with the subdivision reflecting the structure of the results and the appendix. 
 
The aims of the first part (chapter 6.1) were: 
• To elucidate the frequency of contractions/insertions in the 3’UTR of the 
EWSR1 gene on MSI detection in MMR deficient and proficient cancers 
through capillary electrophoresis analysis 319 patients. 
• The role of these modifications in mRNA processing and protein 
expression in vitro (siRNA-mediated poly(A) site selection and pull-
down assays) and in vivo (mRNA and protein expression by RT-PCR 
and tissue microarray analysis). 
 
The aims of the second part (chapter 6.2) were: 
• To understand the type and frequency of genetic as well as epigenetic 
alterations at the SH2D4A locus in colorectal cancer via Sanger 
sequencing, gene dosage analysis by multiplex ligation-dependent 
probe amplification (MLPA), quantitative PCR for mRNA and 
immunohistochemical staining for protein expression. 
• To define the SH2D4A pathway interactions via immunoprecipitation 
and cell transfections. 
•  To test whether SH2D4A expression impacts on cell growth via 
interaction with its partners by knock-down experiments. 
 
The aim of the third part (chapters 6.3 and 6.3.1) was: 
• To investigate the prognostic role of HMGA1 and HMGA2 protein in 
breast and pancreatic cancers applying immunohistochemical 
techniques on tissue microarrays and gathering of clinic-pathological 
information and statistical comparison. 
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The aim of the fourth part (chapter 6.4) was: 
• To explore the prognostic usage of cancer stem cell markers in ampulla 
Vater carcinomas using the tissue microarray technology followed by 
survival analysis. 
•  
The aim of the fifth part (chapter 6.5) was: 
• To develop a specific MAGE monoclonal antibody and investigate its 
expression in a multitumor array by immunohistochemical techniques. 
 
The aims of the sixth part (chapter 8.1) were: 
• To assess the miRNA profile in Lynch syndrome-associated colorectal 
cancers (CRC) and establish their prognostic and/or therapeutic 
significance by deep sequencing of MMR deficient and proficient cell 
lines as well as cancers from Lynch syndrome and sporadic CRC 
patients.  
• Verification and validation of selected, differentially expressed miRNAs 
using quantitative real-time PCR and cell transfection assays.  
 
The aims of the seventh part (chapter 8.2) were: 
• To investigate copy number variation aberrations in CRCs from six 
Lynch syndrome patients using a high-resolution DNA SNP array. 
• To validate the findings in a cohort of 46 Lynch syndrome related and 
50 sporadic CRCs. 
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6. RESULTS 
6.1 3’UTR poly(T/U) tract deletions and altered expression of 
EWSR1 are a hallmark of mismatch repair deficient cancer. 
 
 
 
 
My contribution to this work: 
• RNA and DNA extraction from Lynch syndrome and sporadic colorectal 
cancers  
• Molecular assessment of EWS16T contractions/expansions; 
• Microsatellite instability analyses of Lynch syndrome and sporadic 
cancers; 
• Quantitative real time PCR experiments; 
• Immunohistochemical analysis of CRC whole tissue and microarray 
sections; 
• Data and statistical analysis; 
• Manuscript writing; 
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Microsatellite instability (MSI), the genome-wide accumulation of DNA 
replication errors at repetitive nucleotide sequences, constitutes the 
hallmark lesion of DNA mismatch repair (MMR) deficient cancers1. 
Present in Lynch syndrome-related and about 10-20% of sporadic 
colorectal (CRC), gastric and endometrial cancers MSI testing is widely 
used to guide clinical management. The functional significance of MSI at 
non-coding repeat loci such as the 3’ untranslated region (UTR), 
however, remains largely elusive1-3. Here we describe a mononucleotide 
(T/U)16 tract, EWS16T, located in the 3’ UTR of the Ewing sarcoma break 
point region 1 (EWSR1) gene which discriminates MMR proficient from 
MMR deficient cancers with 100% sensitivity and specificity. We 
demonstrate in vitro and in vivo that contractions at this locus alter 
poly(A) site selection by promoting SFPQ-mediated distal poly(A) site 
usage in EWSR1 pre-mRNAs and result in decreased mRNA as well as 
protein expression. In contrast to their proficient counterparts, MMR 
deficient CRC display altered subcellular localization of EWS with diffuse 
cytoplasmic staining. EWS16T thus not only represents a novel 
monomorphic MSI target locus to accurately identify both, hereditary 
and sporadic, MMR deficient cancers but contractions therein affect 
multiple regulatory mechanisms implicating the RNA-/DNA-binding 
protein EWS in MSI-associated colorectal tumorigenesis.  
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Our investigation of an extra-osseous Ewing sarcoma (ES) from a MSH6 
mutation carrier (c.3696dupT) previously affected by colon cancer revealed 
that the tumor displayed the typical hallmarks of LS, i.e. MSI at 
mononucleotide markers and specific loss of MSH6 expression 
(Supplementary Fig. S1), but none of the molecular features commonly 
associated with ES, i.e. chromosomal translocations involving the EWSR1 
gene on 22q12 (Supplementary Fig. S2). In view of the tumor’s MSI-high 
phenotype we focused on a mononucleotide tract in the 3’ UTR of the EWSR1 
gene consisting of 16 thymines (EWS16T; c.*318_*333). Both of the patient’s 
tumors, ES and colon cancer, were found to carry somatic 
contractions/deletions of 4 and 5 thymines, respectively, prompting us to 
assess the prevalence of somatic alterations at EWS16T in MMR deficient 
cancers in general. In contrast to Wheeler et al.4 who reported a deletion 
variant (c.*331_*333delTTT; dbSNP: rs76631619) in James D. Watson’s 
genome, we found the EWS16T locus to be monomorphic in over 300 
constitutional DNA samples tested. As a first step, we analyzed 85 cancers 
(78 colorectal (CRCs) and 7 endometrial) and matching leukocyte-derived 
DNA samples from 78 Swiss LS patients with confirmed MMR germline 
mutations (58 MLH1, 20 MSH2). In addition, we investigated 14 sporadic 
MMR-deficient CRCs with MLH1 promoter hypermethylation as well as 85 
sporadic MMR-proficient CRCs. Assessment of EWS16T tract length by 
capillary electrophoresis of fluorescently labeled PCR products revealed that 
all MMR-deficient cancers but none of the MMR-proficient ones displayed 
novel alleles, i.e. contractions or expansions at the EWS16T tract (Fig. 1). 
Subsequently, the findings were independently confirmed in a Finnish cohort 
of 122 patients: all 29 MMR-deficient (12 CRC, 17 gastric cancers) but none of 
the 93 MMR-proficient (38 CRC and 55 gastric) cancers showed EWS16T 
tract instability. The majority (72.7%) of somatic alterations consisted of 
contractions/deletions of 4 or more base pairs (Supplementary Fig. 3). 
Consistently, we further found that MMR-deficient cell lines (LoVo, HCT15, 
HCT116) carry only mutated EWS16T alleles (contractions). In contrast, 
MMR-proficient cell lines (HT29, SW480) as well as 12 MMR-proficient, MSI-
low CRCs from Swiss patients were stable at EWS16T (Table 1). The 
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EWS16T tract thus represents a novel, monomorphic MSI target locus 
identifying MMR-deficient cancers with 100% sensitivity and specificity. 
Because somatic EWS16T tract alterations were exclusively present in MMR-
deficient cancers, whether hereditary or sporadic, and occurred in all types of 
cancer investigated (colorectal, gastric and endometrial) we wondered about 
their possible functional role(s) in MMR-related carcinogenesis. The poly(T/U) 
tract deletions occur in a region which encodes the 3’UTR of EWSR1 and do 
not alter the coding sequence of the EWSR1 gene. Nonetheless, 3’UTRs 
contain sequence elements that are important for the post-transcriptional 
regulation of protein levels. Furthermore, it has been recently demonstrated 
that changes in 3’UTR length through alternative polyadenylation activates 
oncogenes5. We thus set out to characterize the effect of EWS16T tract 
deletions on EWSR1 expression levels. The catalog of 3’ end cleavage sites 
that we recently generated through 3’ end sequencing in human embryonic 
kidney (HEK) 293 cells6 shows that EWSR1 undergoes alternative 
polyadenylation, generating two transcript forms that differ in the length of their 
3’UTRs (Supplementary Fig. 4). The ESW16T tract deletions occur very close 
to the distal poly(A) signal and may thus result in changes in 3’ end processing 
factor assembly, thereby altering the poly(A) site selection. To investigate this 
possibility, we cloned the 3’UTR of EWSR1 downstream of the Renilla 
luciferase-coding region in a psiCHECK-2 mutant vector in which the synthetic 
poly(A) site was mutated (psiCHECK-2-SPAm). This construct thus allowed 
only the usage of the poly(A) signal from the cloned 3’UTR of EWSR1. We 
then generated variant constructs containing poly(T/U) tracts of variable 
lengths through deletion mutation. With primers that simultaneously detect 
both the short and the long 3’UTR isoforms in a multiplexed semi-quantitative 
PCR, we found that deletions in the ESW16T tract promoted the usage of the 
distal poly(A) site (Figure 2a-b). We further investigated the MMR-proficient 
and MMR-deficient colon cancer cell lines and found that, consistent with our 
findings in the heterologous system, MMR deficiency is associated with higher 
expression of the longer EWSR1 isoform (Figure 2c). These results indicate 
that the EWS16T tract deletions alter poly(A) site selection. To determine the 
factors involved in EWSR1 poly(A) site selection, we used S1 aptamer-tagged, 
in vitro transcribed wildtype 3’UTR and a 3’UTR variant with 6U deletions in 
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the EWS16T region to pull down the proteins that associated with these RNAs 
(Supplementary Fig. 5). In three independent experiments we reproducibly 
identified a set of A/U-rich element binding proteins that associate with these 
constructs (Figure 3A and 3B). Interestingly, we found that NF45/90/110, 
hnRNPC and HuR associate with the wildtype but not with the mutant 3’UTR. 
NF45 and NF90 have been previously shown to be a part of a heterodimeric 
complex, nuclear factor of activated T-cells (NFAT), which is required for T-cell 
expression of interleukin 2, with NF110 being a larger isoform of NF90. NF90 
has been shown to regulate mRNA stability and redistribution of nuclear 
mRNAs in the cytoplasm7. The EWS16T mutant preferentially associated with 
the SFPQ/NONO heterodimer, which is an essential pre-mRNA splicing factor 
that couples splicing with polyadenlyation as a component of a small nuclear 
ribonucleoprotein (snRNP)-free complex with SNRPA/U1A8. To determine 
which of the RBPs identified above influenced the poly(A) site selection, we 
knocked down their expression individually with siRNAs (Figure 4a) and 
assessed the poly(A) site usage in reporter constructs that had either the 
wildtype or the mutant EWS16T tract (6U deletions) cloned downstream of 
luciferase. None of the siRNAs influenced the poly(A) site usage in the 
wildtype constructs in which only the shorter isoform was expressed (Figure 
4b). When the 6U deletion construct was used however, the knockdown of 
SFPQ and hnRNPC strongly influenced poly(A) site selection. Specifically, 
knockdown of SFPQ promoted proximal site usage, while the knockdown of 
hnRNPC led to increased expression of the longer 3’UTR isoform (Figure 4c). 
This result was consistent with the binding pattern of the RBPs. hnRNPC 
binding was most prominent immediately downstream of the proximal poly(A) 
site (our unpublished PAR-CLIP data on hnRNPC), while SFPQ most likely 
bound to the truncated U-tract immediately upstream of the distal poly(A) site, 
as inferred from the pull down experiments (Figure 3a). Interestingly, 
knockdown of SFPQ did not affect poly(A) site selection in wildtype constructs, 
consistent with our earlier findings that SFPQ specifically associated with the 
construct carrying the 6U deletion. Thus, our results indicate that hnRNPC and 
SFPQ have antagonistic activity on the processing of mutant EWSR1 pre-
mRNA with hnRNPC promoting the generation of the shorter and SFPQ of the 
longer 3’UTR isoform.  
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To finally determine if the choice in polyadenylation site may influence EWSR1 
expression, we performed luciferase assays on the constructs that carried the 
wildtype or various EWS16T deletion variants. The results shown in 
Supplementary Fig. 6 indicate a significant downregulation (up to 30%) of 
protein levels associated with EWS16T tract deletions. We attempted to 
corroborate our observations in vivo, assessing EWSR1 mRNA expression in 
a set of 8 LS-related MMR-deficient and 5 sporadic MMR-proficient CRCs 
relative to matched, tumor-free mucosa by RT-PCR. Four (50%) out of the 8 
LS, but only 1 (20%) out of the 5 sporadic CRC showed significantly (>1.2 
fold) increased expression of the longer 3’UTR isoform (Figure 5A). The total 
EWSR1 mRNA levels, however, were significantly reduced (>1.2 fold) in both 
LS-related and sporadic CRC tissues (Figure 5B), pointing to additional 
mechanisms that regulate EWSR1 expression in sporadic CRCs. To 
determine the consequences of altered EWSR1 mRNA expression, we 
performed immunohistochemical analysis (IHC) of 10 LS-related, MMR-
deficient and 9 sporadic, MMR-proficient CRCs. Consistent with the data at 
the mRNA level, the cancers displayed on average an approx. 30% reduction 
in EWS expression when compared to matched, tumor-free mucosa. 
Unexpectedly, however, MMR-deficient and -proficient cancers significantly 
differed with regard to the subcellular localization of EWS (P<0.001):  tumor-
free colon mucosa and adenomas from LS and sporadic CRC patients as well 
as sporadic carcinomas showed exclusively nuclear expression (Fig. 6). In 
contrast, LS-related CRCs displayed diffuse cytoplasmic EWS expression 
(Fig. 6f). These results were subsequently confirmed by IHC analysis of a 
tissue microarray (TMA) containing 64 sporadic and 94 LS-related CRCs: we 
observed a reduction of approx. 30% in EWS expression in both groups, but 
only the LS-related cancers showed diffuse cytoplasmic staining for EWS 
(61% vs 3% of the sporadic cancers). Thus, MMR-deficient CRCs, all carrying 
somatic EWS16T tract alterations, display a distinct subcellular EWS 
distribution pattern in vivo. Further studies are needed to assess if this is 
directly related to EWS16T tract alterations or, rather, an indirect consequence 
of MSI-associated genetic instability affecting e.g. methyl-transferases like 
PRMT1 known to regulate the localization of EWS9 by methylating 
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Glycine/Arginine-rich motifs located in the arginine-glycine-glycine domains of 
EWS.  
In summary, EWS16T represents a novel, monomorphic MSI target locus 
which identifies both, hereditary and sporadic, MMR deficient cancers with 
100% sensitivity and specificity. The contractions at this locus affect multiple 
regulatory mechanisms including alternative polyadenylation, mRNA / protein 
expression and possibly subcellular localization thereby implicating the RNA-
/DNA-binding protein EWS, critical for the maintenance of genome integrity10, 
in MSI-associated colorectal tumorigenesis. 
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FIGURE LEGENDS 
 
Figure 1: EWS16T tract instability in MMR deficient cancers as determined by 
capillary electrophoresis of fluorescently labeled PCR products. The dotted 
line corresponds to the wild-type allele (16 T). MMR-proficient cancers (a) 
colorectal, (b) gastric; MMR-deficient cancers with expansion (c) or 
contraction of EWS16T (d-h): (c) colorectal, MSH2 germline mutation carrier, 
(d) colorectal, MSH2 mutation, (e) colorectal, MLH1 promoter 
hypermethylation, and cancers with MLH1 mutation (f-h): (f) colorectal, (g) 
gastric, (h) endometrial. 
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Figure 2: Poly(A) site selection assay through multiplexed PCR. a) Schematic 
diagram of the multiplexed semi-quantitative protocol for poly(A) site selection 
assay. A single forward primer, which was either vector specific (for analyzing 
poly(A) usage of reporter constructs) or EWSR1 -3’UTR specific (for analyzing 
endogenous EWSR1 poly(A) usage), was used along with two terminally 
anchored reverse primers to yield amplicons representing both long and short 
variants of EWSR1 3’UTR in a single PCR reaction. b) Poly(A) site usage in 
EWSR1 3’UTR constructs with variable poly(T/U) tracts lengths cloned in 
psiCHECK-2-SPAm vector along with the quantification of distal poly(A) site 
usage (percentages). c) Poly(A) site usage in endogenous EWSR1 gene 
across various MMR-deficient and -proficient cell lines. 
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Figure 3: Identification of proteins associated with the 3’UTR of EWSR1 in a 
pull down assay. A) Colloidal blue stained SDS PAGE gel showing proteins 
specifically interacting with in vitro transcribed, S1 aptamer-tagged EWSR1-wt 
or -6del 3’UTR. “No RNA” refers to the control sample where beads were 
incubated with cellular lysate without a prior incubation with RNA, allowing 
detection of any proteins interacting non-specifically with the MyOne 
Streptavidin beads. Bands specifically present in either wt or 6del lanes were 
excised and submitted to protein identification by mass spectrometry. 
Identified proteins have been labeled next to the corresponding bands.  
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Figure 3: Identification of proteins associated with the 3’UTR of EWSR1 in a 
pull down assay. B) Western blot confirming the results of mass spectrometry. 
Western blot with antibody raised against HuR (a), SFPQ (b) and NF90 (c) 
proteins. The membrane from (b) was used to reblot with anti-NF90 in (c). 
Asterix in (c) depicts the background signal from SFPQ in (b).    
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Figure 4: Knockdown of RNA binding proteins identified from pull down 
assays showing that SFPQ and hnRNPC specifically modulate poly(A) site 
usage in EWSR1 3’UTR reporter constructs. a) Western blot showing the 
knock down of the RNA-binding proteins after 72 hours. Poly(A) site usage in 
b) EWSR1-wt-psiCHECK-2-SPAm and c) EWSR1-6del-psiCHECK-2-SPAm 
reporter constructs upon knock down of RNA binding proteins. d) 
Quantification of the relative poly(A) site usage in c).   
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Figure 5: Quantitative Real-Time PCR showing EWSR1 expression in tumor 
relative to matched normal tissue. A) Difference in polyA site usage in 
endogenous EWSR1 mRNA (distal/proximal).  
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Figure 5: Quantitative Real-Time PCR showing EWSR1 expression in tumor 
relative to matched normal tissue. B) difference in total EWSR1 mRNA levels. 
Samples showing more than 1.2 fold difference are indicated with an asterix. 
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Figure 6: Immunohistochemical staining of EWS. a) Normal colonic mucosa 
from sporadic CRC patient. b) Sporadic, MMR proficient colon adenoma with 
reduced nuclear expression. c) Sporadic, MMR proficient colon 
adenocarcinoma with reduced nuclear expression. d) Normal colonic mucosa 
from Lynch syndrome-related CRC patient. e) MMR deficient colon adenoma 
with reduced nuclear expression. f) MMR deficient colon adenocarcinoma with 
reduced nuclear and diffuse cytoplasmic expression. CRC, colorectal cancer. 
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Tables 
Table 1 
Samples analyzed N MSI status EWS16T 
Status 
wildtype n 
(%) 
EWS16T Status 
contraction n (%) 
EWS16T 
Status 
expansion 
n (%) 
MMR deficient cancers 
• Colorectal 
• MLH1 deficient 
• MSH2 deficient 
• Gastric 
• MLH1 deficient 
• MSH2 deficient 
• Endometrial 
• MLH1 deficient 
• MSH2 deficient  
128 
104 
 
76 
 
28 
 
17 
 
16 
 
1 
 
7 
 
4 
 
3 
MSI-H 
MSI-H 
 
MSI-H 
 
MSI-H 
 
MSI-H 
 
MSI-H 
 
MSI-H 
 
MSI-H 
 
MSI-H 
 
MSI-H 
0 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
126 (98.4) 
102 (98.04) 
 
76 (100) 
 
26 (92.86) 
 
17 (100) 
 
16 (100) 
 
11 (100) 
 
7 (100) 
 
4 (100) 
 
3 (100) 
2 (1.6) 
2 (1.96) 
 
0 
 
2 (7.14) 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
Colon adenomas 
• Lynch syndrome-related 
• MLH1 deficient 
• MSH2 deficient 
• Sporadic 
37 
10 
 
8 
 
2 
 
27 
MSS 
MSS 
 
MSS 
 
MSS 
 
MSS 
37 (100) 
10 (100) 
 
8 (100) 
 
2 (100) 
 
27 (100) 
0 
0 
 
0 
 
0 
 
0 
0 
0 
 
0 
 
0 
 
0 
MMR proficient cancers 
• Colorectal 
• Colorectal 
• Gastric 
190 
123 
 
12 
 
55 
MSS/ MSI-L 
MSS 
 
MSI-L 
 
MSS 
190 (100) 
123 (100) 
 
12 (100) 
 
55 (100) 
0 
0 
 
0 
 
0 
0 
0 
 
0 
 
0 
 
Table 1: EWS16T tract instability in 355 cancer samples. Microsatellite 
instability was determined according to11. MMR MSI-H: MSI-high, MSI-L: MSI-
low, MSS: microsatellite stable. 
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Methods 
DNA and RNA Isolation 
To isolate genomic DNA and total RNA from cell lines and fresh/frozen tumor 
tissue samples Qiagen QIAamp DNA/RNA Mini Kit (Qiagen, Hombrechtikon, 
Switzerland) and for formalin fixed paraffin embedded (FFPE) tumor samples 
RecoverAllTM Total Nucleic Acid Isolation Kit (Ambion, Invitrogen, Carlsbad, 
CA, USA) were used according to the manufacturers' guidelines. 
 
Analysis of Microsatellite Instability (MSI)  
Microsatellite instability was assessed on two independent cohorts of patients 
encompassing 85 Lynch syndrome related cancers (78 CRCs and 7 
endometrial carcinomas), 113 sporadic CRCs, including 14 cases with MLH1 
promoter hypermethylation and 12 MMR proficient, MSI-low cancers, and a 
Finnish cohort including 8 Lynch syndrome gastric related cancers, 50 
sporadic CRCs and 64 sporadic gastric cancers. Based on the 
recommendations of the National Cancer Institute workshop on MSI, a panel 
of microsatellite loci (BAT25, BAT26, D2S123, D5S346, D17S250)12 and two 
additional microsatellite markers (BAT40, MYCL1) were used to determine 
MSI status. The 3’UTR poly T(16) tract (EWS16T) of the EWSR1 gene (Ewing 
sarcoma breakpoint region 1; RefSeq: NM_005243) was amplified by PCR 
with the following primers: 5'- AATGTTCATGGTTGTGATGT-3' (forward FAM-
labeled) and 5'-GAAGGATGACTCTTTATAA-3' (reverse). PCR products were 
analyzed on an ABI 310 Genetic Analyzer with GeneScan Analysis V 3.1 (PE 
Applied Biosystems, Foster City, CA) and Genotyper 2.0 (PE Applied 
Biosystems, Foster City, CA) software. Fragment analysis of PCR products 
allowed determination of novel alleles (expansions or contractions) within the 
repetitive tract of a given marker. The observed expansions or contractions in 
EWS16T were verified using a second set of primers covering the locus 
(Forward primer: 5’-GCATGCTCAGTATCATTGTGG-3’; Reverse primer: 5’-
AGGCCGAGAAGGATGACTCT-3’) for sequencing analysis of selected 
samples. Sequencing reactions using the Big Dye terminator chemistry 
(Applied Biosystems, Foster City, CA) were performed according to the 
manufacturer’s protocol. 
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Relative expression of EWSR1 by qPCR 
EWSR1 mRNA expression on fresh frozen tissues (8 Lynch syndrome related 
CRCs and 5 sporadic CRCs both matched with their tumor free mucosa) was 
assessed using the TaqMan® Probe-Based Gene Expression Analysis 
(Applied Biosystems, Foster City, CA), and the EWSR1 probe 
Hs01580532_g1 (Applied Biosystems, Foster City, CA). The measurements 
were normalized using the HPRT1 probes Hs01003270_g1 (Applied 
Biosystems, Foster City, CA)13,14, and the fold-changes in gene expression 
were calculated using the standard ΔΔCt method15. All retrotranscriptase 
reactions, including no-template controls, were run on an Applied Biosystem 
7900HT thermocycler. Each sample was tested in triplicate unless specified 
otherwise. 
 
Immunohistochemistry 
Several cohorts of patients were studied by immunohistochemical analysis of 
EWS. Briefly, the tissue samples of the following cohorts of patients were 
analysed: 37 colon adenoma (9 of which Lynch syndrome related), 19 CRCs 
(10 of which Lynch syndrome related) and a tissue microarray16. Patient data 
including complete follow-up were obtained by retrospective analysis of 
medical records, regional tumor registries and/or treating physicians. Tissue 
samples were obtained by surgical or endoscopic excision. Tissues sections 
of 4 µm sections of paraffin embedded tissue were immunostained for primary 
antibody against EWS (Abcam clone 84389 dilution 1:800). Staining was 
carried out as previously described17. Immunoreactivity was scored semi-
quantitatively by evaluating the number of positive tumor cells over the total 
number of tumor cells. Nuclear immunoreactivity scores were assigned using 
5% intervals and ranged from 0% to 100%. Regarding cytoplasmic 
expression, the staining intensity was scored as described by Allred et al.18. 
All samples were examined independently by three different pathologists 
(S.P., F.T. and L.T.), blinded to clinicopathological and molecular genetic 
information.  
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Cell lines 
Five colorectal cancer cell lines from the American Type Culture Collection 
(ATCC, Rockville, MD) were used for this study: four three repair deficient cell 
lines (HCT116, LoVo, HCT15) and two mismatch repair proficient (SW480 and 
HT29). HCT116, HCT15, cells (ATCC, Rockville, MD) were cultured in RPMI 
1640 (Invitrogen Basel, Switzerland) supplemented with 10% fetal bovine 
serum FBS, 1% Kanamycin sulphate, 1% GlutaMAX-I, 1% Sodium Pyruvate, 
1% non Essential Amino Acids (NEAA), 1% HEPES (all from Invitrogen Basel, 
Switzerland) and 0.1% 2-mercapto-ethanol (Sigma-Aldrich Basel, 
Switzerland). HT29 cells were grown in McCoy's 5A Medium (Invitrogen 
Basel, Switzerland) with 10% fetal bovine serum FBS, Kanamycin sulphate 
and GlutaMAX-I (all from Invitrogen Basel, Switzerland). SW480 cells were 
cultured in L-15 Medium (Sigma-Aldrich Basel, Switzerland) with 10% FBS, 
1% GlutaMAX-I and 1% Kanamycin sulphate (all from Invitrogen Basel, 
Switzerland). Cells were maintained at 37°C with 5% CO2.  
HeLa cells at earlier passages were cultured in DMEM with GlutaMAX 
(Invitrogen) supplemented with 10% fetal bovine serum FBS. Cells were 
maintained at 37°C with 5% CO2. 
 
Plasmids and antibodies  
Synthetic poly(A) site of Renilla luciferase gene in dual luciferase psiCHECK-2 
vector was mutated using primers psi-ck2polyAmutF: 5’-
GCGGCCGCTGGCCGCAGCTAAATATCTTTATTTTCA-3’ and psi-
ck2polyAmutR: 5’-TGAAAATAAAGATATTTAGCTGCGGCCAGCGGCCGC-3’ 
using QuikChange™ Site-Directed Mutagenesis Kit as per manufacturer’s 
instruction to generate psiCHECK-2-Synthetic polyA mutant (psiCHECK-2-
SPAm). EWSR1 3’ UTR was PCR amplified from HEK293 genomic DNA 
using primers EWSR1_xhoIF: 5’-
CCGACTCGAGCGGCCCTACTAGATGCAGAG-3’ and EWSR1_notIR: 5’-
ATAAGAATGCGGCCGCGAACCAACCGTTTACCTGGA-3’. The PCR 
amplicons were cloned into pGEM-T Easy and subsequently subcloned into 
psiCHECK-2-SPAm using XhoI and NotI restriction site to generate EWSR1-
wt-3’UTR/psiCHECK-2-SPAm reporter. Mutant constructs with U deletions 
(EWSR1-2/3/4/5/6 del-3’UTR/psiCHECK-2-SPAm) and insertions (EWSR1-
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2/4/ins-3’UTR/psiCHECK-2-SPAm) were introduced using standard overlap 
extension PCRs.  
Antibodies for Western blots against NF90, SFPQ and HuR were obtained 
from Santacruz Biotech and Antibody against EWSR1 for Western blots and 
Immunoprecipitation were obtained from Abcam.    
 
In vitro transcription 
In-vitro transcription for pull down assay using S1 aptamer was performed 
using T7 RiboMAX™ Express Large Scale RNA Production System 
(Promega) as per manufacturer’s instructions. Region flanking the wt- and 
deleted poly T/U tracks in the 3’UTR of EWSR1 constructs was amplified 
using primers T7_EWSR1_IVT_Cf: 5’-GCTTCTAATACGACTCACT 
ATAGGGAGAAATGGGAACCCCTTGTGAG-3’ and EWSR1_IVT_Cr: 5’-
GAACAGAGGCCGA GAAGGAT-3’ to introduce T7 promoter sequences at 
the 5’ end of the amplicons. S1 aptamer sequence was introduced at the 3’ 
end using another round of PCR using T7_EWSR1_IVT_Cf: 5’-
GCTTCTAATACGACTCACTATAGGGAGAAATGGGAACCCCTTGT GAG-3’ 
and EWSR1_S1apt_IVT_Cr: 5’-
CATGGCCCGGCCCGCGACTATCTTACGCACTTG CATGATTC 
TGGTCGGTCCCATGGATCCGAACAGAGGCCGAGAAGGAT-3’.  
 
Protein Pull-Down Assay 
For each sample, 100ul of the MyOne Streptavidin Dynal beads (Invitrogen) 
was washed twice with one bead volume of solution A (DEPC-treated 0.1 M 
NaOH, DEPC-treated 0.05 M NaCl) and once with one bead volume of 
Solution B (DEPC-treated 0.1 M NaCl) and once with RNA binding buffer. The 
beads were resuspended in one bead volume of RNA binding buffer (100mM 
NaCl, 50mM Hepes 7.5, 0.5% NP-40 and 10mM MgCl2) with 100ug of in-vitro 
transcribed RNA with S1 aptamer sequence and incubated at 10°C for 40 
minutes in a thermomixer with intermittent shaking. The beads were washed 
twice with one volume of RNA wash buffer prior to incubation with the lysate. 
HEK293 cell pellet from 15cm2 dish was lysed in 3ml native lysis buffer (25mM 
Hepes-KOH pH 7.5, 100mM KCl, 0.5% NP-40, 5mM MgCl2, 0.5mM DTT , 
protease inhibitor cocktail, 1mM NaF, 1 mM Na4VO4 and 300U of RNasin) for 
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15 minutes on ice. The lysate was subsequently gently sonicated and 
centrifuged to remove any cell debris. 200ug of E. coli tRNA was additional 
added to prevent non-specific binding of proteins to the beads. 1 ml of the 
lysate was added to the beads coupled to S1 aptamer RNA and also to the 
beads alone for no RNA control. The mixture was incubated at 4C on 
rotation wheel. After 1 hour of incubation, the beads were washed thrice with 
with Native lysis buffer. The bound proteins were eluted with 100ul Native lysis 
buffer supplemented with 25mM Biotin for 30-45 minutes at 10°C on a 
thermomixer with intermittent shaking. 900ul of 100% ethanol was added to 
the eluate and incubated at -80°C for 2 hours followed by centrifugation to 
precipitate the eluted proteins. The pellet was air dried and dissolved in 35ul of 
(SDS loading dye). Prior to loading on the Nuvex gradient gels, the samples 
were heated at 90°C for 5 minutes. After SDS-PAGE electrophoresis, the gel 
was stained with colloidal blue and bands of interest were excised and sent for 
mass spectrophotometry. 
 
Poly(A) site selection assay 
HeLa cells were transfected with psiCHECK-2-SPAm constructs for 24 hours. 
Total RNA was isolated from the HeLa cells using TriReagent (Sigma) 
followed by DNAse I (Promega) treatment according to the manufacturer’s 
protocol. Reverse transcription was done with oligo d(T)18 primers for 1 hour. 
For poly(A) site selection assay, multiplexed polymerase chain (PCR) reaction 
was set up using a single forward primer specific to the psiCHECK-2 vector 
(psiCHECK-2-SeqFor: 5’-ATGAAATGGGTAAGTACA-3’) and two 4 nucleotide 
terminally anchored oligo d(T)16 reverse primers specific to the two isoform 
variants of EWSR1 (EWSpolyAproxR: 5’-TTTTTTTTTTTTTTTTACCA-3’ and 
EWSpolyAdistR: 5’-TTTTTTTTTTTTTTTTGACT-3’ respectively) to detect only 
the isoforms generated specifically from the psiCHECK-2-SPAm constructs. 
PCR was run for 28 cycles and the products were separated on a 2 % 
Agarose gel. The bands were quantified using the ImageJ software 
(http://rsbweb.nih.gov/ij/).     
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Luciferase assays 
HeLa cells were seeded in a 48 well plate one day prior to transfection. 0.2ug 
of plasmids (psiCHECK-2-SPAm constructs) were transfected with 
Lipofectamine 2000 (Invitrogen) for 24 hours. Luciferase assays were done on 
the transfected cells using The Dual-Luciferase® Reporter Assay System 
(Promega). Both transfections and luciferase assays were done according to 
the manufacturer’s protocol.  
 
siRNA transfections 
Control-siRNAs and siRNAs against hnRNPC, HuR, NF90 and SFPQ and 
were obtained from Santa Cruz Biotechnology. HeLa cells were reverse 
transfected with siRNA oligos using RNAiMAX (Invitrogen). After 48 hours the 
cells were transfected with EWSR1-wt-3’UTR- and EWSR1-6del-3’UTR-
psiCHECK-2-SPAm-constructs for another 24 hours. The cells were 
subsequently harvested and split into two aliquots. One aliquot was used to 
assess the knockdown efficiency of siRNA using Western blot, while the other 
was used for RNA isolation and subsequent poly(A) site selection assay.  
 
 
 
Statistical Analyses 
For statistical analysis, the chi-square test (χ2 test) and Fisher's exact test for 
nonparametric variables and Student’s t-test for parametric variables were 
used, with all probabilities reported as 2-tailed, considering a P<0.05 to be 
statistically significant. Calculations were performed using the software 
program SPSS 17.0 (IBM Corporation, Somers, NY 10589). 
 
Ethical approval 
The study is part of the so-called “Basler Studie über familiaere 
Tumorkrankheiten”, Ref.Nr.EK: 258/05 and has been approved by the 
“Ethikkommission beider Basel”. Furthermore, written informed consent was 
obtained from all Lynch syndrome patients as well as from the sporadic 
patients. 
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Supplementary figures and legends 
Supplementary Figure 1 
 
 
Supplementary Figure 1: Immunohistochemical staining of DNA mismatch 
repair proteins MLH1, MSH2, MSH3, MSH6 and PMS2 in an extra-osseous 
Ewing sarcoma of a MSH6 mutation carrier demonstrating selective loss of 
MSH6 expression. 
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Supplementary Figure 2 
 
 
Supplementary Figure 2: Representative extract from fluorescence in situ 
hybridization (FISH) analysis of the MHS6–related extra-osseous Ewing 
sarcoma specimen using an EWSR1-specific break-apart probe (Poseidon™ 
probe KI-10708 EWS Break). Screening of 200 nuclei gave no evidence for 
the presence of a rearrangement involving the 22q12 locus (i.e. no evidence 
for any split red-green signals). 
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Supplementary Figure 3 
 
Supplementary Figure 3: Frequency distribution of EWS16T repeat 
alterations in 128 MMR deficient cancers (104 colorectal, 17 gastric and 7 
endometrial cancers). Numbers on top of the bars represent percentages. The 
dotted line corresponds to the wild-type allele (T)16. 
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Supplementary Figure 4 
 
Supplementary Figure 4: The 3’UTR of the EWSR1 gene harbors two 
poly(A) signals resulting in the generation of EWSR1 isoforms with short and 
long UTRs. a) Reads (per million) obtained from poly(A) seq7 showing the 
location of the two polyA sites in HEK293 cells, with the proximal poly(A) site 
being predominantly used over the distal. b) Schematic diagram showing the 
location of the EWS16T tract with respect to the distal poly(A) signal 
(AAUAAA), and the binding specificity of important 3’ end processing factors.    
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Supplementary Figure 5 
 
Supplementary Figure 5: Schematic diagram depicting essential steps of the 
protein pull down assay using in vitro transcribed S1 aptamer-tagged RNA. 
For a more detailed protocol please refer to the Materials and Methods section 
of the manuscript.  
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Supplementary Figure 6 
 
Supplementary Figure 6: Luciferase assay showing the changes in Renilla 
luciferase protein expression from psiCHECK-2-SPAm constructs harboring 
different EWS16T tract deletion variants in its multiple cloning site. The signals 
are normalized against internal Firefly luciferase.   
 
 
 
 
 
 
 
 
 
 	
  
6.2 The 8p21.3 encoded SHOCA-2 acts as a tumor suppressor 
in colorectal cancer via repression of STAT3 activation. 
 
My contribution to this work: 
• DNA extraction from sporadic colorectal cancers; 
• SH2D4A mutation analysis by Sanger sequencing of CRC samples; 
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• Loss of heterozygosity analyses on the CRCs; 
• Quantitative real time PCR experiments; 
• Immunohistochemical analysis of CRC whole tissue and microarray 
sections; 
• Statistical and Data analysis; 
• Manuscript writing  
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Summary  
Chromosomal deletions at 8p have been associated with colorectal cancer 
(CRC), but the tumor suppressor function affected has not been described. 
Here, we identify SH2D4A as a suppressor of CRC mapping to 8p21.3. 
SH2D4A encodes SHOCA-2, a SH2 domain-containing adapter protein that, 
upon EGF signaling, interacts with the serine/threonine phosphatase PP1b 
and consequently inhibits STAT3 activity. Conversely, knock-down of SHOCA-
2 stimulates c-Myc, Cyclin D1 and Jun B expression and accelerates CRC 
growth through unopposed STAT3 activity. Loss of SHOCA-2 expression in 
CRC correlates with advanced disease stages and poor prognosis and is 
caused by chromosomal rearrangements, point mutations and epigenetic 
changes. Thus, SHOCA-2 functions as an inhibitor of the EGFR pathway and 
its absence impacts on CRC development and progression. 
 
 
Significance 
Colorectal cancer (CRC) yearly claims more than 655,000 lives worldwide and 
represents the third most frequent cause of death in the Western world. 
Though a 8p21-23 chromosomal deletion has been linked to CRC 
development and progression, the molecular mechanisms related to this 
genomic region have not been recognized to date. Encoded on 8p21.3, the 
SH2 domain-containing SHOCA-2 protein represents a hitherto unrecognized 
CRC tumor suppressor that limits cell proliferation via a negative feedback 
loop controlling EGFR signaling. Consequently, a loss of SHOCA-2 
expression results in the oncogenic activation of STAT3, a hallmark of many 
CRC. Since drugs inhibiting EGFR and STAT3 activity offer only limited 
efficiency, enhancing SHOCA-2 function constitutes a novel insight for the 
treatment of CRC. 
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Introduction 
Oncogene activation and loss of tumor suppressor activity are responsible for 
cancer initiation and progression (Vogelstein and Kinzler, 2004). 
Overexpression of the epithelial cell growth factor receptor (EGFR) is 
frequently observed in colorectal cancer (CRC), and correlates with a poor 
clinical outcome (Saif, 2010). EGFR is receptor tyrosine-kinase that relays its 
activation through the signal transducer and activator of transcription 3 
(STAT3) to the nucleus controlling the transcription of genes involved in cell 
proliferation and survival (Aggarwal et al., 2009). Constitutive activation of the 
STAT3 signaling pathway as a consequence of genetic mutation is oncogenic, 
and a hallmark of many CRC (Bromberg et al., 1999; Klampfer, 2008). 
Genetic and epigenetic alterations in the expression of tumor suppressor 
genes are typical features of neoplastic transformation and contribute to both 
initiation and progression of tumor formation (Weinberg, 1991; Vogelstein and 
Kinzler, 2004). The loss of heterozygosity (LOH) across variable parts of 
chromosome 8p has been identified as a frequent abnormality associated with 
CRC (Emi et al., 1992) and linked to DNA breakage at fragile sites located at 
8p12 and 8p22 (Birnbaum et al., 2003). Although predicted from chromosome 
transfer studies (Tanaka et al., 1996), specific tumor suppressor genes have 
to date not been identified in this critical chromosomal region. It is thus 
unknown how genetic alterations in 8p contribute to CRC development and 
progression. 
Here we report on the identification of a new tumor suppressor, termed 
SHOCA-2. Encoded on 8p21.3, SHOCA-2 interacts with the serine/threonine 
phosphatase PP1b and consequently inhibits STAT3 activity to control EGFR 
signaling. Moreover, we characterize the genetic and epigenetic mechanisms 
that result in a silencing of SHOCA-2 in CRC.  
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Results 
Identification of SHOCA-2 and its loss of expression in colorectal cancer 
cDNA Representational Difference Analysis (cDNA-RDA) comparing epithelial 
cells at two sequential stages of embryonic maturation identified transcripts of 
a previously uncharacterized gene, designated SH2D4B (NCBI gene ID 
387694; S.Z. and G.H., unpublished data). Homology searches identified 
SH2D4A as a paralogue (NCBI gene ID 63898; Figure 1A). Both genes are 
evolutionary conserved (Figure S1A) and ubiquitously expressed, with 
SH2D4A being significantly more abundant than SH2D4B (Figure S1B). The 
proteins encoded by SH2D4A and SH2D4B display 65% amino acid 
sequence identity at their C- and N-termini and share several structural motifs 
including three coiled-coil domains in the middle of the molecule and a Src 
homology (SH2) domain at the C-terminal end (Figure 1A; Figure S1C). It is 
for these motifs and the putative function as an adaptor that we named this 
family of proteins SHOCA, an acronym for SH2-domain containing adaptor 
protein. 
 
SH2D4A maps to human chromosome 8p21.3 (Figure 1A) and encodes 
SHOCA-2. Because the chromosomal region surrounding SH2D4A (8p21-23) 
is frequently lost in CRC and other epithelial tumors (Emi et al., 1992), we 
determined by immunohistochemistry the expression of SHOCA-2 in 400 
consecutive, sporadic CRCs (Figure S1D). The significant differences in 
detectable SHOCA-2 protein correlated with the separate clinical tumor stages 
(I-IV) (Figures 1B and 1C; Table S1A and S1B); SHOCA-2 expression was 
reduced or lost of with advanced CRC pathology. Patients with tumors 
displaying either low or absent SHOCA-2 expression had a poorer outcome 
(log-rank test p=0.0118; Figure 1D; Table S1C) though SHOCA-2 expression, 
when stratified by disease stage, did not serve on its own as a strong 
predictor of survival. An identical conclusion was drawn from a Cox regression 
analysis (p=0.0134 with HR (95%CI)=0.56 (0.35-0.89) and a Wilcoxon test 
(p=0.0133) (Table S1C). Gene expression data available in public databases 
for carcinomas of different origin including bladder, breast, head and neck, 
esophagus, liver and ovary suggested similar correlations between disease 
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stage and SHOCA-2 expression (Figure S1E). Finally, further analysis of 
SHOCA-1 expression (mRNA levels) in CRC samples with absent or reduced 
SHOCA-2 expression revealed a concurrent loss of SHOCA-1 in 
approximately half of the samples whereas SHOCA-1 loss was neither 
observed in healthy mucosa nor in CRC tissues proficient for SHOCA-2 
(Figure S1F).  
 
Genetic and epigenetic alterations of the SH2D4A locus in CRC 
To determine the molecular basis for decreased SHOCA-2 expression, we 
chose from an unselected cohort of 70 CRC patients 27 subjects with 
SH2D4A alleles that could be distinguished by microsatellite markers and 
SNPs (Figure S1D). In 17 of these (63%), the primary tumor had lost or 
diminished SHOCA-2 expression whereas only 3 samples (11%) displayed an 
EGFR gene amplification. A loss of the SH2D4A gene and a simultaneous 
amplification of EGFR were noted in 2 out of these 3 individuals. This result is 
in accordance with the observation that EGFR over-expression in CRC is 
rarely caused by EGFR gene amplification (Saif, 2010). Using 3 flanking 
microsatellite markers and 6 gene-specific SNPs (Figure S2A), we detected 
LOH at SH2D4A in 7 of the 17 tumors (41%). Gene dosage quantification of 
the short arm of chromosome 8 indicated mono- and biallelic deletions in 6 
and 1 of these LOH tumors, respectively (Figure 2A). When normal mucosa 
was examined, four of the six patients with a monoallelic SH2D4A loss in 
tumor tissue were heterozygous for the intronic SNP rs17128221 (c.342-
5T>C). This SNP is located in a mRNA splice acceptor site and causes non-
canonical exon 4 skipping, which in turn causes a translational frame shift and 
premature termination in exon 5 (Figure 2B). Consistent with a pathological 
effect, the cancer tissue of patients heterozygous for the C allele uniformly 
demonstrated a selective loss of the T allele (Chi square p=0.006) whereas 
homozygosity for the C allele was never observed in mucosa tissue samples 
of 83 healthy Caucasian individuals (Figure 2B). 
 
Missense mutations and deletions in the SH2 domain of SHOCA-2 were 
observed in three of the 10 SH2D4A biallelic CRC samples characterized by a 
low or absent SHOCA-2 expression. These alterations either produced single 
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amino acid changes (p.Arg324Trp and p.Ser430Phe) with predicted structural 
effects (Polyphen-2 score of >0.95, SIFT score<0.02), or caused a 
translational frame shift (p.Ile378fsX15) giving rise to a loss of amino acids 
377 to 454 and reduced protein expression (Figure 2C).  
 
To determine causes for low or absent SHOCA-2 expression other than 
LOH and gene mutations, we next analyzed primary CRC tissue and 
surrounding healthy mucosa for DNA cytosine methylation in the 5’ 
untranslated region (5’UTR) of SH2D4A (Figure 2D). Pyrosequencing of 
bisulfite-converted genomic DNA (Bettstetter et al., 2007) revealed two 
specific CpG dinucleotides showing increased methylation in cancer tissue 
when compared to matched normal mucosa. One of these CpGs is within a 
canonical Sp1 transcription factor recognition motif and its methylation 
significantly reduced the Sp1 binding affinity (Figure S2B). Epigenetic 
changes at the DNA level may therefore represent another cause for reduced 
SH2D4A gene expression in CRC. Taken together, in 15 of 17 CRCs 
investigated in molecular detail (Figure 2E), distinct genetic and epigenetic 
alterations explaining the loss or reduction in SHOCA-2 expression could be 
identified: chromosomal deletions at 8p21.3, genetic mutations in the SH2D4A 
gene, a mRNA splicing defect associated with a specific SNP, and site-
specific changes in promoter DNA methylation.  
 
SHOCA-2 negatively regulates EGF-induced STAT3 phosphorylation and 
transcriptional activity  
A proteomic analysis of phospho-tyrosine signaling in non-small-cell lung 
cancer cell lines driven by EGFR-activating mutations identified a target 
peptide with sequence homology to SHOCA-2 (Guo et al., 2008). We 
confirmed that EGFR activation triggered tyrosine phosphorylation of SHOCA-
2 in HeLa cells (Figure 3A). To investigating a potential involvement of 
SHOCA-2 in the activation of the downstream EGFR effectors STAT3, ERK 
and PI3K-Akt, we stimulated HeLa cells with EGF. The ectopic expression of 
SHOCA-2 in these cells specifically decreased the STAT3 phosphorylation at 
Tyr705 (Figure 3B). The phosphorylation of this residue constitutes an 
important post-translational modification of STAT3 as it triggers its 
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dimerization, nuclear translocation and DNA binding (Heinrich et al., 2003). By 
contrast, the relative level of Akt phosphorylation was increased whereas the 
MAP kinase pathway remained unaffected in EGF simulated HeLa cells 
(Figure S3A). Because SHOCA-2 had previously been suggested to be 
associated with the ER alpha/PKC signaling pathway (Li et al., 2009), we 
were unable to observe in ERa-negative HeLa cells (Arao et al., 2011) 
overexpressing SHOCA-2 a change in PKC phosphorylation further 
confirming the regulation of PKC by SHOCA-2 to be dependent on ERa 
(Figure S3B). 
 
To analyze EGF signaling in cells with reduced SHOCA-2 levels, we 
generated short hairpin RNA (shRNA) expressing HeLa cell clones in which 
SHOCA-2 protein was knocked down by 90% (SHOCA-2 KD; Figure 3C). 
When stimulated with EGF, the extent of STAT3 phosphorylation at tyrosine 
705 (Tyr705) and serine 727 (Ser727) was inversely correlated with the SHOCA-
2 protein level (Figure 3C). In keeping with a significant increase in 
phosphorylated STAT3, the transcription of the c-Myc, Jun B and Cyclin D1 
was enhanced (see below). In contrast, the phosphorylation of AKT was 
decreased while that of ERK 1/2 remained unchanged in SHOCA-2 KD cells 
(Figure S3C). These results further corroborated the specific involvement of 
SHOCA-2 in STAT3-mediated signaling following EGF stimulation. 
 
Using a STAT3-driven luciferase reporter assay (Kreis et al., 2007), we 
next examined in HeLa cells whether STAT3 transcriptional activity was 
altered in the presence of decreased or increased SHOCA-2 protein levels. As 
demonstrated in Figure 3D, EGF treatment of HeLa cells with a significant 
loss of SHOCA-2 expression (SHOCA-2 KD cells) resulted in a robust 
transcriptional activity. In contrast, the transcription of the luciferase reporter 
was significantly reduced in HeLa cells overexpressing SHOCA-2 and 
exposed to EGF (Figure 3D; Figure S3D). To investigate the nature of 
SHOCA-2’s influence on STAT3, we also tested porcine aortic endothelial 
cells (PAE) that lack endogenous EGFR expression and mouse embryonic 
fibroblasts (MEF) rendered deficient for STAT3 expression (Huang et al., 
2007; Costa-Pereira et al., 2002). In these cells, SHOCA-2 bound to STAT3 
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and EGFR and this interaction was always independent of the missing binding 
partner normally present in wild type cells (Figure 3E, Figure S3E). Moreover, 
the binding of SHOCA-2 to EGFR and STAT3 was unrelated to its SH2 
domain (Figure S3F) and isoform-specific because SHOCA-1 did not 
physically bind to STAT3 (Figure S3G). Taken together, these results suggest 
that SHOCA-2 inhibits EGF-induced STAT3 activation through its physical 
association with both EGFR and STAT3 independently of its SH2 domain. 
 
 
SHOCA paralogues bind PP1b  
Using tandem affinity purification (TAP) and reciprocal immunoprecipitation, 
we and others (Ewing et al., 2007) identified the serine/threonine Protein 
Phosphatase-1 beta (PP1b) as an interaction partner of SHOCA-1 and 
SHOCA-2 (Figure 4A; Figures S4A-C; Table S2). The eukaryotic PP1 protein 
family is composed of the 3 isoforms a, b and g, whose functionality relies on 
the association with different regulatory proteins (Ceulemans and Bollen, 
2004). Both SHOCA paralogues bound PP1b but neither PP1a or PP1g, 
demonstrating an isoform-specific interaction (Figure 4B). Confocal 
immunofluorescence microscopy and immunoprecipitation of PP1b from 
cytoplasmic and nuclear protein fractions detected the SHOCA-2-PP1b 
interaction in both subcellular compartments further confirming their physical 
association (Figure S4D). 
 
The [RK]-X(0,1)-[VI]-{P}-[FW] sequence has previously been identified as 
a PP1-interacting motif (Hendrickx et al., 2009). We therefore tested whether 
the KXILF and KX[VI][QH]W sequences located in the N-terminus of SHOCA-
1 and -2 may mediate such binding (Figure 4C left panel; Figure S4E). Site-
directed mutagenesis was used to alter in the SHOCA isoforms the first motif 
from KXILF to AXALA (designated PP1Mut1) and the second sequence from 
KX[VI][QH]W to AXA[QH]A (PP1Mut2; Figure 4C). Overexpression of SHOCA 
mutant proteins in HEK293 cells demonstrated that only the PP1Mut2 proteins 
failed to interact with PP1b identifying the KX[VI][QH]W sequence as the 
relevant docking site (Figure 4C, middle and right panels). 
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STAT3 inhibition by SHOCA-2 requires EGF-induced phosphorylation of 
Tyr131 and the recruitment of PP1b 
We next investigated whether EGFR and/or STAT3 could pre-associate with 
SHOCA-2 independently of any EGFR stimulation, or, alternatively, whether 
these interactions required an activation-induced phosphorylation of the 
individual binding partners. Immunoprecipitation experiments showed that 
SHOCA-2-flag and endogenous EGFR, STAT3 and PP1b  co-precipitated in 
serum starved, unstimulated HeLa cells independent of prior EGF stimulation 
(Figure 4D). Following EGF activation, the association of SHOCA-2, STAT3 
and PP1b significantly increased in HeLa cells (Figure 4D). Although STAT3 
can be indirectly activated through c-SRC (Quesnelle et al., 2007), c-SRC was 
not associated with the SHOCA-2, STAT3 and PP1b  complex demonstrating 
a SHOCA-2-related, direct inhibition of STAT3 that was independent of a c-
SRC engagement (Figure S4F). 
 
Following EGF stimulation, STAT3 is recruited to the phospho-sites 
Tyr1068 and Tyr1086 within EGFR (Shao et al., 2003). However, in Figure 4D, 
we demonstrated that EGFR and STAT3 associated prior to EGFR-mediated 
stimulation. To further characterize this interaction, unstimulated HeLa cells 
were transfected with mutant forms of either EGFR or STAT3. The EGFR 
mutant had its Tyr1068 and Tyr1086 replaced by phenylalanine (EGFR 
Y1068/1086F) and hence lost a motif known for classical STAT3 recruitment 
(Shao et al., 2003), whereas Tyr705 was replaced in the STAT3 mutant to a 
phenylalanine thus eliminating several essential functions including STAT3 
dimerization, translocation to the nucleus and transcriptional activity (Heinrich 
et al., 2003). Neither the association of mutant EGFR with wild type STAT3 
nor the interaction of altered STAT3 with EGFR were affected by these 
changes (Figure S4G), thus demonstrating that EGFR’s Tyr1068/Tyr1086 and 
STAT3’s Tyr705 were not critically important for the interaction with each other 
(Figure S4G). The latter finding is in accordance with a pTyr705 independent 
recruitment of STAT3 to the IL-22 receptor, an interaction that however 
requires the coiled-coil domain of STAT3 (Dumoutier et al., 2009).  
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Because EGF-stimulation resulted in Tyr131 phosphorylation of SHOCA-2 
(Figure 3A and (Guo et al., 2008)), we next examined whether this 
modification is essential for the formation of the SHOCA-
2/EGFR/STAT3/PP1b complex and its function. Though changing the tyrosine 
residue to alanine (Y131A) did not disturb SHOCA-2’s ability to complex with 
EGFR, STAT3 and PP1b (Figure S4H), the point mutation resulted in a 
constitutive phosphorylation of other SHOCA-2 tyrosine residues and an 
insensitivity to EGFR signal-mediated inhibition of STAT3 tyrosine 
phosphorylation (Figure S4I). The regulation of STAT3 activity by EGFR is 
therefore critically dependent on the phosphorylation of SHOCA-2’s Tyr 131. 
 
We next characterized in further detail the conditions under which SHOCA-
2 can bind to its partners. Since both wild-type and PP1b interaction-deficient 
SHOCA-2 variants formed a complex with EGFR/STAT3 (Figure S4H), PP1b 
binding does not appear to be a prerequisite for the association of SHOCA-2 
with STAT3. However, the inactivation of STAT3 was dependent on SHOCA-
2’s ability to associate with PP1b as the overexpression of SHOCA-2 PP1Mut2 
failed to alter STAT3 Tyr705 phosphorylation following EGF stimulation (Figure 
4E). Consequently, STAT3-dependent transcription in a reporter assay was 
not diminished in HeLa cells overexpressing SHOCA-2 PP1Mut2 that had been 
treated with EGF  (Figure 4F). SHOCA-2 thus binds to the EGFR/STAT3 
complex independently of PP1b, but requires the association with the 
phosphatase to modulate STAT3 activity. 
 
SHOCA-2 requires PP1b to inhibit STAT3-dependent tumor cell growth 
To address the contribution of SHOCA-2 to cellular growth control, we 
assessed the expression of STAT3-controlled cell proliferation genes 
(Aggarwal et al., 2009; Trenerry et al., 2007) in HeLa cells expressing reduced 
levels of SHOCA-2 (SHOCA-2 KD). The increase of c-Myc, Cyclin D1 and Jun 
B transcripts in these cells upon EGF stimulation inversely correlated with a 
robust reduction in SHOCA-2 expression (Figure 5A, left panel). 
Consequently, the fraction of cells in G2/M of the cell cycle was significantly 
higher in both unstimulated (8.8% vs. 5% G2/M cells [p<0.0002]) and EGF 
activated SHOCA-2 KD HeLa cells (21.2% vs. 9.4% G2/M cells, [p<0.004]) 
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when compared to wild type controls (Figure 5A, right panel). A significantly 
increased cell proliferation (Ki-67 positivity) and higher levels of c-Myc, Jun B, 
and Cyclin D1 transcripts were also detected in tissue sections of clinically 
advanced CRC further confirming an inverse correlation between SHOCA-2 
expression and STAT3 mediated cellular responses (Figure 5B; Figure S5A). 
A decrease in SHOCA-2 expression therefore promotes the transcription of 
cell proliferation factors that in term drive cell cycle progression. 
 
To determine the molecular mechanism by which SHOCA-2 suppresses 
cell proliferation, we next transfected the colorectal cancer cell line SW480 to 
over-express STAT3 alone or in combination with either wild-type or mutant 
SHOCA-2. In a colony formation assay, overexpression of only STAT3 
significantly increased the number of colony forming units (Figure 5C), a 
response that correlated with a higher degree of STAT3 phosphorylation 
(Figure 5D). Overexpression of STAT3 together with wild-type SHOCA-2 
significantly reduced the colony forming potential of SW480 cells as well as 
STAT3 phosphorylation. This growth suppressive effect was less pronounced 
when SHOCA-2 mutants deficient in either PP1b interaction (SHOCA-2 
PP1Mut2) or Tyr131 (Y131A) phosphorylation were co-overexpressed instead 
(Figure 5C). Comparable results using the overexpression of wild type and 
mutant SHOCA-2 were obtained in the adenocarcinoma cell line H1975 which 
expresses an EGFR mutation constitutively activating STAT3 (Figure S5B) 
(Lu et al., 2007). Consistent with a role of SHOCA-2 in suppressing STAT3-
mediated cell growth, SW480 cells in which SHOCA-2 expression was 
knocked down by shRNA diminished their proliferation rate upon exposure to 
pharmacological inhibition of STAT3 by S31-201, a chemical probe blocking 
STAT3-STAT3 complex formation and STAT3-DNA binding (Figure S5C). 
Finally, overexpression of SHOCA-2 in a CRC cell line (SW620) with 
constitutive STAT3 phosphorylation (Maa et al., 2007) and spontaneously low 
endogenous SHOCA-2 expression (Figure S5D) suppressed anchorage-
independent cell growth (Figure 5E). Taken together, these results 
demonstrate under different experimental conditions that SHOCA-2 acts as a 
suppressor of STAT3-driven cancer cell proliferation. 
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Downregulation of SHOCA-2 alters the cell phenotype and promotes in 
vivo tumor growth  
The cobble-stone shape of SW480 cells, which usually express high 
endogenous SHOCA-2 levels, changed to a spindle-like morphology following 
the knock-down of SHOCA-2 transcripts (Figure 6A, Figures S5D and S6A). 
This change in cell shape was paralleled by features of epithelial-
mesenchymal transition (EMT) (Christofori, 2006) such as a reduction in E-
cadherin and an increase in N-cadherin, vimentin, SNAIL and ZEB1 
expression (Figure 6B). These alterations were, however blocked by the 
inhibition of EGFR using Tyrphostin (AG1478; Figure S6B). Moreover, 
SHOCA-2 deficient SW480 cells proliferated at a greater rate and displayed a 
higher sensitivity to EGFR inhibition when compared to mock transfected 
controls (Figure 6C). Re-establishing mouse Shoca-2 expression in human 
SHOCA-2 deficient SW480 cells however decreased their proliferation rate 
(Figure 6D), thus demonstrating again that SHOCA-2 controls STAT3-
mediated tumor growth.  
 
To establish an in vivo role for SHOCA-2 as a tumor suppressor, SW480 cells 
that had their SHOCA-2 expression either knocked-down or left unchanged 
were transplanted into nude mice. Grafts with cells where SHOCA-2 was 
reduced displayed a significant increase both in tumor incidence and size 
when compared to control transplants (Figure 6E). Moreover, significant levels 
of phosphorylated, nuclear STAT3 were detected in tumors that had emerged 
from grafted cells lacking regular SHOCA-2 expression (Figure 6F, upper left 
panel). Consistent with this experimental finding, increased STAT3 
phosphorylation at residues Tyr705 and Ser727 (Figure 6F, upper right and 
lower panels) were also detected in the majority of CRC biopsies with low 
SHOCA-2 expression (H-score <100). Taken together, experimental in vivo 
tumor models using CRC cell lines and the detailed analysis of biopsies taken 
from CRC patients identified the inhibitory role of SHOCA-2 on STAT3 
activation.  
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Discussion 
Genomic deletions within the 8p21-23 region constitute a characteristic 
cytogenetic feature of CRC (Emi et al., 1992) and have been linked to 
carcinogenesis (Macartney-Coxson et al., 2008). How deletions in this 
chromosomal region contribute to CRC development has remained unclear 
since tumor suppressor genes could so far not be allocated to 8p21-23 
(Macartney-Coxson et al., 2008; Emi et al., 1992). With the assignment of the 
SHOCA-2 encoding SH2D4A gene to 8p21.3, we have linked genomic 
instability at this locus with the loss of a specific tumor suppressor activity in 
CRC. We provide experimental evidence and clinical data that a loss of 
SHOCA-2 expression results in unopposed STAT3 activation following EGFR 
stimulation and marks in patients with colorectal cancer accelerated tumor 
growth as well as poor prognosis. Our findings of a role for SHOCA-2 in the 
control of tumor growth also extend to malignancies where the mechanism of 
tumor development and progression are still only poorly understood (Roessler 
et al., 2011). 
 
EGFR is an upstream activator of multiple pathways involved in cell 
proliferation, apoptosis and carcinogenesis. Overexpression of EGFR and 
constitutive activation of its major downstream effector, STAT3, have been 
linked to cancer progression, a higher risk for metastasis and reduced survival 
(Quesnelle et al., 2007; Klampfer, 2008; Saif, 2010). Since STAT3 regulates 
cell growth and tissue homeostasis (Aggarwal et al., 2009), its activation must 
be under stringent control. We found that SHOCA-2 cooperates with PP1b in 
modulating the EGFR-induced STAT3 activation, thereby limiting cell 
proliferation. In view of the specific genetic and epigenetic alterations of 
SH2D4A, that particularly emerge in late stage CRCs, and given the 
correlation between poor clinical outcome and the loss of SHOCA-2 
expression, we conclude that SHOCA-2 is a novel tumor suppressor 
modulating the activation of the EGFR signaling pathway (Walther et al., 
2009). However, in the cohort studied here, the SHOCA-2 status was not a 
reliable predictor of survival in patients stratified by disease stage. This result 
is not surprising as it is consistent with the predictive potential of other tumor 
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suppressors. For example, p53, APC, and DCC also fail to serve as 
prognostic markers though their loss of expression in colorectal cancer is 
correlated with increased tumor aggressiveness (Roth, 1999; Walther et al., 
2009). 
 
Based on the evidence that SHOCA-2 binds to both EGFR and 
phosphatase PP1b and is itself phosphorylated upon EGF signaling, we 
propose that SHOCA-2 controls STAT3 activity through the catalytic activity of 
PP1b. SHOCA-2 and PP1b form a complex with STAT3 in that SHOCA-2 acts 
as an adaptor to bring the PP1b phosphatase into physical proximity of 
STAT3, which in term effects the dephosphorylation of activated STAT3. 
Indeed, phosphorylation/dephosphoryla-tion of Ser727 plays an important role 
in modulating STAT3’s transcriptional activity (Levy and Darnell, 2002; Wen et 
al., 1995; Shen et al., 2004), though the molecular mechanisms underlying 
Ser727 dephosphorylation have not yet been fully delineated. Though the 
serine/threonine phosphatases PP1 and PP2A have already been identified to 
dephosphorylate Ser727 (Lütticken et al., 1995; Woetmann et al., 1999; Togi et 
al., 2009; Haridas et al., 2009), the regulatory subunit that confers selectivity, 
specificity, and subcellular localization of PP1 towards STAT3 has so far and 
contrary to PP2A (Togi et al., 2009) remained unidentified. For the EGF 
pathway, we now demonstrate that Ser727 phosphorylation of STAT3 
decreases on the condition that PP1b associates with activated SHOCA-2.  
 
Dephosphorylation of Tyr705 constitutes another critical step in the events 
leading to STAT3 deactivation  (Heinrich et al., 2003). One of the 
phosphatases involved in this event is the receptor protein tyrosine 
phosphatase delta (PTPRD), which has been shown to act as a tumor 
suppressor in both colon cancer and other neoplasms (Zhang et al., 2007; 
Veeriah et al., 2009). Though PP1b constitutes yet another phosphatase 
involved in STAT3 inactivation, it remains unknown whether it acts indirectly 
via a tyrosine-specific phosphatase (e.g. SHP (Neviani et al., 2005)), or 
directly through target promiscuity (MacKintosh et al., 1996; Shi, 2009). A dual 
specificity of PP1b's catalytic activity is not unparalleled as a comparable 
mechanism has been described for the protein tyrosine phosphatase SHP-2 
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(Wu et al., 2002). Alternatively, the enhanced physical interaction between 
PP1b,  SHOCA-2 and STAT3 following EGF binding to its receptor may be 
sufficient to inactivate STAT3 secondary to conformational changes 
independent of any catalytic activity (Lee et al., 2009). The precise molecular 
mechanism by which Tyr705 is de-phosphorylated remains to date unidentified. 
Irrespective of this lack of knowledge, inappropriate STAT3 regulation is the 
noticeable consequence of aberrant SHOCA-2 expression and results in an 
up-regulation of genes involved in cell proliferation. 
 
The reduction of SHOCA-2 expression in the CRC cell line SW480 also 
produced phenotypic features characteristic of EMT. Such a transformation 
has been implicated in the conversion of early stage malignancies towards 
more aggressive tumors showing invasive growth and the formation of 
metastasis (Thiery et al., 2009). Consistent with a role in EMT, LOH at 
SH2D4A was mostly detected in patients with a disease stage typically 
associated with metastasis. It is thus conceivable that the loss of SHOCA-2 
plays a part in tumor progression not only through its impact on tumor cell 
growth but possibly also via its contribution to EMT. 
 
EGFR and STAT3 constitute promising drug targets in the treatment of 
cancer including CRC (Quesnelle et al., 2007). However, therapeutic 
responses are observed in only 10 to 20% of patients treated with EGFR 
antagonists (Ciardiello and Tortora, 2008) and none of the available STAT3 
inhibitors can to date be considered as viable drug candidates because of 
their limited efficiency in disrupting STAT3 homodimerization (Yue and 
Turkson, 2009). Detailed knowledge about the regulatory network that controls 
STAT3 activity may likely provide provides novel rationale for the design of 
strategies to interfere with a STAT3-mediated activation in cancer cells. 
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Experimental Procedures 
 
A detailed description of the methods used can be found in Supplemental 
Experimental Procedures. 
 
Plasmids, antibodies, cells and reagents. 
Antibodies, expression plasmids, cells and reagents were either gifts from 
investigators or bought commercially, as specified in Extended Experimental 
Procedures. 
 
Bioinformatic analysis. 
The SHOCA-1 (SH2D4B) and SHOCA-2 (SH2D4A) sequences were analyzed 
using NCBI, ENSEMBL (Hubbard et al., 2009), the kinBase database 
(http://www.kinase.com /kinbase/), the TCoffee software (Notredame et al., 
2000), and Oncomine (Rhodes et al., 2007). 
 
TAP purification and mass spectrometry. 
The TAP purification (Chen and Gingras, 2007) and mass spectrometry (Hess 
et al., 2008) were carried out as previously reported. 
 
Western Blot, immunoprecipitation and cell fractionation. 
Cells lysates were either separated on a 8%-12% SDS-PAGE or 
immunoprecipitated with protein G Plus-Sepharose beads coupled to specified 
antibodies and analyzed by western blotting. Cell fractionation was achieved 
using the CelLytic Nuclear extraction kit (Sigma). 
 
Luciferase reporter gene assays. 
HeLa cells were transfected with a firefly luciferase reporter SIE (sis-inducible 
element) plasmid plus a Renilla luciferase plasmid (both Promega) and 
plasmids that encode either STAT3 or SHOCA-2. Cell extracts were tested 
using the Dual Luciferase Assay System (Promega) and analyzed using a 
luminometer. Firefly luciferase activity was normalized to Renilla luciferase 
activity. 
	
   96	
  
Cell cycle analysis. 
Cells were incubated for 15 min with ice-cold hypotonic Propidium Iodide 
staining solution and subsequently analyzed by flow cytometry (FACSCalibur, 
Becton Dickinson) using the FlowJo software (Tree Star, Oregon Corporation). 
G1, S and G2/M phases were defined using the mathematical Watson 
Pragmatic model. 
 
Colony formation and anchorage-independent growth assays. 
For colony formation assay, SW480 cells co-transfected with a control vector 
or plasmids that encode STAT3, SHOCA-2, SHOCA-2 PP1Mut2 or SHOCA-2 
Y131A were cultured for 15 days under neomycin selection (G418: 1 mg/ml) 
and then analyzed for colony frequency following fixation and crystal violet 
staining of the cells. SW620 cells transfected with a control vector or plasmids 
that encode SHOCA-2, SHOCA-2 PP1Mut2 or SHOCA-2 Y131A, cultured under 
neomycin selection (G418, 1 mg/ml) in a soft agar (CytoSelect, Cell Biolabs) 
for 15 days and then analyzed for colony frequency. 
 
In vivo analyses of tumor formation. 
SW480 cells (5 × 106) were grafted to the flank of 6 week-old female BALB/c 
nude mice and the size of the tumor was measured weekly. Mice were 
sacrificed after 5 weeks and tumors were removed for further analysis. The 
animal experiments were carried out in accordance with the legal 
requirements of the Swiss veterinary authorities. 
 
Human tissues and immunohistochemistry. 
For the genetic and epigenetic study, specimens from 70 CRC patients were 
obtained from the Department of Surgery of the Kantonsspital Aarau, 
Switzerland and from of the Department of Gastroenterology of the Inselspital 
in Berne, Switzerland, with approval of the local medical ethics boards and 
written consent from patients. Tissues were stored in RNAlater reagent at -
70°C. Single-punch tumor samples from 501 patients (Institute of Pathology, 
Stadtspital Triemli, Zürich, Switzerland) were analyzed by tissue microarrays 
as described previously (Zlobec et al., 2010). SHOCA-2 expression and 
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STAT3 phosphorylation were quantified using the H score (Hirsch et al., 
2003). 
 
Mutational screening, loss of heterozygosity and gene dosage analysis. 
The complete coding sequence including flanking intronic regions of the 
SH2D4A gene was analyzed in all cancers lacking SHOCA-2 protein 
expression and/or that were positive for LOH. LOH for the SH2D4A locus was 
determined using a set of 3 flanking microsatellite markers and 6 gene-specific 
single nucleotide polymorphisms (SNP) (for details see Extended 
Experimental Procedures). Gene dosage was determined for each cancer 
using a chromosome 8-specific multiplex ligation-dependent probe 
amplification (MLPA) assay (SALSA P014-1A, MRC Holland) and data were 
processed by the GeneMarker software package (Softgenetics).  
 
Methylation analysis. 
Genomic DNA was converted by bisulfite treatment using the EZ DNA 
Methylation KitTM according to the manufacturer´s instructions (Zymo 
Research). CpG island regions were amplified by PCR from bisulfite treated 
DNA and sequenced with the PyroMark Q24 pyrosequencing system (Qiagen) 
allowing the quantitation of methylated CpG sites (PCR conditions and primer 
sequences are given in Extended Experimental Procedures). Bisulfite treated 
genomic DNA, previously in vitro methylated with M.SssI methyltransferase 
(New England BioLabs), served as the positive control. 
 
Statistical analyses. 
Student's t test, Likelihood ratio test, Chi-square test, Gehran-Wilcoxon test, 
Fisher’s Exact test, binomial test for equal proportions, Log-rank test, 
multivariate Cox regression analysis and Kaplan-Meier method were used for 
statistical analyzes, as indicated.  
	
   98	
  
Acknowledgements 
We would like to thank Annick Peter, Dorothea Maass and Ragna Sack for 
expert technical help; Dr. Giancarlo Marra for microarray data; Dr. Fabrizio 
Bianchi for statistical analyzes; Dr. Bérengère Fayard and Dr. Laura Trinkle-
Mulcahy for valuable discussions; Drs. Nancy Hynes, Thomas Barthlott, Poul 
Sørensen and Gerhard Christofori for critical reading of the manuscript; 
Sabrina Harris for secretarial assistance.  
This work was supported by grants from the Swiss National Science 
Foundation (to G.A.H.), the Krebsliga beider Basel (to S.L. and G.A.H.) and 
the Oxford Biomedical Research Centre (to G.A.H.). 
S.L. and G.A.H. designed the experiments, analyzed the data and composed 
together with P.S. the manuscript; S.L. performed experiments including 
Western Blot, immunoprecipitation, luciferase assays, mutagenesis, TAP 
assay, phosphatase assay, bioinformatic analyses, colony formation and 
anchorage-independent growth assays, and in vivo experiments; S.Z., K.H. 
and M.Ke. participated in the identification and cloning of SH2D4B and 
SH2D4A genes; D.H. performed the mass spectrometry analysis; supervised 
by P.S. and K.H., M.Ko. and S.W. performed the human genetic and 
epigenetic studies; immunohistochemistry was done by S.P.; K.T. provided 
human CRC samples; I.Z. performed statistical analyzes; L.T. supplied and 
analyzed CRC tissue microarray.  
The authors declare no competing financial interests. 
	
   99	
  
References 
Aggarwal, B.B., Kunnumakkara, A.B., Harikumar, K.B., Gupta, S.R., 
Tharakan, S.T., Koca, C., Dey, S., and Sung, B. (2009). Signal transducer and 
activator of transcription-3, inflammation, and cancer: how intimate is the 
relationship? Ann N Y Acad Sci 1171, 59-76. 
Arao, Y., Hamilton, K.J., Ray, M.K., Scott, G., Mishina, Y., and Korach, K.S. 
(2011). Estrogen receptor α AF-2 mutation results in antagonist reversal and 
reveals tissue selective function of estrogen receptor modulators. Proc Natl 
Acad Sci U S A 108, 14986-991. 
Bettstetter, M., Dechant, S., Ruemmele, P., Grabowski, M., Keller, G., 
Holinski-Feder, E., Hartmann, A., Hofstaedter, F., and Dietmaier, W. (2007). 
Distinction of hereditary nonpolyposis colorectal cancer and sporadic 
microsatellite-unstable colorectal cancer through quantification of MLH1 
methylation by real-time PCR. Clin Cancer Res 13, 3221-28. 
Birnbaum, D., Adélaïde, J., Popovici, C., Charafe-Jauffret, E., Mozziconacci, 
M.J., and Chaffanet, M. (2003). Chromosome arm 8p and cancer: a fragile 
hypothesis. Lancet Oncol 4, 639-642. 
Bromberg, J.F., Wrzeszczynska, M.H., Devgan, G., Zhao, Y., Pestell, R.G., 
Albanese, C., and Darnell, J.E. (1999). Stat3 as an oncogene. Cell 98, 295-
303. 
Ceulemans, H., and Bollen, M. (2004). Functional diversity of protein 
phosphatase-1, a cellular economizer and reset button. Physiol Rev 84, 1-39. 
Chen, G.I., and Gingras, A.C. (2007). Affinity-purification mass spectrometry 
(AP-MS) of serine/threonine phosphatases. Methods 42, 298-305. 
Christofori, G. (2006). New signals from the invasive front. Nature 441, 444-
450. 
Ciardiello, F., and Tortora, G. (2008). EGFR antagonists in cancer treatment. 
N Engl J Med 358, 1160-174. 
Costa-Pereira, A.P., Tininini, S., Strobl, B., Alonzi, T., Schlaak, J.F., Is'harc, 
H., Gesualdo, I., Newman, S.J., Kerr, I.M., and Poli, V. (2002). Mutational 
switch of an IL-6 response to an interferon-gamma-like response. Proc Natl 
Acad Sci U S A 99, 8043-47. 
	
   100	
  
Dumoutier, L., de Meester, C., Tavernier, J., and Renauld, J.C. (2009). A new 
activation modus of STAT3: A tyrosine-less region of the IL-22 receptor 
recruits STAT3 by interacting with its coiled-coil domain. J Biol Chem  
Emi, M., Fujiwara, Y., Nakajima, T., Tsuchiya, E., Tsuda, H., Hirohashi, S., 
Maeda, Y., Tsuruta, K., Miyaki, M., and Nakamura, Y. (1992). Frequent loss of 
heterozygosity for loci on chromosome 8p in hepatocellular carcinoma, 
colorectal cancer, and lung cancer. Cancer Res 52, 5368-372. 
Ewing, R.M., Chu, P., Elisma, F., Li, H., Taylor, P., Climie, S., McBroom-
Cerajewski, L., Robinson, M.D., O'Connor, L., et al. (2007). Large-scale 
mapping of human protein-protein interactions by mass spectrometry. Mol 
Syst Biol 3, 89. 
Guo, A., Villén, J., Kornhauser, J., Lee, K.A., Stokes, M.P., Rikova, K., 
Possemato, A., Nardone, J., Innocenti, G., et al. (2008). Signaling networks 
assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci U S A 105, 
692-97. 
Haridas, V., Nishimura, G., Xu, Z.X., Connolly, F., Hanausek, M., Walaszek, 
Z., Zoltaszek, R., and Gutterman, J.U. (2009). Avicin D: a protein reactive 
plant isoprenoid dephosphorylates Stat 3 by regulating both kinase and 
phosphatase activities. PLoS One 4, e5578. 
Heinrich, P.C., Behrmann, I., Haan, S., Hermanns, H.M., Müller-Newen, G., 
and Schaper, F. (2003). Principles of interleukin (IL)-6-type cytokine signalling 
and its regulation. Biochem J 374, 1-20. 
Hendrickx, A., Beullens, M., Ceulemans, H., Abt, T.D., Van Eynde, A., 
Nicolaescu, E., Lesage, B., and Bollen, M. (2009). Docking motif-guided 
mapping of the interactome of protein phosphatase-1. Chem Biol 16, 365-371. 
Hess, D., Keusch, J.J., Oberstein, S.A., Hennekam, R.C., and Hofsteenge, J. 
(2008). Peters Plus syndrome is a new congenital disorder of glycosylation 
and involves defective Omicron-glycosylation of thrombospondin type 1 
repeats. J Biol Chem 283, 7354-360. 
Hirsch, F.R., Varella-Garcia, M., Bunn, P.A., Di Maria, M.V., Veve, R., 
Bremmes, R.M., Barón, A.E., Zeng, C., and Franklin, W.A. (2003). Epidermal 
growth factor receptor in non-small-cell lung carcinomas: correlation between 
gene copy number and protein expression and impact on prognosis. J Clin 
Oncol 21, 3798-3807. 
	
   101	
  
Huang, F., Goh, L.K., and Sorkin, A. (2007). EGF receptor ubiquitination is not 
necessary for its internalization. Proc Natl Acad Sci U S A 104, 16904-09. 
Hubbard, T.J., Aken, B.L., Ayling, S., Ballester, B., Beal, K., Bragin, E., Brent, 
S., Chen, Y., Clapham, P., et al. (2009). Ensembl 2009. Nucleic Acids Res 37, 
D690-97. 
Klampfer, L. (2008). The role of signal transducers and activators of 
transcription in colon cancer. Front Biosci 13, 2888-899. 
Kreis, S., Munz, G.A., Haan, S., Heinrich, P.C., and Behrmann, I. (2007). Cell 
density dependent increase of constitutive signal transducers and activators of 
transcription 3 activity in melanoma cells is mediated by Janus kinases. Mol 
Cancer Res 5, 1331-341. 
Levy, D.E., and Darnell, J.E. (2002). Stats: transcriptional control and 
biological impact. Nat Rev Mol Cell Biol 3, 651-662. 
Li, T., Li, W., Lu, J., Liu, H., Li, Y., and Zhao, Y. (2009). SH2D4A regulates 
cell proliferation via the ERalpha/PLC-gamma/PKC pathway. BMB Rep 42, 
516-522. 
Lu, Y., Liang, K., Li, X., and Fan, Z. (2007). Responses of cancer cells with 
wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor 
(EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-
inducible factor-1alpha. Mol Cancer 6, 63. 
Lütticken, C., Coffer, P., Yuan, J., Schwartz, C., Caldenhoven, E., Schindler, 
C., Kruijer, W., Heinrich, P.C., and Horn, F. (1995). Interleukin-6-induced 
serine phosphorylation of transcription factor APRF: evidence for a role in 
interleukin-6 target gene induction. FEBS Lett 360, 137-143. 
Maa, M.C., Lee, J.C., Chen, Y.J., Chen, Y.J., Lee, Y.C., Wang, S.T., Huang, 
C.C., Chow, N.H., and Leu, T.H. (2007). Eps8 facilitates cellular growth and 
motility of colon cancer cells by increasing the expression and activity of focal 
adhesion kinase. J Biol Chem 282, 19399-9409. 
Macartney-Coxson, D.P., Hood, K.A., Shi, H.J., Ward, T., Wiles, A., O'Connor, 
R., Hall, D.A., Lea, R.A., Royds, J.A., et al. (2008). Metastatic susceptibility 
locus, an 8p hot-spot for tumour progression disrupted in colorectal liver 
metastases: 13 candidate genes examined at the DNA, mRNA and protein 
level. BMC Cancer 8, 187.
	
   102	
  
MacKintosh, C., Garton, A.J., McDonnell, A., Barford, D., Cohen, P.T., Tonks, 
N.K., and Cohen, P. (1996). Further evidence that inhibitor-2 acts like a 
chaperone to fold PP1 into its native conformation. FEBS Lett 397, 235-38. 
Neviani, P., Santhanam, R., Trotta, R., Notari, M., Blaser, B.W., Liu, S., Mao, 
H., Chang, J.S., Galietta, A., et al. (2005). The tumor suppressor PP2A is 
functionally inactivated in blast crisis CML through the inhibitory activity of the 
BCR/ABL-regulated SET protein. Cancer Cell 8, 355-368. 
Notredame, C., Higgins, D.G., and Heringa, J. (2000). T-Coffee: A novel 
method for fast and accurate multiple sequence alignment. J Mol Biol 302, 
205-217. 
Quesnelle, K.M., Boehm, A.L., and Grandis, J.R. (2007). STAT-mediated 
EGFR signaling in cancer. J Cell Biochem 102, 311-19. 
Rhodes, D.R., Kalyana-Sundaram, S., Mahavisno, V., Varambally, R., Yu, J., 
Briggs, B.B., Barrette, T.R., Anstet, M.J., Kincead-Beal, C., et al. (2007). 
Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 
cancer gene expression profiles. Neoplasia 9, 166-180. 
Roessler, S., Long, E.L., Budhu, A., Chen, Y., Zhao, X., Ji, J., Walker, R., Jia, 
H.L., Ye, Q.H., et al. (2011). Integrative Genomic Identification of Genes on 8p 
Associated with Hepatocellular Carcinoma Progression and Patient Survival. 
Gastroenterology  
Roth J. A. (1999). Clin Cancer Res. In p53 prognostication: paradigm or 
paradox?. UNITED STATES:  [UNKNOWN REFERENCE TYPE] 
Saif, M.W. (2010). Colorectal cancer in review: the role of the EGFR pathway. 
Expert Opin Investig Drugs 19, 357-369. 
Shao, H., Cheng, H.Y., Cook, R.G., and Tweardy, D.J. (2003). Identification 
and characterization of signal transducer and activator of transcription 3 
recruitment sites within the epidermal growth factor receptor. Cancer Res 63, 
3923-930. 
Shen, Y., Schlessinger, K., Zhu, X., Meffre, E., Quimby, F., Levy, D.E., and 
Darnell, J.E. (2004). Essential role of STAT3 in postnatal survival and growth 
revealed by mice lacking STAT3 serine 727 phosphorylation. Mol Cell Biol 24, 
407-419. 
Shi, Y. (2009). Serine/threonine phosphatases: mechanism through structure. 
Cell 139, 468-484. 
	
   103	
  
Tanaka, K., Kikuchi-Yanoshita, R., Muraoka, M., Konishi, M., Oshimura, M., 
and Miyaki, M. (1996). Suppression of tumorigenicity and invasiveness of 
colon carcinoma cells by introduction of normal chromosome 8p12-pter. 
Oncogene 12, 405-410. 
Thiery, J.P., Acloque, H., Huang, R.Y., and Nieto, M.A. (2009). Epithelial-
mesenchymal transitions in development and disease. Cell 139, 871-890. 
Togi, S., Kamitani, S., Kawakami, S., Ikeda, O., Muromoto, R., Nanbo, A., and 
Matsuda, T. (2009). HDAC3 influences phosphorylation of STAT3 at serine 
727 by interacting with PP2A. Biochem Biophys Res Commun 379, 616-620. 
Trenerry, M.K., Carey, K.A., Ward, A.C., and Cameron-Smith, D. (2007). 
STAT3 signaling is activated in human skeletal muscle following acute 
resistance exercise. J Appl Physiol 102, 1483-89. 
Veeriah, S., Brennan, C., Meng, S., Singh, B., Fagin, J.A., Solit, D.B., Paty, 
P.B., Rohle, D., Vivanco, I., et al. (2009). The tyrosine phosphatase PTPRD is 
a tumor suppressor that is frequently inactivated and mutated in glioblastoma 
and other human cancers. Proc Natl Acad Sci U S A 106, 9435-440. 
Vogelstein, B., and Kinzler, K.W. (2004). Cancer genes and the pathways 
they control. Nat Med 10, 789-799. 
Walther, A., Johnstone, E., Swanton, C., Midgley, R., Tomlinson, I., and Kerr, 
D. (2009). Genetic prognostic and predictive markers in colorectal cancer. Nat 
Rev Cancer 9, 489-499. 
Weinberg, R.A. (1991). Tumor suppressor genes. Science 254, 1138-146. 
Wen, Z., Zhong, Z., and Darnell, J.E. (1995). Maximal activation of 
transcription by Stat1 and Stat3 requires both tyrosine and serine 
phosphorylation. Cell 82, 241-250. 
Woetmann, A., Nielsen, M., Christensen, S.T., Brockdorff, J., Kaltoft, K., 
Engel, A.M., Skov, S., Brender, C., Geisler, C., et al. (1999). Inhibition of 
protein phosphatase 2A induces serine/threonine phosphorylation, subcellular 
redistribution, and functional inhibition of STAT3. Proc Natl Acad Sci U S A 
96, 10620-25. 
Wu, T.R., Hong, Y.K., Wang, X.D., Ling, M.Y., Dragoi, A.M., Chung, A.S., 
Campbell, A.G., Han, Z.Y., Feng, G.S., and Chin, Y.E. (2002). SHP-2 is a 
dual-specificity phosphatase involved in Stat1 dephosphorylation at both 
tyrosine and serine residues in nuclei. J Biol Chem 277, 47572-580. 
	
   104	
  
Yue, P., and Turkson, J. (2009). Targeting STAT3 in cancer: how successful 
are we? Expert Opin Investig Drugs 18, 45-56. 
Zhang, X., Guo, A., Yu, J., Possemato, A., Chen, Y., Zheng, W., Polakiewicz, 
R.D., Kinzler, K.W., Vogelstein, B., et al. (2007). Identification of STAT3 as a 
substrate of receptor protein tyrosine phosphatase T. Proc Natl Acad Sci U S 
A 104, 4060-64. 
Zlobec, I., Molinari, F., Kovac, M., Bihl, M.P., Altermatt, H.J., Diebold, J., Frick, 
H., Germer, M., Horcic, M., et al. (2010). Prognostic and predictive value of 
TOPK stratified by KRAS and BRAF gene alterations in sporadic, hereditary 
and metastatic colorectal cancer patients. Br J Cancer 102, 151-161. 
 
	
   105	
  
Figure legends  
Figure 1. Reduced SHOCA-2 expression in human colorectal cancers 
correlates with advanced disease stage. 
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(A) Left, location of SHOCA-2 on human chromosome (huChr) 8p. Middle, 
degree of conservation between the two human SHOCA sequences with 
higher degrees of conservation specified by darker shades of grey; box, a 
consensus MyPhoNE sequence typically present in myosin homologues 
(Hendrickx et al., 2009). Right, predicted domain organization of SHOCA; the 
amino acid identity between SHOCA-1 and -2 is given for the MyPhoNE and 
SH2 domains. Of note, SHOCA-2 protein contains only one coiled-coil domain 
(CC), namely CC2. 
(B) Immunohistochemical analysis of a single tissue microarray containing 400 
samples from unselected, untreated patients with sporadic CRC. SHOCA-2 
expression was quantified using the H-score that determines the percentage 
of positive tumor cells multiplied by their staining intensity generating 
individual groups with scores of >200 (n=275), defining a strong expression 
(green); 100-200 (n=87), identifying a moderate expression (blue); <100 
(n=38), characterizing a low or absent expression (red).  
(C) Representative immunohistochemical analysis of tumor tissue of distinct 
CRC stages depicting either diffuse (>90% cells stained; left), patchy (<30%; 
middle) or no SHOCA-2 expression (right). T = tumor tissue, N = normal 
tissue. Scale bar, 200 mm. 
(D) Kaplan-Meier survival analysis of patients with high (green), moderate 
(blue) and low SHOCA-2 expression (red) for which sufficient clinical 
information was available (log-rank test p = 0.0118 when comparing high to 
low SHOCA-2 expression).  
See also Figure S1 and Table S1 
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Figure 2. Genetic and epigenetic silencing of SH2D4A encoding SHOCA-
2. 
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(A) HuChr8p copy number variation profiles in SHOCA-2-positive and 
SHOCA-2-negative CRC. Values <0.75 indicate chromosomal deletions (Del) 
whereas values >1.25 designate chromosomal duplications (Dup). Red 
dashed lines, threshold. 
(B) Top, comparison of the SH2D4A c.342-5T>C (rs17128221) SNP 
frequency between 83 unrelated healthy Caucasian controls and 16 CRC 
patients (Chi square p value = 0.006). Bottom, SNP rs17128221 RT-PCR 
(right) and sequencing analysis (left), the diagram depicts exon usage and the 
arrows indicate the annealing sites for the primers.  
(C) i: top, alignment of amino acid sequences for the SH2 domain (AA 320-
454) of human SHOCA-2 (AAH82982) with homologues of mus musculus 
(AAI16683), rattus norvegicus (NP_001012048), and gallus gallus 
(XP_420452); bottom, sequence analysis of patient tumors. ii: immunoblot 
analysis of HeLa cells transfected to express Flag-fusion proteins of the 
indicated human SHOCA-2 mutations.  
(D) DNA methylation analysis of CpG island located in the 5’UTR of SH2D4A 
comparing normal and tumor tissue. 
(E) Summary of all genetic and epigenetic changes detected in a cohort of 27 
informative CRC samples; CNV = copy number variation, SNP = single 
nucleotide polymorphism. Green = normal finding, red = pathological result, 
n.d. = not done, roman numerals = number of alleles affected. 
See also Figure S2 
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Figure 3. SHOCA-2 is phosphorylated following EGFR activation and 
inhibits STAT3 activity.  
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(A) SHOCA-2-Flag expressing, serum-starved HeLa cells were stimulated as 
indicated with EGF (100 ng/ml). Cell lysates were immunoprecipitated with 
anti-phosphotyrosine (pTyr) antibody or rabbit IgG and immunoblotted to 
detect Flag and pTyr. 
(B) Serum-starved HeLa cells were transiently transfected with either a control 
vector or a vector encoding the human SHOCA-2-Flag and stimulated as 
indicated with EGF (100 ng/ml); immunoblotting for the detection of the 
indicated proteins. The ratio of phosphoprotein to total protein (designated 
P/Total) was determined by densitometry.  
(C) Serum-starved HeLa cells that express normal (control, 100%) or 10% of 
SHOCA-2 (SHOCA-2 KD) were stimulated for 5, 10 and 15 min with EGF (100 
ng/ml). The indicated proteins were detected by immunoblotting. Densitometry 
was used to determine the ratio of phosphoprotein to total protein (designated 
P/Total).  
(D) Serum-starved HeLa cells and SHOCA-2 KD HeLa cells transiently co-
transfected with a SIE firefly luciferase reporter, a renilla luciferase plasmid 
and a SHOCA-2 expression plasmid were stimulated for 6 hrs with EGF (100 
ng/ml; filled bar) or left untreated (open bar). Luciferase assay was performed 
on lysates. Renilla luciferase activity was used to normalize transfection 
efficiency. Data represent the mean ± SD of three independent, triplicate 
assays (Student's t test, **p < 0.01; ***p < 0.005). 
(E) Immunoblotting of HeLa, PAE and MEF lysates immunoprecipitated with 
anti-EGFR, anti-SHOCA-2, anti-Flag or mouse IgG antibodies for the detection 
of EGFR, STAT3, SHOCA-2 and Flag. 
See also Figure S3 
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Figure 4. SHOCA-2 controls STAT3 activity in a PP1b-dependent fashion.  
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(A) Lysates from HEK293 cells (bottom) and HEK293 cells expressing 
SHOCA-2-Flag (top) were immunoprecipitated with anti-PP1b antibody or IgG 
and immunoblotted for PP1b, and Flag (top) or SHOCA-2 (bottom). Human 
SHOCA-2 is detected as isoforms due to exon 5 skipping. 
(B) Lysates from HEK293 cells expressing CTAP fusion proteins and EGFP-
tagged PP1 isoforms were immunoprecipitated with IgG sepharose beads 
(recognizing CTAP fusion proteins) and immunoblotted for the detection of 
CTAP and EGFP fusion proteins. 
(C) Left, diagram representing wild-type and mutant SHOCA altered PP1b -
binding sites (boxes) are marked by crosses. Middle, CTAP fusion proteins 
and PP1b were detected in total and immunoprecipitated lysates from 
transfected HEK293 cells. Right, SHOCA-2, Flag and PP1b, respectively, 
were detected in total lysates and anti-Flag immunoprecipitates from HEK293 
cells expressing wild type or mutant SHOCA fusion proteins. 
(D) Left, serum-starved HeLa cell expressing the human SHOCA-2-Flag 
fusion protein were stimulated with EGF (100 ng/ml) for the indicated times. 
Lysates were analyzed unmanipulated or were immunoprecipitated with anti-
EGFR antibody for the detection of EGFR, STAT3, Flag and PP1b by 
immunoblotting. Right, ratio of immunoprecipitated protein to total protein 
(designated IP/Total) as determined by densitometry. 
(E) Serum-starved HeLa cell co-expressing the indicated proteins were 
stimulated with EGF (100 ng/ml) for the specified times. Lysates were 
immunoblotted for the detection of phospho-EGFR (Tyr845), phospho-STAT3 
(Tyr705/Ser727), STAT3, Flag, and GAPDH. 
(F) Serum-starved HeLa cells transiently co-transfected with a SIE firefly 
luciferase reporter, a renilla luciferase plasmid and plasmids encoding either 
STAT3, the human SHOCA-2-Flag fusion protein or a mutant human SHOCA-
2-Flag fusion protein unable to associate with PP1b (PP1Mut2) were stimulated 
for 6 hrs with EGF (100 ng/ml; filled bar) or left untreated (open bar). 
Luciferase assay was performed on lysates. Renilla luciferase activity was 
used to normalize transfection efficiency. Data represent the mean ± SD of 
three independent, triplicate assays (Student's t test, *p < 0.05; **p < 0.01; 
***p < 0.005). 
See also Figure S4 and Table S2 
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Figure 5. SHOCA-2 and PP1b arrest tumor cell proliferation sustained by 
STAT3. 
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(A) Left panel: Serum-starved HeLa cells that expressed wild type (control) or 
reduced (SHOCA-2 KD) SHOCA-2 levels were either left untreated or 
stimulated with EGF (100 ng/ml) for 6 and 12 hrs. Cell lysates were 
immunoblotted for the detection of phospho-STAT3 (Tyr705), STAT3, c-Myc, 
Jun B, Cyclin D1, SHOCA-2 and GAPDH. Right panel: After 24 hrs of serum 
starvation, control and SHOCA-2 KD HeLa cells were stimulated with EGF 
(100 ng/ml) for 12 hrs. The cell cycle profile was evaluated by flow cytometry 
using propidium iodide staining (PI). The bar graph shows the percentage of 
cells in the indicated phases of the cell cycle. The data is representative of 3 
separate experiments, each performed in triplicate (*p < 0.05; ***p < 0.005 
using Student's t test). 
(B) CRC tissue sections from a cohort of 27 informative CRC patients (see 
Figure 2E) were analyzed for the proportion of tumor cells that stained for 
SHOCA-2 and Ki-67 (Wilcoxon test, *p < 0.05; ***p < 0.005). 
(C) SW480 cells transfected to express the indicated empty (pYN3218, Flag) 
and recombinant vectors were grown for 15 days under neomycin selection 
and then scored for the number (top) and appearance of colonies (bottom). 
The graph is representative of two independent experiments performed in 
triplicates (Student's t test, *p < 0.05; **p < 0.01; ***p < 0.005). 
(D) SW480 cells were transiently transfected with a control vector or 
recombinant vectors as indicated, serum-starved, and then stimulated with 
EGF (100 ng/ml) for 10 and 15 min. Lysates were immunoblotted to detect 
phospho-STAT3 (Tyr705 and Ser727), STAT3, phospho-Akt (Ser473), Akt, 
phospho-ERK1/2 (Thr202/Tyr204), Flag and GAPDH. 
(E) SW620 cells expressing wild-type human SHOCA-2 or a SHOCA-2 mutant 
(PP1Mut2, Y131A) were grown for 15 days under neomycin selection in soft 
agar and then scored for the number (top) and appearance of colonies 
(bottom). The graph is representative of two independent experiments 
performed in triplicates (Student's t test, ***p < 0.005). 
See also Figure S5 
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Figure 6. SHOCA-2 is required for maintaining epithelial morphology and 
its down-regulation promotes tumorigenesis in vivo  
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(A) Phase-contrast images of control SHOCA-2 expressing SW480 cells and 
polyclonal SHOCA-2 knockdown (KD) SW480 cells grown at different 
densities. Scale bar, 100 mm. 
(B) Immunoblot analysis of E-cadherin, N-cadherin, Vimentin, ZEB-1, SNAIL, 
SHOCA-2 and GAPDH protein expressions in lysates from SW480 stable 
transfectants (shRNA control, SHOCA-2 KD). 
(C) Proliferation of SW480 cells that have been stably transfected with shRNA 
for the knock-down of SHOCA-2. The cells have been grown in the presence 
or absence of EGFR inhibitor (AG1478). Data represent the mean ± SEM of 
two independent experiments. 
(D) SW480 cells with or without a knock-down of SHOCA-2 were transfected 
to express either a control plasmid (designated Flag) or a murine (m) SHOCA-
2-Flag fusion protein that was not targeted by the shRNA used. Transfected 
cells selected with neomycin and scored for the number of colonies detected 
(top). Cell lysates were immunoblotted for SHOCA-2 and GAPDH protein 
expression (bottom). The data are representative of two independent 
experiments. 
(E) Monitoring tumor incidence and size in nude mice (n=5 mice per group) 
grafted with either SHOCA-2 wild type (shRNA CT) or knock-down SW480 
cells (SHOCA-2 KD). Data represent the mean ± SEM of two independent 
experiments. 
(F) Immunohistochemistry of grafted SW480 tumor cells either wild type or 
knock-down for SHOCA-2 expression (upper left panel; scale bar, 100 mm) 
and of human CRC tissues (right; scale bar, 50 mm). Left upper panel: 
Immunohistochemical analysis of in vivo grafted SW480 cells for STAT3 
phosphorylated at Tyr705; Left lower panel: H-score analysis for Tyr705 and 
Ser727 STAT3 phosphorylation in CRC samples with low to absent SHOCA-2 
expression, displayed as a relative percentage of the biopsies investigated. 
Right: analysis of CRC tissues on consecutive section for the detection of 
SHOCA-2 and STAT3 phosphorylated either at Tyr705 or Ser727. 
See also Figure S6 
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6.3 HMGA1 and HMGA2 protein expression correlates with 
advanced tumour grade and lymph node metastasis in 
pancreatic adenocarcinoma. 
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HMGA1 and HMGA2 protein expression correlates with advanced tumour grade and lymph
node metastasis in pancreatic adenocarcinoma
Aims: Pancreatic ductal adenocarcinoma follows a
multistep model of progression through precursor
lesions called pancreatic intraepithelial neoplasia (Pa-
nIN). The high mobility group A1 (HMGA1) and high
mobility group A2 (HMGA2) proteins are architectural
transcription factors that have been implicated in the
pathogenesis and progression of malignant tumours,
including pancreatic cancer. The aim of this study was
to explore the role of HMGA1 and HMGA2 in pancre-
atic carcinogenesis.
Methods and results: HMGA1 and HMGA2 expression
was examined in 210 ductal pancreatic adenocarcino-
mas from resection specimens, combined on a tissue
microarray also including 40 examples of PanIN and
40 normal controls. The results were correlated with
the clinicopathological parameters of the tumours and
the outcome of the patients. The percentage of tumour
cells showing HMGA1 and HMGA2 nuclear immuno-
reactivity correlated positively with increasing malig-
nancy grade and lymph node metastasis. Moreover,
HMGA1 and HMGA2 expression was significantly
higher in invasive carcinomas than in PanINs. No, or
very low, expression was found in normal pancreatic
tissue.
Conclusions: Our results suggest that HMGA1 and
HMGA2 are implicated in pancreatic carcinogenesis
and may play a role in tumour progression towards a
more malignant phenotype.
Keywords: HMGA1, HMGA2, immunoreactivity, pancreatic ductal adenocarcinoma, pancreatic intraepithelial
neoplasia
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Introduction
Pancreatic ductal adenocarcinoma is a common cause
of death from cancer, and has a dismal prognosis with
currently no effective treatment.1 Despite important
advances in our understanding of the molecular
biology of the early stages of neoplastic development,
late molecular events that lead to tumour progression
are largely unknown. Clinicopathological parameters
such as tumour size, lymph node metastases and
evidence of blood vessel or lymphatic invasion have
been proven to be reliable prognostic determinants in
pancreatic cancer.1 The identification of reliable and
reproducible biomarkers would enable better stratifica-
tion of patients, and eventually provide a guide for
individualized therapy. Pancreatic cancer follows a
multistep model of progression through non-invasive
precursor lesions. Pancreatic intraductal lesions have
been classified into four groups of pancreatic intraepi-
thelial neoplasias (PanINs): PanIN-1A, PanIN-1B,
PanIN-2, and PanIN–3.2 PanIN-3 shows severe epi-
thelial dysplasia, and is most likely to progress to
invasive carcinoma.2
The high mobility group A (HMGA) genes encode a
family of non-histone chromatin-binding proteins,
named for their rapid electrophoretic mobility in
polyacrylamide gels.3 HMGA1a and HMGA1b isoforms
result from alternative splicing of HMGA1 mRNA,
whereas HMGA2 is encoded by the related gene
HMGA2.3 HMGA proteins bind the minor groove of
AT-rich DNA sequences. Their DNA-binding domain is
located in the N-terminal region of the protein, and
contains three short basic repeats, the so-called AT-
hooks.4 Once bound to DNA, the HMGA proteins alter
chromatin structure and thereby regulate the tran-
scriptional activity of several genes.5 HMGA proteins
are normally expressed at high levels during embryonic
development, and at very low levels in adult, differen-
tiated tissues.6 HMGA proteins participate, as tran-
scriptional regulators, in many cellular functions,
including regulation of the cell cycle, cell differentia-
tion, senescence, and neoplastic transformation.7 Both
HMGA1 and HMGA2 have been reported to function as
oncogenes and to be overexpressed in almost all
human malignancies so far analysed, including ductal
pancreatic adenocarcinoma.8–20 Moreover, HMGA pro-
tein overexpression has been regarded as a poor
prognostic feature, as it has often been found to
correlate with the presence of metastasis and with
reduced survival.21
The objective of the present study was to investigate
the role of HMGA1 and HMGA2 expression in pancre-
atic carcinogenesis and to evaluate its prognostic
significance. Using immunohistochemistry we analysed
expression in different stages of pancreatic carcinogen-
esis, including invasive adenocarcinomas, PanINs, and
normal pancreatic tissue, in a tissue microarray (TMA)
combining 210 ductal adenocarcinomas of the pan-
creas from resection specimens, 40 cases of PanIN-3,
and 40 normal controls.
Materials and methods
patients and specimens
Formalin-fixed and paraffin-embedded tumours and
control specimens were retrieved from the archives of
the Institute of Pathology, University of Bern. All
tumours and controls were reviewed by an experienced
pathologist (E.K.). Histological subtypes other than
ductal carcinoma were excluded. Tumours were re-
staged according to the American Joint Committee on
Cancer Staging Manual (seventh edition). Representa-
tive tumour areas were selected for the construction of
the TMA. The TMA consisted of 210 surgically-
resected ductal adenocarcinomas of the pancreas, and
included 40 examples of PanIN-3 and 40 normal
controls (normal pancreatic tissue and PanINs were
selected from areas distant from the carcinomas). The
210 patients comprised 110 males and 100 females,
with a mean age of 66.5 years (range: 20–92 years).
The study was approved by the ethics committee of the
University of Bern.
assessment of behaviour
Medical charts were available for 77 of the 210
patients. Of these 77 patients, 60 (78%) died from the
disease, and 7 (9%) were alive with recurrent ⁄ meta-
static disease. The other 10 patients (13%) were alive
without disease. The median follow-up time was
16 months. The clinicopathological features of these
cases with survival information are given in Table 1.
construction of the tma
One core tissue biopsy with a diameter of 0.6 mm was
taken from a representative region of individual paraf-
fin-embedded pancreatic carcinomas (donor blocks),
and placed into a new recipient paraffin block with a
semi-automated tissue-arraying device. The presence of
tumour tissue on the TMA was verified on a haemat-
oxylin and eosin-stained slide. Two to three tissue cores
of each tumour were available for biomarker analysis.
Five-micrometre sections were cut with an adhesive-
coated slide system (Instrumedics, Hackensack, NJ,
398 S Piscuoglio et al.
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USA) and examined by immunohistochemistry. The
number of samples differed slightly between the indi-
vidual markers, because of variability in the number of
interpretable specimens on TMA sections.
immunohistochemistry
Freshly cut sections of TMA blocks were used for
immunohistochemical staining with anti-HMGA1 and
anti-HMGA2 antibodies. Briefly, punches were de-
waxed and rehydrated in distilled water. Endogenous
peroxidase activity was blocked with 0.5% H2O2. The
sections were incubated with 10% normal goat serum
(Dako Cytomation, Carpinteria, CA, USA) for 20 min,
and then with the primary antibody at room temper-
ature. Optimal staining was achieved after pretreat-
ment in a microwave oven (98!C for 30 min, pH 6,
dilution 1:250). Subsequently, sections were incubated
with peroxidase-labelled secondary antibody (Dako
Cytomation) for 30 min at room temperature. 3,3¢-
Diaminobenzidine was used as chromogen. Sections
were then counterstained with Gill’s haematoxylin. As
a positive control, a TMA with various normal tissue
samples was stained in parallel.
The antibodies used for HMGA1 immunostaining
were raised against the synthetic peptide SSSKQQPL-
ASKQ, which is specific for HMGA1. They were affinity
purified against the synthetic peptide.9 For HMGA2
immunohistochemistry, antibodies raised against a
synthetic peptide located in the N-terminal region were
used.22
The specificity of immunolabelling was validated by
the absence of tumour staining when using antibodies
preincubated with the peptide against which the
antibodies were raised (data not shown). Similarly, no
positivity was observed when tumour samples were
incubated with a preimmune serum (data not shown).
immunohistochemical evaluation
Nuclear HMGA1 and HMGA2 staining was scored by
two independent observers (S.P. and L.T.) blinded for
clinical parameters. Slides were screened semiquanti-
tatively for the percentage of positive cells and the
intensity of the signal. At least 100 cells were counted
for each punch. The percentage of positive cells per
number of cells counted was scored in 10 groups from
0 (0–9%) to 9 (91–100%). The intensity of the signal
was graded semiquantitatively into four groups from 0
(no positivity) to 3 (strong positivity). A case was
considered to be positive if belonging at least to group 1
for the percentage (i.e. ‡10%), irrespective of intensity.
In PanINs and normal controls, the epithelial cells of
ductal structures were evaluated.
statistical methods
The selection of clinically important cut-off scores was
based on receiver operating characteristic (ROC) curve
analysis.23,24 At each percentage score, the sensitivity
and specificity for each outcome under study were
plotted, generating an ROC curve. The score having the
closest distance to the point with both maximum
sensitivity and specificity, i.e. point (0.0, 1.0) on the
curve, was selected as the cut-off score leading to the
greatest number of tumours that were correctly clas-
sified as having or not having the outcome. In order to
Table 1. Clinicopathological characteristics of cases with
survival information (N = 77)
Clinicopathological features Frequency, N (%)
Diagnosis
Ductal carcinoma 77 (100.0)
Sex
Female 33 (42.9)
Male 44 (57.1)
Tumour grade
G1 16 (20.8)
G2 42 (54.6)
G3 19 (24.7)
pT stage
pT1 3 (4.1)
pT2 12 (16.2)
pT3 52 (70.3)
pT4 7 (9.5)
pN stage
pN0 27 (38.0)
pN1 44 (62.0)
Metastasis
Absent 72 (93.5)
Present 5 (6.5)
Tumour diameter (mm),
mean ± SD
31.4 ± 14.0
Survival time (months),
median (range)
12.0 (0.5–48.0)
SD, Standard deviation.
HMGA proteins in pancreatic cancer 399
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enable the use of ROC curve analysis, the following
clinicopathological features were dichotomized: T stage
(early, T1 + T2; late, T3 + T4), N stage (N0, no lymph
node involvement; N1, any lymph node involvement),
tumour grade (low, G1 + G2; high, G3), and survival
(death from pancreatic carcinoma or alive).
Chi-square tests were used to study the relationship
between HMGA1 and HMGA2 expression and histo-
logical subgroups. Differences in HMGA1 and HMGA2
expression between normal tissue, PanIN and carci-
noma were investigated with the non-parametric
Wilcoxon rank sum test. Univariate survival analysis
was carried out with the Kaplan–Meier log-rank test,
and multivariate analysis with Cox proportional haz-
ards regression. Hazard ratios and 95% confidence
intervals (CIs) were used to determine the effect of each
variable on survival time. In addition, logistic regres-
sion was performed in univariate and multivariate
settings to determine the associations of protein
expression and its independent effect on binary out-
comes. The odds ratios and 95% CIs were evaluated. A
Bonferroni correction for multiple comparisons was
performed. A P-value £0.01 (two-sided) was required
for the association to be statistically significant. All
analyses were carried out with SAS (V9; SAS Institute,
Cary, NC, USA).
Results
analysis of hmga1 and hmga2 express ion by
immunohistochemistry
Table 2 shows the differences in protein expression
between normal pancreas, PanIN, and cancer, and
Table 3 the correlation of HMGA1 and HMGA2
expression with pT stage, pN stage, and tumour grade.
Survival related to protein marker expression is anal-
ysed in Table 4. Some representative images of immu-
nohistochemical staining are illustrated in Figures 1
and 2.
pancreatic carcinomas versus normal
controls
Pancreatic carcinoma cases generally displayed strong
nuclear HMGA1 and HMGA2 immunoreactivity,
whereas absent or very low immunoreactivity was
observed in normal pancreatic tissue. The mean ± stan-
dard deviation (SD) for the percentage of cells showing
HMGA1 and HMGA2 protein expression were found to
be 0 ± 0 and 0.2 ± 0.9, respectively, in normal tissue,
as compared with 26.6 ± 30.5 and 16.3 ± 28.4,
respectively, in carcinomas (P < 0.001; Table 2).
pancreatic carcinoma versus panin
Percentages of cells showing HMGA1 and HMGA2
protein expression were significantly higher in ductal
pancreatic adenocarcinomas (mean ± SD: 26.6 ± 30.5
and 16.3 ± 28.4, respectively) than in PanIN cases
(11.1 ± 15.0 and 2.7 ± 13.5, respectively)
(P < 0.001; Table 2).
pan in versus normal controls
Means for the percentages of cells showing HMGA1
and HMGA2 protein expression were significantly
higher in PanIN cases (11.1 ± 15.0 and 2.7 ± 13.5,
respectively) than in normal tissue (0 ± 0 and
0.2 ± 0.9, respectively) (P < 0.001; Table 2).
Table 2. Differences in marker expression between normal pancreas, pancreatic intraepithelial neoplasia (PanIN) and cancer
Normal PanIN Cancer P-value
HMGA1
n 31 31 183 <0.001
Mean ± SD 0 ± 0 11.1 ± 15.0 26.6 ± 30.5
Median (min)max) 0 (0–0) 5.0 (0–50) 10.0 (0–100)
HMGA2
n 29 37 191 <0.001
Mean ± SD 0.2 ± 0.9 2.7 ± 13.5 16.3 ± 28.4
Median (min)max) 0 (0–5) 0 (0–80) 0 (0–100)
HMGA, High mobility group A; SD, standard deviation.
Expression is given as percentage of immunoreactive cells. Wilcoxon rank sum test.
400 S Piscuoglio et al.
! 2012 Blackwell Publishing Ltd, Histopathology, 60, 397–404.
 
	
   151	
  
Table 3. Protein marker expression related to stage (pT, pN),
and tumour grade
HMGA1 HMGA2
pT stage
pT1–2 25.7 ± 28.7; 15.0 16.0 ± 28.4; 0.0
pT3–4 27.1 ± 31.3; 10.0 16.9 ± 28.9; 0.0
P-value 0.83 0.952
pN stage
pN0 18.3 ± 22.8; 5.0 8.4 ± 19.0; 0.0
pN1 32.7 ± 33.6; 20.0 21.5 ± 32.4; 0.0
P-value 0.012 0.039
Tumour grade
G1–2 22.2 ± 27.3; 10.0 12.0 ± 23.3; 0.0
G3 37.3 ± 35.1; 30.0 26.8 ± 36.0; 5.0
P-value 0.009 0.008
HMGA, High mobility group A.
Expression is given as the percentage of immunoreactive
tumour cells. Mean ± standard deviation; median values.
Wilcoxon rank sum test.
Table 4. Survival analysis related to protein markers using
cut-off scores [median values, namely 10% for HMGA1
(nuclear), and 0% for HMGA2 (nuclear)]*
Total
no. of
patients
No. of
deaths
Median survival
time (months)
(95% CI) P-value
HMGA1
Negative 40 30 14 (10–17) 0.816
Positive 24 20 12.5 (10–22)
HMGA2
Negative 37 27 15 (10–24) 0.196
Positive 26 21 14 (12–18)
CI, Confidence interval; HMGA, high mobility group A.
Log-rank test.
*Similar results were obtained when expression was analysed
as a continuous variable by Cox regression analysis.
A
B
C
Figure 1. Examples of nuclear immunohistochemical detection of
high mobility group A1 (HMGA1). Absent expression in normal
pancreatic tissue (A) and moderate expression in pancreatic intra-
epithelial neoplasia (PanIN) (B), compared with strong, diffuse
expression in pancreatic carcinoma (C).
HMGA proteins in pancreatic cancer 401
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protein express ion and tumour grading
Extent of nuclear HMGA1 and HMGA2 expression
showed a positive correlation with higher tumour
grade. Cells within poorly differentiated tumours (grade
3) more frequently expressed HMGA1 and HMGA2
(mean percentage expression ± SD: 37.3 ± 35.1 and
26.8 ± 36.0, respectively) than those in better-differ-
entiated (grade 1 and 2) tumours (22.2 ± 27.3 and
12.0 ± 23.3, respectively) (P = 0.009 and P = 0.008,
respectively; Table 3).
protein express ion and tnm classif ication of
the tumours
HMGA1 and HMGA2 expression showed a significant
association with the pN stage of the tumours.
Mean ± SD percentage expression levels for HMGA1
and HMGA2 were 18.3 ± 22.8 and 8.4 ± 19.0,
respectively, for nodal negative (pN0) carcinomas, as
compared with 32.7 ± 33.6 and 21.5 ± 32.4, respec-
tively, for nodal positive (pN1) carcinomas (P = 0.012
and P = 0.039, respectively; Table 3). No association
was noted between protein expression and pT stage of
the tumours (P = 0.83 and P = 0.952, respectively;
Table 3).
prognostic signif icance
Median survival times were 12.5 and 14 months for
HMGA1-positive and HMGA2-positive tumours,
respectively, as compared with 14 and 15 months for
HMGA1-negative and HMGA2-negative tumours,
respectively. These differences were not statistically
significant (P = 0.816 and P = 0.196, respectively;
Table 4).
Discussion
Although most patients with pancreatic cancer present
with advanced disease, the molecular events involved
in tumour progression, invasion and metastasis are
poorly understood.
In the present study, we investigated the immuno-
histochemical expression of HMGA1 and HMGA2 in
210 cases of ductal adenocarcinoma of the pancreas
combined on a TMA including in addition 40 examples
of PanIN-3 and 40 normal controls.
A major finding was the increasing mean protein
expression of HMGA1 and HMGA2 between normal
pancreatic tissue, PanIN cases, and invasive adenocar-
cinoma (Table 2). Mean HMGA1 and HMGA2 expres-
sion appeared to progressively increase through the
A
B
C
Figure 2. Examples of nuclear immunohistochemical detection of
high mobility group A2 (HMGA2). A, Normal pancreatic tissue
without HMGA2 expression. B, Pancreatic intraepithelial neoplasia
(PanIN) with moderate HMGA2 expression. C, An example of ductal
adenocarcinoma with strong nuclear HMGA2 expression.
402 S Piscuoglio et al.
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transition from normal tissue to pancreatic cancer.
Moreover, HMGA1 and HMGA2 expression showed a
positive correlation with malignancy grade and neo-
plastic progression, becoming higher with the dediffer-
entiation of the neoplasms and with the presence of
lymph node metastasis. Therefore, our data suggest
that HMGA1 and HMGA2 expression correlates with a
more aggressive phenotype in pancreatic adenocarci-
noma. These findings are in keeping with the recent
studies of Hristov et al.,19,20 who also noted an
association between HMGA1 and HMGA2 expression
and a more malignant phenotype in pancreatic cancer.
HMGA1 was found to correlate with advanced tumour
grade and decreased survival of their patients, whereas
HMGA2 correlated with increasing tumour grade and
lymph node metastasis. However, in our study, both
HMGA1 and HMGA2 showed a positive correlation
with lymph node metastasis. Although we found that
patients with HMGA1 and HMGA2 negative tumours
tended to survive longer, the association with patient
outcome was not statistically significant. This may be
because of the short survival time of most patients with
pancreatic cancer. In addition, Hristov et al.19 reported
that HMGA1 expression correlated with a more
advanced PanIN grade, whereas possible differences
in protein expression between PanIN and adenocarci-
noma were not discussed. In our study, only PanIN-3
lesions were included. Moreover, we demonstrated that
mean protein expression was significantly higher in
pancreatic ductal adenocarcinomas than in PanIN
lesions.
A number of other groups have reported involve-
ment of HMGA genes and proteins in the pathogenesis
of pancreatic cancer. In one study, HMGA1 was found
to be overexpressed in a small number of pancreatic
adenocarcinomas and metastatic lesions, but without
association with tumour grade.25 More recently, Liau
et al.26 reported HMGA1 protein positivity in a high
proportion of ductal pancreatic adenocarcinomas, also
without correlation with tumour differentiation. How-
ever, in this study, in contrast to ours, only staining
intensity was analysed, and the number of carcinomas
was smaller. HMGA1 expression was also found to be
increased in other pancreatic tumours, such as intra-
ductal papillary mucinous neoplasms.26 Studies in
pancreatic ductal adenocarcinoma cell lines have
shown that HMGA1 knockdown decreases cellular
invasion, anchorage-independent cell growth, and
resistance to chemotherapeutic agents.26,27 In addi-
tion, high-level expression of HMGA1 has been
reported in almost all neoplastic tissues, including
colon, breast, lung, ovarian, uterine, prostatic, gastric
and head and neck carcinomas.8–15 HMGA2 has also
been implicated in the development and progression of
human malignancies, including lung adenocarcino-
mas, breast cancer, and squamous cell carcinomas of
the oral cavity.16–18 Additionally, HMGA2 has been
reported to play a role in the epithelial–mesenchymal
transition that takes place during invasion and metas-
tasis.28 A previous study found increased HMGA2
expression by reverse transcription polymerase chain
reaction in ductal pancreatic adenocarcinomas, and
HMGA2 expression by immunohistochemistry.29 How-
ever, associations with grade and outcome were not
included in the analysis, and HMGA2 expression was
also found in pancreatic islet cells and, focally, in non-
neoplastic ductal epithelial cells. In our study, focal
HMGA2 immunoreactivity was also observed in a very
small number of non-malignant ductal epithelial cells.
Regarding the processes underlying the involvement
of HMGA genes in neoplastic transformation, it has
been hypothesized that this probably occurs through
oncofetal transcriptional mechanisms that have not yet
been characterized.21 It has been suggested that the
elevated expression of HMGA1 in tumour cells requires
a complex cooperation between SP1 family members
and AP1 factors, induced by the activation of Ras
GTPase signalling.30 Moreover, the main function of
the HMGA proteins, the regulation of gene transcrip-
tion, is probably based on the ability of HMGA proteins
to down-regulate or up-regulate the expression of
genes that have a crucial role in the control of cell
proliferation and invasion.21 In particular, emerging
evidence suggests that HMGA1 modulates gene expres-
sion, including pathways involved in inflammation,
proliferation, transformation, metastatic progression,
angiogenesis, and DNA repair. Most transcriptional
targets include regulatory elements of nuclear factor-
jB (NF-jB), a mediator of inflammatory pathways,
suggesting that HMGA1 and NF-kB may cooperate to
induce inflammatory signals and drive transforma-
tion.31
One of the advantages of this study is the use of
TMAs, which have provided us with an efficient and
cost-effective way of testing a large number of tumour
specimens. Concerns could be raised about the TMA
technique with regard to the possible limitations in
sampling large, heterogeneous tumours. However,
previous studies have shown comparable results
between whole tissue sections and TMA cores, and
have been able to reproduce numerous clinicopatho-
logical associations previously found with whole tissue
sections.32
In conclusion, we found increasing mean HMGA1
and HMGA2 expression during neoplastic progression
in ductal pancreatic adenocarcinoma, accompanied by
HMGA proteins in pancreatic cancer 403
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a positive correlation of protein expression with both
increasing malignancy grade and the presence of
lymph node metastasis. Our results support the idea
that HMGA1 and HMGA2 may play a significant role
in the late stages of pancreatic carcinogenesis and in
the progression towards a more aggressive tumour
phenotype.
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6.3.1 HMGA1 over-expression represents a poor prognostic index 
in human breast carcinoma. 
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ABSTRACT 
 
Aim: Breast cancer represents the second leading cause of cancer mortality among 
women and accounts for more than 40,000 deaths annually. HMGA1 expression has 
been implicated in the pathogenesis and progression of human malignant tumours, 
including breast carcinomas. The aim of this study was to evaluate HMGA detection 
as a possible prognostic index in breast carcinoma by analyzing a large number of 
breast carcinoma samples.  
 
Methods: HMGA1 expression has been analyzed by immunohistochemistry in a 
large series of breast carcinoma resections (n=1202) combined on a Tissue 
Microarray (TMA) mainly including the ductal carcinoma variant. Then, the results 
were correlated with clinic-pathological parameters and outcome of the patients. 
 
Results: HMGA1 over-expression was found in the large majority of breast 
carcinoma samples, and its over-expression positively correlates with Her2/neu 
amplification and progesterone receptor status, while a negative correlation was 
found with estrogen receptor status. Conversely, no HMGA1 expression was found 
in normal breast tissues.  
 
Conclusions: The data reported here indicate that the level of HMGA1 expression is 
related to an unfavourable breast cancer phenotype and poor prognosis, as 
supported by its strong association with the Her2/neu, PR and ER status that could 
explain, at least in part, the different behaviour of the human breast carcinoma over- 
expressing HMGA1. 
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INTRODUCTION 
 
Breast cancer represents the second leading cause of mortality caused by 
cancer in women (Ellis et al. 2003). Neoplastic breast diseases comprise benign 
form, like fibroadenoma, and very aggressive forms, like undifferentiated breast 
carcinoma. It has been reported that a large series of molecules and patterns 
(growth factors and their receptors, signal transduction molecules, cell cycle 
regulators) are altered and deregulated in sporadic breast cancers (Vogelstein and 
Kinzler 1994).  
Nowadays, a series of genetic markers are evaluated to assess the prognosis 
of breast cancer patients: the BRCA mutational status of patients, the expression of 
estrogen receptor (ER), progesterone receptor (PR), and the Her2/neu receptor 
(Her2) (Deroo et al. 2006, Gao et al. 2002, Hynes et al. 1994, Miecznikowski et al. 
2010). More recently, TGF-beta has also been considered as a potential prognostic 
marker for breast cancer patients (Koumoundourou et al. 2007). Moreover, the 
genetic status has a critical role in assigning the treatment. Indeed, tamoxifen (anti-
estrogen agent) and trastuzumab (monoclonal antibody) are the elected 
chemotherapeutic agents for treating estrogen receptor (ER)–positive breast tumors 
and human Her2–over-expressing tumors, respectively (Carter et al. 1992, Arteaga 
et al. 2003). However, these markers are insufficient to predict the prognosis and to 
indicete the appropriate therapy, and many patients remain over- or under-treated 
(Cianfrocca and Gradishar, 2009). 
HMGA1 protein belongs to the high-mobility group A (HMGA) family that 
consists of three members: HMGA1a, HMGA1b and HMGA2. Two distinct genes, 
HMGA1a and HMGA1b generates these three proteins by alternative splicing 
(Johnson et al. 1989). These proteins are able to bind AT-rich DNA sequences, but 
do not have transcriptional activity per se. However they can alter chromatin 
structure, therefore modulating the transcriptional activation of genes (Thanos and 
Maniatis 1992, Grosschedl et al. 1994).  
HMGA over-expression is a feature of malignant tumours. Both HMGA genes 
are widely expressed during embryogenesis and in neoplastic tissues (including 
pancreas, thyroid, colon, breast, lung, ovary, uterine cervix, prostate, gastric 
carcinomas, squamous carcinomas of the oral cavity, head and neck tumours), 
whereas their expression is absent or very low in adult tissues. Their over-
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expression represents a poor prognostic index and often correlates with metastases 
and reduced survival (Fusco and Fedele, 2007). Their oncogenic role has been 
extensively reported (Wood et al. 2000, Reeves et al. 2001, Berlingieri et al. 2002).  
Previous studies of our group performed on a limited number of breast 
carcinoma samples, of which the clinic-pathological data were available only in a 
small number of cases, did not show any association between HMGA1 expression 
and histological grading. Conversely, we found that HMGA1 expression tended to be 
associated with c-erbB-2 expression (Spearman rho: 0.36; p=0.065), but not with the 
expression of the receptors for estrogenes and progesterone. These results 
appeared in contrast with previous results, showing that enforced expression of 
HMGA1 in breast carcinoma cells induced the ability to form primary and metastatic 
tumours in athymic mice, and that HMGA1 is able to bind to BRCA1 promoter down-
regulating its expression (Baldassarre et al. 2003).  
The aim of the present work was, therefore, to analyse HMGA1 expression in 
a very large number of breast carcinoma tissues (n=1024), all of them provided with 
the most important clinicopathological parameters of patients, such as tumour size, 
lymph node status, endocrine receptors and Her2 status. Here, we confirm the 
HMGA1 over-expression in human breast carcinomas, with respect to the normal 
breast tissues. Moreover, we found that a strong HMGA1 over-expression identifies 
a subset of breast carcinomas characterized by Her2/neu amplification and 
progesterone receptor (PR) expression, but lacking estrogen receptor (ER) 
expression, a signature correlated with a patient poor prognosis.  
 
	
   160	
  
MATERIALS AND METHODS 
 
Human breast tissue samples 
Neoplastic human breast tissue samples and normal controls were collected 
at the Department of Pathology, University of Basel Switzerland. Specimen obtained 
from surgical resections were formalin-fixed and paraffin embedded and stored in the 
archive of the institute. Several expert pathologists (SP, LT and LMT) proceeded to 
examinate and classify tumours according to the American Joint Committee on 
Cancer (AJCC) staging manual (sixth edition). Tumour areas were accurately 
selected to be representative of the tumor specimen in the construction of the TMA. 
The TMA consisted of n=1388 “punches”, n=1202 of which (%) were evaluable. 
Diverse tumoral histotype, as well as clinicopathological characteristic of breast 
carcinoma samples are precisely indicated in Table 1.  
 
Construction of tissue microarray 
Construction of TMA was reported elsewhere (Torhorst et al., 2001). Briefly, 
representative regions of paraffin-embedded donor blocks corresponding to a single 
tumor specimen were used to take core biopsies with 0.6 mm diameter. 
Subsequently, semi-automated apparatus for tissue arraying (Beecher Instruments, 
Silver Spring, MD) was used to transfer core biopsies into a new recipient. Sections 
of 5 micrometer thick were cut using an adhesive-coated slide system (Instrumedics 
Inc., Hackensack, NJ) and analyzed by immunohistochemistry, after verification of 
TMA by H&E staining.  
 
Immunohistochemistry and immunohistochemical evaluation 
TMA sections were used for immunohistochemical analysis of HMGA1 protein 
expression by using an antibody raised against the N-terminal region of the HMGA1 
protein as described elsewhere (Chiappetta et al. 2004). Staining procedures are 
performed as reported elsewhere (Piscuoglio et al. 2012). Negative controls, to 
confirm the specificity of the reaction, were performed by omitting the first antibody 
and by pre-incubating of the first antibody with molar excess of the HMGA1 synthetic 
peptide. Standard indirect immunoperoxidase procedure (ABC Elite, Vector 
Laboratories, Burlingame, CA) was used to develop signals. HMGA1 staining was 
scored by three expert pathologists (SP, LT and LMT) blinded for the clinic-
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pathological parameters. A semi-quantitative methodology was used to perform the 
screening for the percentage of positive cells and for the signal intensity. At least 100 
cells were counted in each punch.  
 
Statistical analysis 
Statistical correlations between variables were tested using a T student test 
(paired and upaired), where appropriate. All tests were two-sided. A p-value <0.05 
was considered statistically significant. Analysis was performed using SAS V9.1 
(SAS Institute, Cary, NC, USA). 
 
Ethics 
All the analyses of this study were performed according to the ethical 
standards required by the local ethic committee of Dipartimento di Biologia e 
Patologia Cellulare e Molecolare, Universita' degli Studi di Napoli “Federico II”, 
IEOS-CNR, Napoli, Italy, and Department of Pathology, University of Basel, Basel, 
Switzerland.  
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RESULTS 
 
Analysis of HMGA1 expression by immunohistochemistry.  
A tissue micro array (TMA) comprising n=1338 cases of human breast 
carcinomas was analyzed by immunohistochemistry for HMGA1 protein expression 
using specific antibodies raised against the N-terminal region of the HMGA1 protein 
as described elsewhere (Chiappetta et al. 2004). TMA consisted mainly of ductal 
carcinoma tissues (n=963), and also including several normal breast tissue samples 
as positive controls. The whole set of clinic-pathological features of the patients are 
reported in Table 1.  
A total of n=1202 samples were informative for determination of the HMGA1 
expression pattern that resulted always nuclear.  
We found that HMGA1 staining was negative in all the normal cases 
analyzed, while HMGA1 expression was positive in all the breast carcinoma tissues 
analyzed (Figure 1). As shown in Table 1, no association was found between 
HMGA1 positivity and the ductal or other histotypes (p=0.883) of breast carcinomas. 
Indeed, HMGA1 staining, expressed as percentage (mean % ± sd, median %) of 
HMGA1-positive cells, was similar among ductal breast carcinomas with different 
histologic grading (Table 1). No significant association was also found with the pT 
stage of the tumours (p=0.402, Table 1). As well, no association was observed 
between HMGA1 protein expression and BRE grade of patients (p=0.2, Table 1). 
Conversely, an inverse correlation was found between HMGA1 over-
expression and the lymph node status of patients (p=0.293, Table 1), In fact, breast 
carcinomas not showing lymph-node colonization (pN0) expressed higher HMGA1 
levels than their counterpart >pN0. However, this result failed to reach the statistical 
significance (Table 1), but if we consider only pN0, pN1 and pN2, this relationship is 
statistically significant  (Table 1).  
Therefore, these findings indicate a lack of association between HMGA1 
expression and the morphologic grading of ductal breast carcinomas.  
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HMGA1 expression correlates with Her2/neu expression and ER and PR status 
Subsequently, we have evaluated the relationship between HMGA1 
expression and several indicators of breast carcinoma invasion (Her2/neu 
amplification, ER and PR status). As reported in Table 1, HMGA1 expression was 
significantly associated with that of Her2/neu (p=0.004). Indeed, HMGA1 and 
Her2/neu staining are positively correlated: low levels of HMGA1 (26.5±29.7) are 
associated with a weak Her2 staining (0+1), whereas high levels of HMGA1 
(32.2±30.9) are correlated with an intense Her2 staining (2+3).  
As far as the correlation of HMGA1 expression with the endocrine status of 
the breast carcinoma samples is concerned, a significant association has been found 
with the retention of PR (p=0.003) and loss of ER expression (p=0.007). Indeed, 
expression of PR was found positively correlated with high levels of HMGA1 
(29.3±31.1) in breast carcinomas (Table 1), while ER expression was found 
negatively correlated with high levels of HMGA1 (31.1±30.9, Table 1). Therefore, in 
human breast carcinomas the over-expression of HMGA1 is positively and 
negatively correlated with PR and ER status, respectively (Table 1). Representative 
cases of breast carcinomas expressing HMGA1, PR and ER are reported in Figure 2 
(Figure 2A, B, C, D). 
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DISCUSSION 
 
The aim of our study was to verify whether HMGA1 protein might be an 
indicator for the diagnosis and prognosis of human breast carcinoma. Therefore, we 
investigated by immunohistochemistry the expression of the HMGA1 protein in 
n=1202 breast carcinoma tissues combined on a TMA and a compare it with multiple 
clinicopathological parameters.  
Consistently with our previous studies showing that HMGA1 protein over-expression 
was found in 60% of ductal carcinomas and in almost all of the lobular carcinomas 
(Chiappetta et al. 2004), we found that the HMGA1 protein resulted over-expressed 
in the breast carcinoma specimens compared to the breast normal control tissues 
and, in addition, a differential HMGA1 protein expression was found between all the 
carcinoma samples analysed. No association was found between HMGA1 
expression and histological grade of ductal carcinomas. Conversely, we have 
observed an inverse trend between the over-expression of HMGA1 and the pN stage 
(if we exclude the pN3 value).  
A strong association was, instead, observed between HMGA1 over-
expression and Her2/neu amplification in breast carcinoma. This result is in line with 
our previously published data, obtained on a shorter series of human breast 
carcinomas where HMGA1 over-expression correlated with the amplification of 
ErbB2 (Chiappetta et al. 2004). Her2 is a transmembrane protein with substantial 
homology to epidermal growth factor receptor. Amplification of this gene coupled 
with resultant over-expression of the protein occurs in about 25% of human breast 
cancers. It has been reported that amplification of c-ErbB2 is associated with a fast 
proliferation and a poor prognosis of breast cancer (Vogelstein and Kinzler, 1994). 
Therefore, HMGA1 over-expression could not only represent a predictor of prognosis 
and outcome, as exerted by amplification of Her2, but it can be also predicted a 
functional link with the amplification of the Her2 gene. In fact, several studies have 
demonstrated an accumulation of amplifications of different genomic regions in 
certain breast cancers considered to exhibit an “amplifier” phenotype (Al-Kuraya et 
al. 2004, Courjal et al. 1997). Therefore, we could hypothesize that that HMGA1 
over-expression may contribute to the accumulation of Her2/neu amplifications, or 
alternatively that the activation of the ErbB2 transduction pathway may lead to 
increased HMGA1 protein synthesis. 
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Likewise, we found a strong relationship between the HMGA1 over-
expression and the presence or absence of PR and ER, respectively. It is well known 
that breast carcinomas not expressing ER are insensitive to estrogen antagonists 
such as tamoxifen and, as consequence, these carcinomas are insensitive to 
hormonal treatments and display a negative outcome (Teschendorff et al. 2007). 
These findings are consistent with HMGA1 over-expression seems associated with a 
highly malignant phenotype, also representing a poor prognostic index since HMGA1 
over-expression often correlates with the presence of metastasis, and with a reduced 
survival, as it has been extensively reported elsewhere (Abe et al. 2003, Meyer et al. 
2007).  
On the other hand, the positive correlation between the HMGA1 over-
expression and the presence of the PR (Table 1), apparently would link the 
expression of HMGA1 to a better prognosis, since PR+ breast carcinoma patients 
respond to the hormonal treatment, even though there are reports indicating that 
breast cancer patients with ER-/PR+ tumours arose primarily premenopausal and in 
younger people (Rakha et al. 2007, Rhodes et al. 2009, Cserni et al. 2011). Although 
these ER-/PR+ patients are generally considered candidates for endocrine therapy, 
they gain less benefit from adjuvant tamoxifen treatment than ER+/PR+ patients and 
ER-/PR+ patients <55 years old were found to have significantly worse survival than 
younger ER+/PR+ patients (Yu et al. 2008). Therefore, considering the outcome, the 
PR expression needs to be evaluated together with the ER status, whose expression 
is negatively related to that of HMGA1. Since HMGA1 is a chromatin protein able to 
up- or down-regulate the expression of important cancer-related genes (Fusco and 
Fedele, 2007), it could be envisaged that HMGA1 proteins could be able to modulate 
the expression of both ER and PR expression acting on its promoter. This could 
have important prognostic significance, since the over-expression of HMGA1 could 
influence the hormonal responsiveness and, therefore, the outcome of breast cancer 
patients. 
In conclusion, taken together, our findings indicate that the level of HMGA1 
expression is related to an unfavourable breast cancer phenotype and poor 
prognosis, as supported by its strong association with the Her2/neu, PR and ER 
status that could explain, at least in part, the different behaviour of the human breast 
carcinoma over-expressing HMGA1. These findings further support the HMGA1 as 
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an appropriate target for the therapy of human cancer, as suggested by numerous in 
vitro and in vivo studies modulating its expression in cancer cells. 
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Figures and Tables: 
 
Table 1: Patient characteristics and association of HMGA1 with clinico-pathological 
features of breast cancer patients. Raw, continuous scores (% positive staining) are 
used. 
 
Clinico-
pathological 
feature 
 HMGA1 
Mean (%) ± SD, 
median (%) 
P-value 
     
Histological 
subtype 
Ductal carcinoma 
(n=963) 
27.4±30.4 12.5 0.883 
 Other (n=375) 26.9±28.4 15  
     
pT stage pT1 (n=447) 28.4±30.2 15 0.402 
 pT2 (n=656) 27.2±29.9 11.3  
 pT3 (n=84) 26.9±27.9 18.8  
 pT4 (n=134) 24.7±29.7 10  
     
pN stage pN0 (n=598) 29.0±30.4 20 0.293 
 pN1 (n=452) 26.4±29.5 10  
 pN2 (n=105) 24.7±28.3 10  
 pN3 (n=27) 34.4±34.5 20  
     
Her2/neu Staining 0+1 (n=1059) 26.5±29.7 10 0.004 
 Staining 2+3 (n=201) 32.2±30.9 20  
     
ER status 0% (n=322) 31.1±30.9 20 0.007 
 >0% (n=978) 26.2±29.5 10  
     
PR status 0% (n=603) 23.6±28.0 10 0.003 
 >0% (n=402) 29.3±31.1 20  
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Figure 1 
Representative IHC staining of human breast cancers 
 
  
  
 
 
Figure 1. Immunohistochemical analysis of a human breast cancer TMA for HMGA1 
protein expression. Examples of HMGA1 immunohistochemistry results in breast 
carcinomas: negative (A), weak (B), moderate (C), and strong (D) staining.  
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Figure 2 
Representative IHC staining of human ductal breast cancers. 
 
  
  
 
 
Figure 2. Immunohistochemical analysis of HMGA1 expression in breast ductal 
carcinomas. ER- breast carcinoma (A). ER+ breast carcinoma (B). PR- breast 
carcinoma (C). PR+ breast carcinoma (D). 
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6.4 Effect of EpCAM, CD44, CD133 and CD166 expression on 
patient survival in tumours of the ampulla of Vater. 
 
My contribution to this work:  
• Immunohistochemical analysis of whole tissue and microarray sections; 
• Statistical comparison and survival analysis; 
• Data analysis and manuscript writing; 
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Effect of EpCAM, CD44, CD133 and CD166
expression on patient survival in tumours of the
ampulla of Vater
Salvatore Piscuoglio,1 Frank S Lehmann,2 Inti Zlobec,1 Luigi Tornillo,1
Wolfgang Dietmaier,3 Arndt Hartmann,4 Peter H Wu¨nsch,5 Fausto Sessa,6
Petra Ru¨mmele,3 Daniel Baumhoer,1 Luigi M Terracciano1
ABSTRACT
Background Carcinomas of the Vaterian system are rare
and presumably arise from pre-existing adenomas.
According to the cancer stem cell (CSC) hypothesis, only
a small subset of tumor cells has the ability to initiate
and develop tumor growth. In colorectal cancer, CD44,
CD133, CD166 and EpCAM have been proposed to
represent CSC marker proteins and their expression has
been shown to correlate with patient survival.
Aims To evaluate a potential role of these CSC proteins
in tumors of the ampulla of Vater, we investigated their
expression in 175 carcinoma, 111 adenoma and 152
normal mucosa specimens arranged in a Tissue
Microarray format.
Materials and methods Membranous
immunoreactivity for each protein marker was scored
semi-quantitatively by evaluating the number of positive
tumor cells over the total number of tumor cells. Median
protein expression levels were used as cut-off scores to
define protein marker positivity. Clinical data including
survival time were obtained by retrospective analysis of
medical records, tumor registries or direct contact.
Results The expression of all evaluated marker proteins
differed significantly between normal mucosa, adenoma
and carcinoma samples. In all markers, we found
a tendency towards more constant expression from
normal to neoplastic tissue. EpCAM expression was
significantly correlated with better patient survival. The
increased expression of CD44s, CD166 and CD133 from
normal mucosa samples to adenoma and carcinoma was
linked to tumor progression. However, there was no
statistically significant correlation with survival.
Conclusion Our findings indicate, that in ampullary
carcinomas, loss of expression of EpCAM may be linked
to a more aggressive tumor phenotype.
INTRODUCTION
The ampulla of Vater combines the terminal and
common segment of the bile and pancreatic duct
before they enter the duodenum.1 Carcinomas
originating from this complex anatomical unit are
uncommon and have an incidence of approximately
four to six cases per million population.2 3 Carci-
nomas of the papilla of Vater, defined as junction of
the biliary, and pancreatic ducts within the
duodenum account for 6%e20% of all peripancre-
atic tumours4 and represent 10%e50% of all
cancers resected by pancreaticoduodenectomy.5
They can be sited in the ampulloduodenal part of
the papilla of Vater, which is lined by intestinal
mucosa. They also can develop in deeper parts of
the ampulla, which are lined by pancreaticobiliary
duct mucosa. Clinically, tumours of the ampulla of
Vater are rapidly detected due to biliary outflow
obstruction.6 7 Early symptoms as well as differ-
ences in tumour biology are held responsible for
their favourable clinical outcome (median survival
30e50 months, 5-year survival rate 21%e64%).8 9
Histologically, intestinal, pancreaticobiliary, intes-
tinal-mucinous, invasive papillary and poorly
differentiated subtypes can be distinguished.10 The
subtypes differ in several clinical and histological
aspects including cell type-specific markers, onco-
gene expression, modes of tumour spread as well as
extent and interaction with the extracellular
matrix.11 Most authors agree that local spread of
the tumour (T stage) is the only significant and
independent prognostic factor for this cancer,
whereas the predictive value of tumour grade and
lymph node metastases is still debated.12 13 More
recent research data suggest that the prognosis of
ampullary cancer may be related to the histological
differentiation in intestinal or pancreatobiliary
types.14 In the last years, several molecular markers
have been proposed as additional prognostic
factors. However, most of these studies have
yielded conflicting results and have not been still
validated by other reports.15e19 Several sources of
discrepancy between different reports have been
acknowledged mainly due to non-standardised
assays often performed on underpowered patient
samples that are too small to enable meaningful
conclusions to be drawn. Therefore, there is
undoubtedly a need for additional prognostic
markers for such neoplasia. Recent findings support
the concept that cells with the properties of stem
cells are integral to the development and perpetu-
ation of several forms of human cancer.20 21 Cancer
stem cells (CSCs) have low replicative ability,
multipotency and resistance to apoptosis and are
responsible for tumour development.22 In the
different types of digestive tumours, different sets
of markers have emerged as the most useful for the
identification of CSC. In particular, in intestinal as
well as in pancreatic cancer, some markers
including CD44, EpCAM, CD166 and CD133 have
been indicated as possible CSCs markers. Further-
more, in colorectal cancer, we have shown that
their expression inversely correlated with patient
survival.23 However, conflicting results have been
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reported about the role of some putative CSC markers in
gastrointestinal tract tumours. In particular, contradictory
findings have been reported about the association of CD44, in
particular of its v6 splicing variant, and tumour
progression.24e26 Furthermore, while CD133 molecule was
initially identified as a reliable CSC marker in human colorectal
cancers,27 28 a subsequent study has shown that in both mouse
and human colorectal cancers, CD133 expression is not
restricted to rare cell subsets, but it is detectable in a large
majority of tumour cells, irrespective of their tumourigenicity.29
Because of the lacking studies dealing with CSC markers in
ampullary tumours, the aim of this study was to elucidate the
expression and the prognostic role of CD133, CD166, CD44s,
EpCAM expression in ampullary tumours by using a tissue
microarray (TMA) including 175 carcinoma, 111 adenoma and
152 normal mucosa specimens of the papilla of Vater.
MATERIAL AND METHODS
Ethics
The study has been approved by the institutional review board
of the Department of Pathology, University of Basel,
Switzerland. All the analyses were performed according to the
ethical standards required by each local ethic committee.
Patients’ characteristics and tissue samples
Patients’ characteristics have been previously described by our
study group.30 31 Briefly, the files of the Institute of Pathology,
University Hospital Basel (Switzerland), the Institute of
Pathology, University of Regensburg (Germany), the Institute of
Pathology Nuernberg and the Anatomic Pathology Unit,
Department of Human Morphology, University of Insubria,
Varese (Italy), were searched for adenomas or carcinomas of the
ampulla of Vater over the period from 1985 to 2005. In total, 175
carcinoma, 111 adenoma and 152 normal mucosa samples were
retrieved. Sufficient paraffin-embedded tissue for TMA
construction was available in all cases. The male-to-female ratio
was 3:2; mean age at diagnosis was 63 years (range
15e81 years). To our knowledge, no case was associated with
Familial adenomatous polyposis (FAP).
TMA construction
TMAs were constructed from formalin-fixed and paraffin-
embedded specimens using a custom-built instrument (Beecher
Instruments, Silver Spring, Maryland, USA) as previously
described.30 31 Briefly, H&E-stained sections were obtained from
each selected primary block (donor block) to define representa-
tive tissue regions. Core biopsies (0.6 mm cylinders) were taken
from the selected tissue regions and then transferred to
a paraffin recipient block. The resulting TMAwas cut into 4 mm
sections, which were used for immunohistochemistry. The
number of punches per patient ranged from one to three for
both normal tissue and carcinoma and from one to five for
adenomas. If more than one punches was obtained, the addi-
tional punches were taken from different representative blocks.
Histology and immunophenotyping
All tumours were classified according to the guidelines of the
Armed Forces Institute of Pathology using only H&E stains.10
Mild dysplasia was designated as low-grade dysplasia, whereas
moderate and severe dysplasia was considered as high-grade
dysplasia. Carcinomas histologically indistinguishable from
colorectal carcinomas were classified as intestinal types, whereas
carcinomas showing a dense desmoplastic stroma surrounding
small glands or solid nests of tumour cells were referred to as the
pancreaticobiliary subtype. Invasive papillary carcinomas typi-
cally formed papillary and micropapillary structures in their
invasive component and poorly differentiated adenocarcinomas
lacked histologic features of glandular or other differentiation.
Additionally, an intestinal-mucinous subtype, characterised by
any mucinous differentiation, was defined.
For immunohistochemistry, sections were pre-treated with
CC1 (Ventana Medical Systems, Tucson, Arizona, USA) and
incubated with primary antibodies against CD133, CD44s,
CD166 and EpCAM (table 1). Staining procedures were
performed on a Benchmark immunohistochemistry staining
system (Ventana Medical Systems) using iVIEW-DAB as
chromogen.
Membranous immunoreactivity for each protein marker was
scored semiquantitatively by evaluating the number of positive
tumour cells over the total number of tumour cells. Scores were
assigned using 5% intervals and ranged from 0% to 100%. All
tissues were scored by an experienced pathologist (LT), blinded
to clinicopathological information. To define interobserver
agreement, all samples were examined independently by
a second pathologist (DB).
Statistical analysis
Statistical correlations between categorical variables were tested
using a c2 or Fisher exact test, where appropriate. Differences in
patient survival were demonstrated using the KaplaneMeier
method and analysed using the log-rank test in univariate
analysis. All tests were two sided. p Values <0.05 were consid-
ered statistically significant. Cut-off scores were selected by
evaluating the receiver operating characteristic curves for each
protein marker and the end-point survival. The point on the
curve with the shortest distance to the coordinate (0, 1) was
selected as the threshold value to classify cases as ‘positive/
overexpressing’ or ‘negative/loss’.32 Analysis was performed
using SAS V.9.1 (SAS Institute).
RESULTS
Patients’ characteristics and tissue samples
Overall, 175 carcinoma, 111 adenoma and 152 normal mucosa
samples were retrieved. In patients with carcinomas, we found
19 pT1 (11%), 59 pT2 (34%), 63 pT3 (36%) and 13 pT4 (7%)
tumours as well as 17 G1 (10%), 82 G2 (47%) and 55 G3 (31%)
cases (no data concerning T stage and grading in 21 samples).
Seventy-three (42%) carcinoma patients were node positive and
two (1%) had haematogenous metastases at initial diagnosis.
Full clinical data including survival time were available in 133
patients with ampullary carcinoma (76%). Patients were studied
up to 164 months after operation. Median follow-up time was
36 months.
The histological classification of 175 ampullary carcinomas
identified 85 intestinal types, 42 pancreaticobiliary types, 23
poorly differentiated adenocarcinomas, 16 intestinal-mucinous
types and nine invasive papillary types.
Table 1 Primary antibodies against CD133, CD44, CD166 and EpCAM
Antibody Dilution/detection Pretreatment
CD44 (Dako, DF1485) 1:50/BOND BOND ER2
CD133 (cell signalling, C24B9) 1:100/BOND Steamer 1208C, pH8
CD166 (Novocastra, MOG/07) 1:200/BOND BOND ER2
EpCAM (Novocastra, VU-1D9) 1:200/BOND BOND ER2
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Histological grading was evaluable in 76 of 111 (68%)
adenomas and disclosed low-grade dysplasia in 57 of 76 (75%)
and high-grade dysplasia in 19 of 76 (25%) cases. All adenomas
demonstrated tubular or tubulovillous architecture. Seventy-
eight of 111 (70%) adenoma samples were derived from patients
with coexisting carcinoma.
Immunophenotyping
Tissue samples of ampullary carcinoma patients expressing
CD44, CD133, CD166 and EpCAM are shown in figure 1.
Moreover, in table 2, the distribution of the different biomarkers
across different diagnostic categories is shown.
The expression of all marker proteins differed significantly
between carcinoma, adenoma and normal mucosa samples
(table 3).
We have also evaluated the positivity in the two principal
histologic types (intestinal type vs pancreatobiliary type).
EpCAM was significantly more expressed in intestinal type
(table 4).
We have tried also to evaluate if there is some difference
between adenomas without coexisting carcinoma and adenomas
without coexisting carcinomas. Only CD44 was significantly
more expressed in adenomas with coexisting carcinomas
(p¼0.043).
No difference was found between low-grade and high-grade
adenomas (data not shown).
Survival
Five-year survival (95% CI) was 45.2 (34 to 56) in EpCAM-
positive versus 28.2 (11 to 48) in EpCAM-negative patients
(p<0.05). EpCAM was not an independent prognostic factor
after adjusting for pT and pN stages. Survival curves of
both patient groups using the KaplaneMeier method are
demonstrated in figure 2.
DISCUSSION
Tumours of the papilla of Vater are a relatively rare neoplastic
entity that came into focus in recent years. Significant overlap
exists in phenotypic and molecular characteristics between
ampullary and colorectal carcinomas. As in colorectal cancer, the
development of ampullary carcinoma from adenomas as
precancerous lesions has been well documented, and studies
investigating molecular alterations associated with the proposed
adenomaecarcinoma sequence have been also performed,
including our group.33 However, still missing is a comprehensive
analysis of the expression of putative CSC markers in very large
groups of patients, amenable to detailed statistical analysis.
Moreover, the prognostic significance of the co-expression of
multiple CSC markers within the same tumour has not been
evaluated so far.
This is the first systematic study assessing the prognostic
value of four CSC markers, namely EpCAM, CD44, CD133 and
CD166, in a large series of patients with ampullary tumours.
Figure 1 Immunophenotyping in
tissue samples from patients with
ampullary carcinoma (4003). (A) CD44.
(B and C) CD133. (D and E) CD166. (F)
EpCAM.
Table 2 Distribution of biomarkers between different diagnostic categories
Number of cases within each expression category
Sum0% 1%e5% 6%e20% 21%e40% 41%e60% 61%e80% 81%e100%
Normal
CD133 9 63 30 0 1 1 0 104
CD44 67 20 8 7 3 6 4 115
CD166 81 5 6 3 6 1 13 115
EpCAM 7 1 0 0 2 2 89 101
Adenoma
CD133 10 61 14 0 0 0 0 85
CD44 25 13 17 5 3 14 12 89
CD166 58 9 5 1 4 3 6 86
EpCAM 0 0 0 1 2 1 89 93
Cancer
CD133 16 83 45 6 1 0 0 151
CD44 38 15 27 19 9 18 18 144
CD166 84 19 14 9 5 7 10 148
EpCAM 2 0 1 1 3 3 136 146
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The overexpression of EpCAM was significantly correlated with
better survival time. The increasing expression of CD44, CD166
and CD133 from normal mucosa samples to adenoma and
carcinoma was linked to tumour progression. However, there
was no statistically significant correlation with survival.
EpCAM is a glycosylated, 30e40 kDA type I membrane
protein, which is expressed in a variety of human epithelial
tissue cancers, as well as in progenitor and stem cells. It is
composed of an extracellular domain with epidermal growth
factor and thyroglobulin repeat-like domains, a single trans-
membrane domain and a short 26 amino acid intracellular
domain called EpICD. In normal cells, EpCAM is predominantly
located in intercellular spaces, where epithelial cells form very
tight junctions. Therefore, on normal epithelia, it is sequestered
and may be much less accessible to antibodies than in cancer
tissue, where it is homogeneously distributed on the cell
surface. Furthermore, EpCAM is part of the signature of cancer-
propagating cells in numerous solid tumours as well as in normal
progenitor and stem cells.34
EpCAM was one of the first tumour-associated antigens
identified in the late 1970s. Systematic analysis of EpCAM
expression for intensity and frequency showed that EpCAM
is expressed on essentially all human adenocarcinoma, on
certain squamous cell carcinoma, on retinoblastoma and on
hepatocellular carcinoma.35
Importantly, EpCAM is part of the signature of cancer-
propagating cells in numerous solid tumours and of normal
progenitor and stem cells.34 The controversial biological role of
EpCAM has recently been discussed by van der Gun et al.36 It is
of interest that EpCAM overexpression has been associated
with both decreased and increased survival time. EpCAM exerts
different effects on cell adhesion, either promoting or
preventing metastasis.36 The correlation of EpCAM expression
and poor survival has been described in several tumour types,
including invasive breast cancer,37 urothelial carcinoma of the
bladder,38 gallbladder carcinoma39 40 and squamous cell carci-
noma of the oesophagus.41 In different tumours, studies on
EpCAM-directed immunotherapeutic therapies are currently in
clinical development. Therapeutic trials of monoclonal anti-
bodies directed against EpCAM have shown that they may
induce antibody-based cellular cytotoxicity by adhering
to cytokines such as interleukin 2 or complement-based
cytotoxicity by activating T cytotoxic cells.42 43
Previous studies have yielded conflicting results regarding
EpCAM expression and survival in ampullary carcinoma. By
Scheunemann et al,44 EpCAM expression has been associated
with poorer survival in tumours of the papilla of Vater. This
study, however, was mainly focused on the frequency and
prognostic impact of minimal tumour cell spread in lymph
nodes classified as ‘tumour free’ in routine histopathologic
evaluation, and EpCAM expression in primary tumours was not
analysed.
More recently, Fong et al45 were unable to prove a prognostic
value of EpCAM overexpression in pancreatic and ampullary
carcinoma. In contrast, in our study, we showed that decreased
EpCAM membranous expression significantly correlated with
biological features of aggressive tumour behaviour. Our study
therefore suggests that diminished EpCAM expression is related
to tumour invasiveness and progression and it is linked to a more
aggressive tumour phenotype. This could also be confirmed by
the more frequent expression of EpCAM in intestinal-type than
in pancreatobiliary-type tumours. Intestinal-type tumours are in
fact associated with a better prognosis.14
Several reasons for the discrepancies between our results and
previous studies can be hypothesised including differences in
sample size (power for detecting prognostic differences), meth-
odology (TMA vs whole tissue sections), different clones of
antibody and, most importantly, the choice of cut-off scores for
the definition of positive staining or staining intensity.
EpCAM is intensely used as a therapeutic target for antibody-
based approaches. Future development of EpCAM-directed
therapeutics may profit from newly identified functions of
EpCAM as mitogenic signal transducer in various ways. An
important insight is that EpCAM is apparently needed to
maintain distinct cancer cell attributes46 and, potentially, the
CSC phenotype as well. This function can reduce the risk of
immune escape by loss of EpCAM target expression from cancer
cells. EpCAM-directed therapies may be selective for those
cancer cells with the strongest negative impact on prognosis and
for cancer-propagating subsets of malignant cells.
Discrepant results have also been reported regarding the
effect of CD44 gene or protein and its splice variants on survival
in tumour patients and it is an important receptor that binds
hyaluronan (HA). CD44 has previously been considered to be
a marker of tumour invasiveness and metastasis. Only recently,
it has been described as putative colorectal CSC marker.
Table 3 Expression of all evaluated marker proteins in normal mucosa,
adenoma and carcinoma samples
Normal Adenoma Carcinoma p Value
CD44+ (>5%) 29/118 (24.6%) 52/90 (57.8%) 91/145 (62.8%) <0.001
CD133+ (>5%) 30/104 (28.9%) 11/74 (12.9%) 44/151 (29.1%) 0.012
CD166+ (>0%) 34/120 (28.3%) 28/87 (32.2%) 64/151 (42.4%) 0.044
EpCAM +(100%) 89/104 (85.6%) 88/93 (94.6%) 115/145 (79.3%) 0.005
Table 4 Expression of evaluated markers in the two principal histologic
subtypes of ampullary carcinoma
Intestinal Pancreatobiliary p Value
CD44+ (>5%) 82/99 (82.8%) 33/41 (80.5%) 0.805
CD133+ (>5%) 27/88 (30.7%) 12/40 (30.0%) 0.938
CD166+ (>0%) 73/97 (76.8%) 32/44 (72.7%) 0.672
EpCAM+ (100%) 68/75 (90.7%) 25/33 (75.8%) 0.039
The bold value means that EpCAM overexpression is statistically significant.
Figure 2 Survival of patients with EpCAM-positive and -negative
ampullary carcinoma using the KaplaneMeier method.
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However, CD44 does not seem to belong to the group of genes,
such as OCT4 and NANOG, that are central for maintaining
stem cell characteristics. Nonetheless, two connections
between CD44 and genes that regulate stem cell characteristics
have been described. First, CD44 is a target of the WNT
pathway. Loss of adenomatous polyposis coli (APC) function
leads to the constitutive activation of b catenin, a constituent
of the WNTsignalling pathway. CD44s and CD44v6 expression
is restricted to the intestinal crypts in non-transformed tissue,
but both CD44 isoforms are strongly overexpressed in
dysplastic crypts and adenomas in humans and mice with
mutant APC.47 Second, HAeCD44 binding promotes protein
kinase C (PKC) activation and this increases NANOG phos-
phorylation and translocation to the nucleus. Here, it associates
with Drosha and an RNA helicase, p68, leading to the tran-
scription of the oncogenic microRNA (miRNA) miR-21 and
a reduction in the expression of the tumour suppressor
programmed cell death 4. These events initiate the upregulation
of the inhibitor of apoptosis (IAP) proteins and multidrug
resistant protein 1 (MDR1). CD44, in turn, associates with and
stabilises MDR1 expression.48 This could be one mechanism
through which CD44 contributes to stem cell resistance to
chemotherapy, as MDR1 exports several drugs from cells.
In several gastrointestinal tumours, including colorectal
cancer,23 stromal49 as well as neuroendocrine tumours,50 loss of
CD44 expression has been associated with disease progression
and reduced survival. In our study, CD44 expression was
more frequently associated with adenomas with coexisting
carcinomas.
Our study is also the first to evaluate the prognostic impact of
CD166 in ampullary carcinoma. We found an increasing
expression of CD166 from normal tissue to carcinoma,
suggesting that the increased expression of this marker might be
linked to tumour progression. Our data are supported by
a recent study in colorectal cancer patients, where a similar
increasing expression of CD166 from normal to neoplastic tissue
has been described by Weichert et al.51
We speculate that our findings of decreased rather than
increased expression of membranous EpCAM expression and its
association with features of tumour progression are mainly
a consequence of its cell adhesion function.
In colorectal cancer, Kojima et al52 and Horst et al53 reported
a significant correlation of increased CD133 expression and poor
clinical outcome. In contrast, in a study on non-small-cell lung
cancer, CD133 expression was not a prognostic factor for
survival.54 Consistent with the latter study, we found no
significant impact of CD133 on survival in our series of
ampullary cancer patients.
In summary, we have provided evidence that in ampullary
carcinoma, loss of expression of EpCAM, but not of CD44,
CD133 or CD166, is linked to poor survival.
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6.5 MAGE-A10 is a nuclear protein frequently expressed in high 
percentages of tumor cells in lung, skin and urothelial 
malignancies. 
 
 
 
My contribution to this work:  
• Immunohistochemical analysis of whole tissue and microarray sections; 
• Data analysis and statistical comparison; 
 
	
  	
   184	
  
MAGE-A10 is a nuclear protein frequently expressed
in high percentages of tumor cells in lung,
skin and urothelial malignancies
Elke Schultz-Thater1*, Salvatore Piscuoglio2*, Giandomenica Iezzi1, Cle´mentine Le Magnen1, Paul Zajac1,
Vincenza Carafa2, Luigi Terracciano2, Luigi Tornillo2* and Giulio C. Spagnoli1*
1 Institute for Surgical Research and Hospital Management and Department of Biomedicine, University of Basel, Basel, Switzerland
2 Institute of Pathology, University of Basel, Basel, Switzerland
MAGE-A10 is a highly immunogenic member of the MAGE-A family of cancer/testis tumor-associated antigens (C/T TAAs).
Studies performed with broadly reactive antibodies have helped to initially characterize this TAA. However, no specific
reagents have been developed so far, thus preventing a thorough analysis of its expression in healthy and tumoral tissues.
We have produced MAGE-A10 gene product in soluble recombinant form, and we have used it to generate specific monoclonal
antibodies (mAbs). One of these reagents, recognizing an epitope located at the COOH terminus of the MAGE-A10 gene
product, was used to stain a multitumor tissue microarray comprising more than 2,500 paraffin-embedded specimens
including healthy tissues, benign tumors and malignancies of different histological origin. MAGE-A10 protein was identified as
an intranuclear protein of an apparent molecular weight of 70 kDa, expressed in normal spermatogonia and spermatocytes
but in no other healthy tissue. Most importantly, this C/T TAA appears to be expressed in high (>50%) percentages of cancer
cells from a number of malignancies, including lung, skin and urothelial tumors. Unexpectedly, high expression of MAGE-A10
TAA at the protein level was also detectable in gynecological malignancies and stomach and gall bladder cancers.
The characterization of MAGE-A10-specific reagents might set the stage for the development of targeted active
immunotherapy by clarifying potential indications and by allowing the selection of patients eligible for treatment and the
monitoring of its effectiveness.
MAGE-A tumor-associated antigens of the cancer/testis
family are expressed in a very limited number of healthy
tissues typically including spermatogonia, and, for some of
them, thymus and placenta. In contrast, they are expressed in
a large variety of malignancies derived from diverse tissues,
including, among others, melanoma, lung cancers, prostate
cancers, breast cancers, hepatocellular carcinoma and head
and neck cancers.1,2
In these tumors, their expression can be used for diagnos-
tic purposes or for the identification of patients potentially
benefiting of targeted immunotherapies. Quantitative real-
time PCR (qRT-PCR) is currently used for the detection, at
the gene level, of the expression of MAGE-A tumor-associ-
ated antigens. On the other hand, only a limited number of
reagents are available to detect the corresponding proteins.3
MAGE-A10 is probably the most immunogenic antigen
of the MAGE-A family,4–8 and, therefore, it represents a
potentially highly attractive target of active specific immuno-
therapies. This antigen, expressed in the form of a 72-kDa
nuclear protein, has been identified thanks to broadly reactive
monoclonal antibodies (mAbs) recognizing it together with
other members of the MAGE-A family.9 However, no exqui-
sitely specific reagents have been developed so far, thus
preventing a precise identification of cells expressing it in
healthy and cancerous tissues and, in particular, in paraffin-
embedded specimens. This information is of critical relevance
in the selection of patients potentially eligible for targeted
active immunotherapies and for the monitoring of their
effectiveness.
Upon expression cloning, we have produced MAGE-A10
in soluble form and we have used it to generate highly spe-
cific mAbs. Here, we report that MAGE-A10-specific mAbs
are able to identify their target antigen in the nuclei of tumor
cells in paraffin-embedded clinical samples. Staining of a
multitumor array including more than 2,000 specimens indi-
cates that MAGE-A10 cancer/testis tumor-associated antigen
(C/T TAA) is highly expressed in lung, skin and urothelial
malignancies.
Key words: cancer/testis tumor-associated antigens, MAGE-A10,
immunohistochemistry, tissue microarray, cancer immunotherapy
Grant sponsor: SNF; Grant numbers: 320030-120320, 3100A0-
122235/1
*E.S.-T., S.P., L.T. and G.C.S. contributed equally to this work
DOI: 10.1002/ijc.25777
History: Received 30 Jun 2010; Accepted 14 Oct 2010; Online 15
Nov 2010
Correspondence to: Giulio C. Spagnoli, Institute for Surgical
Research and Hospital Management and Department of
Biomedicine, University of Basel, 20 Hebelstrasse, 4031 Basel,
Switzerland, Tel.: þ41-61-265-2378, Fax: þ41-61-265-3990,
E-mail: gspagnoli@uhbs.ch
T
um
or
Im
m
un
ol
og
y
Int. J. Cancer: 129, 1137–1148 (2011) VC 2010 UICC
International Journal of Cancer
IJC
 
	
  	
   185	
  
Material and Methods
Cell lines
MZ-2 and A375 cell lines are gifts of Dr. Rimoldi (Ludwig Insti-
tute, Lausanne, Switzerland). RE cell line is a gift of Dr. Siegrist,
formerly at the University of Basel, whereas WM115 cell line was
obtained from American Type Culture Collection (Rockville,
MD). SK-Mel-37 cell line is a gift of Dr. Jungbluth (Ludwig Insti-
tute at Memorial Sloan Kettering Cancer Center, New York, NY).
Na8 cell line is a gift of Dr. Jotereau (Nantes, France).10 All cell
lines were cultured in RPMI 1640 medium, supplemented with
10% FCS, nonessential amino acids, glutamine and antibiotics (all
from Invitrogen, Basel, Switzerland).
Preparation of MAGE-A10 fusion protein
MAGE-A10 entire gene11 was PCR amplified from cDNA
derived from the SK-Mel-37 melanoma cell line by using the
following primers, allowing the cloning into a suitable expres-
sion vector and including EcoR I and Hind III restriction sites:
forward: 50 CCCGAATTCCCTCGAGCTCCAAAGCG
TCAG 30
reverse: 50 CCCAAGCTTATTCAGGGTAGGAGAA 30.
A 1110-bp band was excised and inserted into pET-32a
vector (Novagen, Madison, WI) allowing inducible expression
of inserted genes in the form of fusion proteins containing
thioredoxin and a six-histidine tail.12 The plasmid was used
to transform BL21(pLysS) E. coli strain. After a 4-hr induc-
tion in the presence of IPTG (1 mM final concentration),
bacterial cultures were lysed and recombinant proteins were
purified under native conditions upon binding to nickel
resins (Ni-NTA, Qiagen, Basel, Switzerland) and eluted in
the presence of 250 mM imidazole. Production and purifica-
tion of the recombinant proteins were monitored by SDS-
PAGE and Coomassie blue staining (Fig. 1a).13 Additional
recombinant C/T TAAs was similarly produced in E. coli.
Production of monoclonal antibodies
BALB/c mice were repeatedly injected i.p. at 2-week intervals
with 100 lg Ni-purified material containing MAGE-A10
gene product, in the presence of Sigma adjuvant system
(Sigma, Buchs, Switzerland). Three days after a last injection,
animals were sacrificed, and fusions were carried out accord-
ing to standard methods. Screening of HAT-resistant hybrid-
oma supernatants was performed by ELISA.
Detection of MAGE-A10 gene expression
Total cellular RNA was extracted from the cell lines under
investigation (see below), reverse transcribed and tested in
qRT-PCR assays in the presence of primers and probes spe-
cific for b-actin-positive control gene5 and of the following
MAGE-A10-specific reagents:
forward: 50 CAGGGAGAGCAAGAGGTCAAGA 30
reverse: 50 GGGAGTGTGGGCAGGACTT 30
FAM probe: CAGCACTGAAGGAGAAGACCTGCCTGTG.
Specific gene expression was quantitated by using the 2-
DDCT method on data normalized by using b-actin as refer-
ence gene.14 Results were expressed as ratio to SK-Mel-37
reference cell line.
Epitope mapping
The FliTrx random peptide library (Invitrogen, Basel, Switzer-
land) composed of 1.77 ! 108 primary clones of E. coli with a
dodecamer peptide sequence inserted within the Thioredoxin
(TrxA) active-site loop was used to identify epitopes recog-
nized by MAGE-A10-specific mAb, as previously detailed.15
Briefly, 2 ml of the FliTrx library was induced in the presence
of IMC medium containing ampicillin and 100 lg/ml trypto-
phan at 25"C. Bacteria were then ‘‘panned’’ on 60-mm tissue
culture plates (Becton Dickinson, Franklin Lakes, NJ) pretreated
with the mAb under investigation (50 lg/ml in sterile water).
After the removal of unbound cells, bacteria were amplified o/n
in IMC medium at 25"C. After five rounds of panning and cul-
ture, E. coli were streaked onto RMG medium plates containing
100 lg/ml ampicillin and incubated overnight at 30"C. Individ-
ual clones tested positive in Western blot7 were selected and
amplified o/n at 30"C in RM medium containing ampicillin.
DNA was isolated using the NucleoSpin kit (Macherey-Nagel,
Oensingen, Switzerland), and plasmids were sequenced by using
the FliTrx forward or Rsr reverse sequencing primers.
Tissue microarrays and immunohistochemistry
Tissue microarray (TMA) construction and staining were
described in detail elsewhere.15 Briefly, formalin-fixed and
paraffin-embedded tissues were obtained from the archives of
the Institute of Pathology at the University of Basel. The mul-
titissue TMA used in our study comprised a total of 2,587 sam-
ples including 218 normal tissues, 518 benign tumors and
1,851 malignancies from more than 100 different tumoral tis-
sues. Slides were independently scored by three members of
the team, including two experienced pathologists (LTe and
LTo). Samples were considered positive if at least 5% of cells
showed evidence of staining of moderate or strong intensity.
Results
Production of recombinant MAGE-A10
MAGE-A10 complete open reading frame was PCR amplified
from SK-Mel-37 cell line16 cDNA and cloned into the pET 32a-
inducible expression vector. Upon IPTG treatment, the TAA
was produced in soluble form within a fusion protein, inclusive
of thioredoxin and a polyhistidine tail. After purification on
nickel columns, this protein was detectable in Coomassie blue-
stained gels with an apparent molecular weight (MW) of 79 kDa
(Fig. 1a).9 This material was used to immunize mice and screen
hybridomas. Similarly produced soluble thioredoxin (TrxA)
served as negative control in screening procedures.
Generation of MAGE-A10-specific mAbs recognizing
recombinant and native gene products
A number of mAbs (>20) appeared to recognize recombinant
MAGE-A10 protein in ELISA assays (data not shown). To
verify their capacity to identify the native protein, they were
T
um
or
Im
m
un
ol
og
y
Int. J. Cancer: 129, 1137–1148 (2011) VC 2010 UICC
1138 MAGE-A10 detection in cancers
 
	
  	
   186	
  
tested in ‘‘Western’’ blot assays on lysates from SK-Mel-37
cell line, originally utilized for the cloning of the MAGE-A10
gene (see above). Although all reagents recognized the posi-
tive control 79-kDa recombinant fusion protein, notably, 15
of 20 mAbs identified a single band of an apparent MW of
70 kDa in SK-Mel-37 lysates. Other mAbs, however, identi-
fied extra bands of an apparent 50-kDa MW, suggesting that
they might recognize target epitopes shared with additional
proteins and, possibly, with other members of the MAGE-A
family. Figure 1b reports representative examples of the reac-
tivities observed.
To obtain additional evidence of the specificity of the reagents
under investigation, SK-Mel-37, RE, WM115, MZ-2, A375 and
Na8 melanoma cell lines were tested for MAGE-A10 expression
by qRT-PCR. Expectably, all lines expressed b-actin house keep-
ing gene, whereas MAGE-A10 was expressed to decreasing
extents in RE, MZ-2-37, SK-Mel, WM115 and A375 but not in
Na8 cell line (Fig. 1c). Lysates from all cell lines, equalized in
total protein content, were then tested in ‘‘Western’’ blot assays
in the presence of the mAbs under investigation. Recognition
of the 70-kDa band in cell lysates closely reflected MAGE-A10
gene expression, as detected in the corresponding RNA prepa-
rations. A representative blot is reported in Figure 1d.
Specificity assessment and epitope mapping
TAAs of the MAGE family are characterized by high
sequence homology. As a result, mAbs raised by using one
TAA as immunogen are frequently characterized by extensive
Figure 1. Generation and characterization of MAGE-A10-specific monoclonal antibodies. MAGE-A10 full gene was cloned from SK-Mel-37
cell line and inserted in an IPTG-inducible vector encoding it together with thioredoxin and a polyhistidine tail. IPTG-induced transgene
products could be purified on Ni columns (a). Supernatants of selected hybridomas were tested in ‘‘Western" blot assays on recombinant
MAGE-A10 protein preparation (lane 1) and on SK-MEL-37 lysates. Although six supernatants recognize a single 70-kDa protein, CD12.1
hybridoma supernatant also identifies an additional lower MW band (b). Total cellular RNA was extracted from the indicated cell lines,
reverse transcribed and tested in quantitative real-time PCR assays in the presence of MAGE-A10-specific primers and probes. Data
are expressed as fold increase by using SK-MEL-37 cell line as reference (c). Panel d reports a ‘‘Western" blot assay performed by using
lysates of the indicated cell lines and GA11.1 hybridoma supernatant.
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cross reactivities with other MAGE TAA.3,9,17 To unambigu-
ously assess the specificity of the mAbs under investigation,
we tested them in ‘‘Western’’ blot assays, by using as target
recombinant proteins, lysates of E. coli cultures transformed
with plasmids encoding different MAGE-A or unrelated pro-
teins, following IPTG induction (Fig. 2). Although 77B mAb
only recognized its MAGE-A1 putative target protein, 57B
mAb recognized, in addition to its putative MAGE-A3 target,
also MAGE-A1 and MAGE-A11.13,18 Neither reagent was
able to identify MAGE-A10. In contrast, a number of anti-
bodies produced during our study only identified MAGE-
A10, as shown, for GA11.1 representative mAb in Figure 2.
In no case, evidence of recognition of NY-ESO-1 or thiore-
doxin (TrxA) could be observed.
Capitalizing on these data, we mapped the specific epitope
recognized by GA11.1 IgG1 mAb by using a random peptide
library. Clones from six single colonies expanded following
repeated panning on the mAb under investigation were
sequenced (Table 1). Notably, all of them expressed the
(F)SYPE motif, detectable at the COOH end of the MAGE-A10
protein. Most importantly, this motif is not present in a num-
ber of additional members of the MAGE family, including
MAGE-B1,-B2,-B6 and MAGE-A1,-2,-3,-4,-5,-6,-9 and -12.
MAGE-A10 is a nuclear protein
Considering its unambiguous specificity, supported by
epitope mapping data, we used GA11.1 mAb to identify the
intracellular location of MAGE-A10 TAA. Testis sections
stained with this mAb showed that the target antigen in
healthy testis is exquisitely expressed in spermatogonia and
spermatocyte nuclei (Fig. 3a), but, at difference with other C/
T TAA, e.g., NY-ESO-1,19,20 it is largely undetectable in cell
cytoplasms. No other healthy tissue scored positive upon
GA11.1 mAb staining (see below).
MAGE-A10 protein expression in cancers
Expression of MAGE-A10 gene has been detected in different
types of cancer.8,21–29 However, because of the lack of specific
reagents, no comprehensive analysis at the protein level on
large tumor databases was possible. We used the anti-
MAGE-A10 mAbs described above to stain a multitumor
TMA, including cancers, benign tumors and corresponding
normal tissues for a total of 2,587 samples (Table 2).
Expression in benign tumors was extremely rare (n ¼ 6/
518, 1.1% of cases). Most interestingly, it was detectable in
two cases of moderately dysplastic adenomas of the colon
and in benign tumors with remarkable malignant transforma-
tion potential, such as paraganglioma (n ¼ 2) and a mixed
tumor of the salivary glands (n ¼ 1).
In contrast, positive staining, limited to tumor cell nuclei,
was detectable in 215 of 1,851 cancers (11.6%). For 43 differ-
ent malignancies, representative numbers of cases (n ¼ 20)
were available in the TMA under investigation. In 18 of these
Figure 2. Specificity of anti-MAGE-A monoclonal antibodies. E. coli
cultures were transformed with expression vectors encoding the
indicated proteins, IPTG induced and lysed, as described in
‘‘Material and Methods.’’ Equal amounts of proteins were run on a
12% SDS-PAGE gel and blotted. Blots were used in ‘‘Western’’
assays in the presence of 77B, 57B or GA11.1 mAbs generated by
immunizing mice with recombinant MAGE-A1, MAGE-A3 and
MAGE-A10, respectively.
Table 1. Mapping of the epitopes recognized by GA11.1 monoclonal
antibody on MAGE-A10 sequence
MAGE-A10 A T G S F S Y P E
GA11-3 G G P H T V S Y P E T
GA11-5 A D N I I S Y P V S G P
GA11-8 S F S Y P S T G A Q T G
GA11-15 L G R S Y P E S E G S Q
GA11-4 F P A G R S Y P N T E A
GA11-12 D A G P S Y P D A T M D
MAGE-A10 sequence:
MPRAPKRQRCMPEEDLQSQSETQGLEGAQAPLAVEEDASSSTSTSSSFPSSFPSS
SSSSSSSCYPLIPSTPEEVSADDETPNPPQSAQIACSSPSVVASLPLDQSDEGSS
SQKEESPSTLQVLPDSESLPRSEIDEKVTDLVQFLLFKYQMKEPITKAEILESVIK
NYEDHFPLLFSEASECMLLVFGIDVKEVDPTGHSFVLVTSLGLTYDGMLSDVQSMP
KTGILILILSIIFIEGYCTPEEVIWEALNMMGLYDGMEHLIYGEPRKLLTQDWVQENYL
EYRQVPGSDPARYEFLWGPRAHAEIRKMSLLKFLAKVNGSDPRSFPLWYEEALKDE
EERAQDRIATTDDTTAMASASSSATGSFSYPE.
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Figure 3. Detection of MAGE-A10 cancer/testis tumor-associated antigens in normal testis and in malignancies of different histological
origin. A multitumor tissue microarray from paraffin-embedded sections was stained with GA11.1 hybridoma supernatant according to
standard methods. Representative examples of positive stainings of different extents are shown. They include: (a) healthy testis, (b, c)
urothelial carcinomas, (d, e) larynx carcinomas, (f, g) colon adenocarcinomas, (h, i) serous carcinomas of the endometrium, (j, k)
squamous cell lung carcinoma, (l, m) ovarian serous carcinomas and (n, o) seminomas.
T
um
or
Im
m
un
ol
og
y
Int. J. Cancer: 129, 1137–1148 (2011) VC 2010 UICC
Schultz-Thater et al. 1141
 
	
  	
   189	
  
cancer types, MAGE-A10-specific staining was detectable in
>10% of cases, with average percentages of positive malig-
nant cells ranging between 20 (mesothelioma and seminoma)
and >60% (lung and bladder cancers, laryngeal squamous
cell carcinoma).
In particular, among gynecological cancers,30,31 breast
tumors of the medullary subtype and endometrioid adenocarci-
nomas displayed similar levels of positivity (>10% of cases, with
>40% positive tumor cells). Ovarian and endometrium serous
adenocarcinomas expressed MAGE-A10 more frequently, as
Figure 3. Continued
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Table 2. Distribution of MAGE-A10-specific staining (GA11.1 mAb) across organs and tissue types (n ¼ 2,587)
Organ Tissue group
Total
number
of cases
Negative
expression
(<5%)
Positive
expression
(>5%)
Average
percentage
of positive cells
Adrenal gland Cortical adenoma 12 12 (100)
Pheochromocytoma 26 26 (100)
Brain Meningioma 35 35 (100)
Glioblastoma multiforme 29 29 (100)
Oligodendroglioma 13 13 (100)
Normal 7 7 (100)
Breast Ductal cancer 25 25 (100)
Lobular cancer 29 29 (100)
Medullary cancer 49 44 (89.8) 5 (10.2) 45
Tubular cancer 13 13 (100)
Mucinous cancer 15 15 (100)
Normal 3 3 (100)
Colon Adenoma, mild dysplasia 27 27 (100)
Adenoma, moderate dysplasia 51 49 (96.1) 2 (3.9) 22.5
Adenoma, severe dysplasia 23 23 (100)
Adenocarcinoma 46 42 (91.3) 4 (8.7) 38.8
Normal 1 1 (100)
Endometrium Endometrioid adenocarcinoma 49 44 (89.8) 5 (10.2) 45
Serous adenocarcinoma 32 22 (68.8) 10 (31.3) 57
Normal 13 13 (100)
Esophagus Adenocarcinoma 6 6 (100)
Squamous cell carcinoma 31 23 (74.2) 8 (25.8) 25
Small cell carcinoma 1 1 (100)
Normal 7 7 (100)
Gall bladder Adenocarcinoma 34 29 (85.3) 5 (14.7) 44
Normal 3 3 (100)
Kidney Clear cell renal cell carcinoma 50 50 (100)
Papillary renal cell carcinoma 25 25 (100)
Chromophobe renal cell carcinoma 10 9 (90.0) 1 (10.0) 85
Oncocytoma 19 19 (100)
Normal 16 16 (100)
Larynx Squamous cell carcinoma 24 19 (79.2) 5 (20.8) 61
Liver Hepatocellular carcinoma 82 78 (95.1) 4 (4.9) 13.8
Normal 15 15 (100)
Lung Squamous cell carcinoma 43 28 (65.1) 15 (34.9) 65.3
Adenocarcinoma 75 66 (88.0) 9 (12.0) 56.1
Large cell carcinoma 20 17 (85.0) 3 (15.0) 63.3
Small cell carcinoma 44 38 (86.4) 6 (13.4) 60
Bronchioloalveolar adenocarcinoma 6 6 (100)
Normal 11 11 (100)
Lymphatic tissue Diffuse large B-cell lymphoma 10 10 (100)
Non-Hodgkin lymphoma, others 52 52 (100)
Mixed cellularity Hodgkin lymphoma 14 14 (100)
T
um
or
Im
m
un
ol
og
y
Int. J. Cancer: 129, 1137–1148 (2011) VC 2010 UICC
Schultz-Thater et al. 1143
 
	
  	
   191	
  
Table 2. Distribution of MAGE-A10-specific staining (GA11.1 mAb) across organs and tissue types (n ¼ 2,587) (Continued)
Organ Tissue group
Total
number
of cases
Negative
expression
(<5%)
Positive
expression
(>5%)
Average
percentage
of positive cells
Nodular sclerosis Hodgkin lymphoma 23 22 (95.7) 1 (4.4) 30
Normal 13 13 (100)
Myometrium Leiomyoma 47 47 (100)
Normal 9 9 (100)
Neuroendocrine tissue Extra-adrenal paraganglioma 8 6 (75.0) 2 (25.0) 15
Typical carcinoid of the lung 33 33 (100)
Oral cavity Squamous cell carcinoma 42 38 (90.5) 4 (9.5) 46.3
Normal 5 5 (100)
Ovary Serous adenocarcinoma 40 32 (80.0) 8 (20.0) 36.3
Mucinous adenocarcinoma 15 15 (100)
Endometrioid adenocarcinoma 42 41 (97.6) 1 (2.4) 25
Pancreas Adenocarcinoma 48 48 (100)
Normal 9 9 (100)
Parathyroid Adenoma 31 31 (100)
Normal 2 2 (100)
Peripheral nerves Neurofibroma 17 17 (100)
Schwannoma 23 23 (100)
Pleura Mesothelioma 28 23 (82.1) 5 (17.9) 21
Prostate Adenocarcinoma, hormone-refractory 29 29 (100)
Adenocarcinoma, untreated 48 48 (100)
Normal 17 17 (100)
Salivary gland Warthin tumor 18 18 (100)
Pleomorphic adenoma 39 38 (97.4) 1 (2.6) 65
Adenoid cystic carcinoma 24 24 (100)
Normal 13 13 (100)
Skin Basalioma 59 40 (67.8) 19 (32.2) 50.5
Squamous cell carcinoma 33 31 (93.9) 2 (6.1) 60
Appendageal tumors (benign) 11 11 (100)
Malignant melanoma 50 31 (62.0) 19 (38.0) 45.8
Benign nevus 12 12 (100)
Fibrous histiocytoma 12 11 (91.7) 1 (8.3) 10
Kapillary hemangioma 22 22 (100)
Kaposi sarcoma 15 15 (100)
Normal 6 6 (100)
Small intestine Adenocarcinoma 22 22 (100)
Normal 4 4 (100)
Soft tissue Liposarcoma 22 22 (100)
Malignant fibrous histiocytoma 26 24 (92.3) 2 (7.8) 62.5
Leiomyosarcoma 45 43 (95.6) 2 (4.4) 52.5
Tendon sheath, giant cell tumor 14 14 (100)
Normal (skeletal muscle) 16 16 (100)
Normal (smooth muscle) 5 5 (100)
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detected by immunostaining (30 and 20% of cases, with >50
and >30% positive tumor cells, respectively).
MAGE-A10-specific staining was detectable in squamous
cell carcinomas of the esophagus24 (8 of 31 cases in 25% of
cells on an average) and of the larynx (5 of 24 cases in
>60% of tumor cells on an average).
Notably, MAGE-A10 protein expression appears to be par-
ticularly frequent in lung cancers. In more than 34% of squa-
mous cell carcinomas and 12, 15 and 13% of adenocarcinomas,
large and small cell carcinomas, respectively, more than 50% of
tumor cells do express MAGE-A10 protein. Positivities were
also observed in mesothelioma (5 of 28 cases), albeit with rela-
tively low average numbers of stained tumor cells (20%).
Skin malignancies frequently expressed MAGE-A10. In
particular, in 19 of 59 basalioma, more than 50% of tumor
cells expressed the C/T TAA under investigation. Similarly,
in 19 of 50 melanoma (38%), on an average, 45% of tumor
cells stained positive with anti-MAGE-A10 GA11.1 mAb.
In keeping with previously published gene expression
data,29 MAGE-A10 protein expression was also observed in
stomach cancers of the ‘‘intestinal’’ type (11 of 49 cases in
>35% of tumor cells on an average). Similarly, as expected,
MAGE-A10 C/T TAA was also detectable in seminoma
specimens.19,20
A sizeable fraction of bladder cancers of noninvasive (7 of
36) or infiltrating (21 of 67) type were found to express
MAGE-10 in >60% of tumor cells. Unexpectedly, high (38–
40%) percentages of neoplastic cells were stained by GA11.1
mAb in sizeable percentages of colorectal (8.7%) and gall
bladder (14%) cancers.
All in all, the highest percentages of MAGE-A10-positive
cells were detectable in lung, skin and urothelial cancers. Fig-
ures 3b–3o report representative examples of MAGE-A10-
specific staining in different types of tumors from the TMA
under investigation.
Discussion
MAGE-A10 ranks among the most antigenic members of the
C/T TAA family, together with NY-ESO-1. Specific cytotoxic
T lymphocytes (CTLs) have been generated from lympho-
cytes of untreated patients bearing melanoma,8,32 hepatocellu-
lar carcinoma,4 non-small cell lung cancers5 and healthy
donors.33 Furthermore, vaccination has been found to pro-
mote specific CTL responsiveness.34 A mAb generated by
using recombinant MAGE-1 as immunogen9,11 and recogniz-
ing MAGE-A10 together with other members of the MAGE-
A family has helped to preliminarily characterize a specific
gene product and its putative intracellular location. However,
the identification of MAGE-A10-positive tumor cells in clini-
cal specimens, a key prerequisite for the development of spe-
cific immunotherapy strategies and for their monitoring, has
suffered from the absence of mAb of exquisite specificity.
Table 2. Distribution of MAGE-A10-specific staining (GA11.1 mAb) across organs and tissue types (n ¼ 2,587) (Continued)
Organ Tissue group
Total
number
of cases
Negative
expression
(<5%)
Positive
expression
(>5%)
Average
percentage
of positive cells
Stomach Adenocarcinoma, diffuse type 25 25 (100)
Adenocarcinoma, intestinal type 49 38 (77.6) 11 (22.5) 36.8
Normal 8 8 (100)
Testis Seminoma 47 32 (68.1) 15 (31.9) 22.7
Nonseminomatous germ cell tumors 41 39 (95.1) 2 (4.9) 50
Normal 17 4 (23.5) 13 (76.5) 24.3
Thymus Thymoma 37 37 (100)
Normal 3 3 (100)
Thyroid Follicular adenoma 36 36 (100)
Follicular carcinoma 51 51 (100)
Papillary carcinoma 19 17 (89.5) 2 (10.5) 17.5
Normal 12 12 (100)
Urinary bladder Noninvasive urothelial carcinoma 36 29 (80.6) 7 (19.4) 64.3
Infiltrating urothelial carcinoma 67 46 (68.7) 21 (31.3) 68.6
Normal 3 3 (100)
Uterus, cervix Intraepithelial neoplasia, high-grade (CIN III) 17 17 (100)
Vulva Squamous cell carcinoma 26 25 (96.2) 1 (3.9) 90
Samples were considered positive when >5% of the indicated cell type showed evidence of positive staining with MAGE-A10-specific GA11.1 mAb.
Average percentages of positive cells within individual samples are also reported. Shaded areas refer to types of tissues where a representative
("20) number of cases was available and at least 10% of them showed evidence of MAGE-A10-specific staining.
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Here, we report the generation and the characterization of
MAGE-A10-specific mAbs. One of these reagents, recognizing
a discrete MAGE-A10-specific epitope, has been used to stain
a multitissue array comprising more than 2,000 specimens
and including malignancies and benign tumors of different
histological origin together with corresponding healthy tissues.
This reagent has helped to reveal similarities and differ-
ences between MAGE-A10 and the other members of the
MAGE-A family. First, this TAA is exclusively intranuclear.
In this context, its relatively high immunogenicity might be
related to the release of nuclear proteins following necrotic
cell death, detectable in specific areas, in different types of
tumors.35 Second, it identifies relatively large percentages of
tumor cells expressing the target proteins in cancers known
to express C/T TAA, including squamous cell carcinoma of
different histological origin, melanoma, lung and gynecologi-
cal malignancies and bladder cancers. Third, MAGE-A10
protein, at difference with other C/T TAA, appears to be of
limited expression in soft tissue cancers. Fourth, in contrast,
it appears to be relatively frequently detectable in gall blad-
der tumors and, interestingly, in a sizeable subgroup of colo-
rectal cancers.
Considering the high potential immunogenicity of
MAGE-A10, the reagents described in our study might prove
of critical relevance in the development of targeted active,
specific immunotherapies by helping to establish clear indica-
tions for treatment and in the monitoring of their impact on
tumor progression. Furthermore, as the prognostic relevance
of C/T TAA expression in tumors of diverse histological ori-
gin is emerging,22,36–39 the availability of these mAbs might
set the stage for investigations addressing the role of MAGE-
A10 expression in individual tumor entities.
On the other hand, the biological function of the proteins
of the MAGE-A family remains largely elusive. MAGE-A
gene expression has been shown to suppress p53-dependent
apoptosis and to promote the ‘‘in vitro’’ and ‘‘in vivo’’ viabil-
ity of mast cell lines.40,41 Previous studies in a thyroid carci-
noma model have suggested that selected MAGE-A genes
might control fibronectin-mediated tumor progression.42
Notably, MAGE-A11, also characterized by a putatively spe-
cific intranuclear location, has been shown to coregulate
androgen receptor-mediated transcriptional activity.43,44
Most interestingly, MAGE-A gene expression has been
found to be correlated with genome-wide demethylation,45
frequently representing an early event during carcinogenesis,
associated with hypermethylation of defined tumor suppres-
sor genes.46 Strikingly, a number of tumors showing evidence
of high MAGE-A10 expression in our study, including
lung,46 skin,47 bladder48 and head and neck49 cancers, are
also known to be characterized by a frequent genome-wide
hypomethylation. Also, considering the specific nuclear loca-
tion of MAGE-A10, further studies are warranted to compa-
ratively address its expression together with the DNA meth-
ylation status of repetitive elements, including long
interspersed nuclear elements (LINE-1).50
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7. GENERAL DISCUSSION 
 
7.1 3’UTR poly(T/U) tract deletions and altered expression of 
EWSR1 are a hallmark of mismatch repair deficient cancers 
 
In this study we describe a mononucleotide (T/U)16 tract, EWS16T, located in the 3’ 
UTR of the Ewing sarcoma break point region 1 (EWSR1) gene which discriminates 
MMR proficient from MMR deficient cancers with 100% sensitivity and 99.5% 
specificity. We demonstrate in vitro and in vivo that contractions at this locus alter 
poly(A) site selection by promoting SFPQ-mediated distal poly(A) site usage in 
EWSR1 pre-mRNAs and result in decreased mRNA as well as protein expression. In 
contrast to their proficient counterparts, MMR deficient CRC display altered 
subcellular localization of EWS with diffuse cytoplasmic staining. EWS16T thus not 
only represents a novel monomorphic MSI target locus to accurately identify both, 
hereditary and sporadic, MMR deficient cancers but contractions therein affect 
multiple regulatory mechanisms implicating the RNA-/DNA-binding protein EWS in 
MSI-associated colorectal tumorigenesis. 
The Ewing sarcoma (EWS) protein is a member of the TET family (TLS/FUS, EWS, 
and TAF15) of RNA- and DNA-binding proteins, with proposed functions in 
transcription and RNA processing. The domain composition of TET proteins includes 
a transcription activation domain at the N terminus and RNA-binding domains, 
including three RGG boxes and one RRM motif, at the C terminus. Additional 
domains harbored by TET proteins include an IQ domain, which interacts with 
calmodulin and is phosphorylated by PKC [198], and one zinc finger motif [199]. 
EWS interacts with the preinitiation complex TFIID and with subunits of the RNA 
polymerase II (RNAPII) [200], suggesting its involvement in transcriptional regulation. 
EWS also interacts with splicing factors, including the U1 snRNP protein U1C, which 
recognizes 5′ splice sites [201], the branchpoint binding protein BBP/SF1 [202], and 
the spliceosome component YB-1 [203, 204], suggesting a function for EWS in pre-
mRNA splicing. Consistent with this potential dual role, EWS has been shown to 
regulate cyclin D1 transcripts both transcriptionally and at the level of splicing, with 
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the oncogenic fusion protein EWS-FLI1 promoting the expression of the oncogenic 
cyclin D1b splice variant in Ewing sarcoma cells [205]. More recently, EWS has been 
shown to regulate alternative splicing (AS) of the p53 repressor MDM2 [204, 206]. In 
addition EWS has been described as component of the microprocessor complex that 
mediates the genesis of microRNAs [207]. 
The physiological role of EWS is largely unknown but based on its structural 
properties this protein is thought to be involved in diverse processes including gene 
expression, RNA processing / transport and cell signaling. Knockout of EWS in mice 
results in postnatal lethality, defects in pre-B cell development, meiotic arrest/germ 
cell apoptosis, premature cellular senescence, and hypersensitivity to ionizing 
radiation (IR) [208]. These observations suggest additional roles for EWS in 
homologous recombination, DNA damage response, and maintenance of genome 
integrity [206]. 
With respect to tumorigenesis, genetic alterations in EWSR1 were first observed in 
Ewing sarcoma, the second most common malignant bone tumor in children [209, 
210]. The EWSR1-FLI1 fusion is the most common, being found in 85% of the cases 
[211]. The fusion protein retains the N-terminal transcription activation domain but 
loses the RNA-binding domains, which are replaced with the DNA binding domain of 
the fusion partner. The fusion proteins are constitutively active and have been shown 
to alter the transcription of several downstream targets. Ewing Sarcoma is largely 
thought of as a gain of function phenotype. Loss of the normal EWSR1 function has 
been largely overlooked, in spite of the fact that the protein has a very canonical 
RNA binding domain and has been shown to regulate several RNA processing 
events in the nucleus [212, 213].  
Our results described in details in chapter I suggest that the poly T/U tract in 3’UTR 
of EWSR1 gene (EWS16T) represents a novel, quasi-monomorphic MSI target locus 
which identifies both, hereditary and sporadic, MMR deficient cancers with 100% 
sensitivity and 99.5% specificity. The contractions at this locus affect multiple 
regulatory mechanisms including alternative polyadenylation, mRNA / protein 
expression and possibly subcellular localization thereby implicating the RNA-/DNA-
binding protein EWS, in MSI-associated colorectal tumorigenesis. Furthermore we 
demonstrated the biological effects of MSI-associated 3’UTR contractions on gene 
expression in vivo and in vitro for the first time. 
In summary, due to only few and sketchy data concerning the role of EWS in normal 
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cell physiology and in CRC-related tumorigenesis, future investigations are needed.  
In particular to comprehensively characterize the major EWSR1–related downstream 
targets/pathways involved in cell physiology and differentiation the transcriptomes 
and miRNAomes of human fibroblasts and their progenitor cells, the mesenchymal 
stem cells should be investigated. 
On the other hand, The role(s) of EWSR1 in colorectal carcinogenesis by the 
generation of stable EWSR1 overexpressing/downregulating normal and CRC cell 
lines, in order to investigate EWSR1 effect on apoptosis and cell migration in vitro as 
well as its impact in tumorigenesis and it metastatic potential in vitro and in vivo. 
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7.2 SH2D4A as a novel tumor suppressor gene in CRCs 
 
It is well accepted that the key genetic mutations underlying initiation, progression 
and transformation of adenomas into CRC include APC, KRAS and TP53, 
respectively [214]. Mutations of known genes are identified in 60%, 35% and 50% 
[215] suggesting the existence of more than just one single dominant pathway to 
CRC development [216]. 
Heterozygous loss of variable parts of chromosome 8p constitutes a frequent feature 
of CRC [217] and has been linked to DNA breakage at fragile sites located at 8p12 
and 8p22 [218]. Tumour suppressor genes have not been localized to this critical 
chromosomal region, thus precluding the identification of a likely mechanism for how 
genetic alterations in 8p contribute to CRC development and progression.  
Looking at Oncomine signature of mRNA, we noted that SH2D4A protein was 
deregulated in various cancer types but no information concerning colorectal cancer 
were available. We started to investigate LOH and copy number variation in an 
unselected cohort of 70 CRC patients. In 27 subjects the two SH2D4A alleles could 
be separated by microsatellite markers and SNPs. In 14 of these patients (52%), the 
primary tumour had lost or diminished SH2D4A expression. The rate of metastasis 
was significantly increased among these tumours (12/14; 86%) when compared to 
SH2D4A expressing primary CRC (3/13). Using 3 microsatellite markers and 5 
SNPs, SH2D4A LOH was detected in 7 of the 14 tumours (50%) marked by a partial 
or complete lack of SH2D4A expression. Gene dosage quantification of the short 
arm of chromosome 8 revealed a monoallelic deletion in 6 and a biallelic deletion in 
one of these 7 tumours with LOH. Though 4 of the 6 patients with monoallelic 
tumours were heterozygous for the intronic SNP rs17128221 (c.342-5T>C) the T 
allele was selectively lost in their tumour and the C allele provided a splice donor site 
causing the skipping of exon 4 and a premature termination of translation in exon 5. 
In addition we demonstrated that SH2D4A, physically interacts with the 
EGFR/STAT3 pathway and controls cell proliferation. Upon EGF signalling, SH2D4A 
protein recruits the serine/threonine phosphatase PP1β to the receptor complex and 
represses activated STAT3 via dephosphorylation. SH2D4A expression reduces 
anchorage-independent tumour cell growth and its loss promotes the expression of 
c-Myc, Cyclin D1 and Jun B.  
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Recently in according with our data Roessler et al. published unsupervised analyses 
of array comparative genomic hybridization data associated loss of chromosome 8p 
with poor outcome (reduced survival); somatic copy number alterations correlated 
with expression of 27.3% of genes analyzed. They associated expression levels of 
10 of these genes with patient survival in 2 independent cohorts (comprising 319 
cases of hepatocellular carcinoma (HCC) with mixed etiology) and 3 breast cancer 
cohorts (637 cases). Among the 10-gene signature, a cluster of 6 genes on 8p, 
(DLC1, CCDC25, ELP3, PROSC, SH2D4A , and SORBS3 ) were deleted in HCCs 
from patients with poor outcomes. In vitro and in vivo analyses indicated that the 
products of PROSC, SH2D4A, and SORBS3 have tumor-suppressive activities, 
along with the known tumor suppressor gene DLC1 [219].  
Thus, SH2D4A could represent novel tumor suppressor gene acting in different 
tumor entities. Due to its interaction with STAT3 in the control of the EGFR signaling 
pathway, which is involved in the development and progression of several human 
tumors, including colorectal cancer [220], it may be represent a novel promising 
target for CRC treatment. 
In order to understand if germline mutations in SH2D4A could contribute in familial 
colorectal cancer development, whole genome sequencing of 200 index patients 
from familial colorectal cancer patients, without mutations in any of the known genes, 
will be done.  
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7.3 HMGA proteins as prognostic markers in different tumor 
entities 
 
Our work demonstrates that the percentage of tumour cells showing HMGA1 and 
HMGA2 nuclear immunoreactivity correlates positively with increasing malignancy of 
breast and pancreatic tumors. These studies indicate that the overexpression of 
HMGA1 and HMGA2 is linked to proliferation in the cancer and may have important 
implications, promoting the growth and spread of tumors. On the molecular basis 
HMGA1 and HMGA2 interact with several transcription factors, influence gene 
expression patterns and regulate cell growth, differentiation, apoptosis, and 
transformation [156]. Their expression has been detected in many kinds of benign 
and malignant tumors and it is associated with a highly malignant phenotype (poor 
prognostic index) [221]. 
HMGA is high wexpressed during embryogenesis, but is undetectable or very low in 
differentiated adult tissues [222, 223], being confined, at least for HMGA2, to the 
staminal compartment [224-226]. In vivo studies revealed an important role of HMGA 
proteins in adipogenesis [222, 225], somatic growth [227], cardiac cell growth control 
[228] and glucose homeostasis [229, 230]. In accordance with this, HMGA mutations 
have been detected in human diseases such as lipomas [231-233], gigantism [234], 
dwarfism [235], and diabetes [229]. Moreover, HMGA2 has also been suggested 
recently by genome-wide SNP studies to influence human height variation [236, 
237]. HMGA overexpression is a constant feature of human malignant neoplasms 
and is frequently associated, with or without gene rearrangements, with human 
tumors [221, 238]. In addition HMGA proteins also regulate the transcription of genes 
that are involved in DNA repair. Reeves et al. described a number of genes involved 
in DNA repair that were negatively regulated by HMGA1in MCF7 human breast-
cancer cells, suggesting that HMGA proteins can influence DNA repair by negatively 
regulating the transcriptional activity of genes involved in various aspects of DNA-
damage recognition and removal [239]. Consistently, in another study made by 
Borrmann et al. HMGA2 has been linked to the promoter of the nucleotide excision-
repair gene ERCC1 where it negatively modulates its activity [240]. Moreover, it has 
been shown that HMGA1 can downregulate BRCA1 expression, which is involved in 
homologous recombination, by binding directly to its promoter region, and that there 
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is an inverse correlation between HMGA1 and BRCA1 expression in human breast 
carcinomas [241]. Consistent with the role of BRCA1 in DNA double-strand break 
(DSB) repair, it has been shown that HMGA proteins potentiate genotoxic stress 
induced by different DNA-damaging agents causing DSBs, such as cisplatin, 
bleomycin, doxorubicin and X-rays [242, 243]. HMGA proteins can indirectly inhibit 
DNA repair through cyclin A induction, and it recently has been reported that the 
cyclin A1–cyclin-dependent kinase 2 complex also regulates DSB repair [221, 244]. 
Essentially, the data reported in this thesis indicate that HMGA1 and HMG2 are 
implicated in carcinogenesis and may play a role in the development of a particular 
phenotype of breast and pancreas carcinomas. Therefore, HMGA1 and HMGA2 
expression may represent an indicator of poor prognosis of human tested cancers. 
Then studies are needed to elauate their role as prognostic factor in tumor 
progression and maybe as potential target in molecular therapy. 
To understand which are the downstream targets directly regulated by HMGA1 and 
HMGA2, a transcriptome analysis of different tumors developed in HMGA1 KO mice 
(Prof. Alfredo Fusco laboratory) is planned; this strategy allow us to define an 
expression pathway and thus understand the relationship with the most important 
tumour related pathway and test them in vivo.   
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7.4 MAGE-A10 overexpression in lung, skin and urothelial 
malignancies 
In this study we produced a MAGE-A10 protein in soluble recombinant form, and 
used it to generate specific monoclonal antibodies (mAbs). One of these reagents, 
recognizing an epitope located at the COOH terminus of the MAGE-A10 gene 
product, was used to stain a multitumor tissue microarray comprising more than 
2,500 paraffin-embedded specimens including healthy tissues, benign tumors and 
malignancies of different histological origin. MAGE-A10 was identified as an 
intranuclear protein of an apparent molecular weight of 70 kDa, expressed in normal 
spermatogonia and spermatocytes but in no other healthy tissue. Most importantly, 
this cancer/testis tumor associated antigen (C/T TAA) appears to be expressed in 
high (>50%) percentages of cancer cells from a number of malignancies, including 
lung, skin and urothelial tumors. Unexpectedly, high expression of MAGE-A10 TAA 
at the protein level was also detectable in gynecological malignancies and stomach 
and gall bladder cancers.  
MAGE-A proteins are known to be highly expressed in a wide range of cancers like 
breast, ovary, lung, skin, urothelial and bladder [181, 245-248] and their expression 
is observed mainly in cancers with malignant phenotypes, [181]. MAGE detection 
also correlates with poor prognosis in cancer patients, underpinning the idea that 
MAGE proteins may contribute actively towards malignancy [247]. The mechanism 
by which MAGE-A overexpression occurs in tumor cells is not totally understood. 
Usually the expression of MAGE-A in somatic tissues is repressed by DNA 
hypermethylation of CpG dinucleotides in promoters, which acts to prevent access of 
transcription factors like Ets and SP1 [249, 250]. In tumor cells epigenetic 
reprogramming can result in promoter hypo-methylation leading to the aberrant 
expression of one or more of these genes, in fact MAGE-A expression can be 
induced by demethylating agents such as 5-aza-2′-deoxycytidine in non-expressing 
cells of various origins [249, 250]. Seems to be also that chromatin remodelling 
events which occur during tumour development, like histone acetylation and 
methylation, can contribute to changes in MAGE-A levels in cancer cells and, at least 
in some circumstances, can be under control of hormones such as FGF, estrogen, 
leutenising hormone and directly regulated by microRNAs miR-34a [247, 251-254]. 
Tumors also show significant differences in signal localization (nuclear vs. 
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cytoplasmic) [245], suggesting that either different MAGE-A family members display 
differential localization or that the mechanisms controlling localization are cancer 
cell-specific.  
Several studies have established that MAGE-A proteins can repress p53-mediated 
transcription, through direct and indirect mechanisms, and inhibit both p53-mediated 
apoptosis and senescence, two major tumour suppressor mechanisms utilized by 
p53 [247, 255-259]. These studies also establish the principle that elimination of 
MAGE-A expression in cultured cells is sufficient to induce p53-mediated apoptosis 
without the need to use genotoxic agents. This suggests that the development of 
compounds that block the p53/MAGE-A interaction in cancer cells expressing these 
proteins could have enormous therapeutic potential that minimizes the requirement 
for genotoxic approaches and the accompanying side effects. Advances in our 
knowledge of MAGE structure and interaction with partner proteins are beginning to 
cover the way towards developing such therapeutic approaches. 
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8. APPENDIX 
8.1 microRNA expression profiling in mismatch repair associated 
colorectal cancer 
 
 
 
 
My contribution to this work:  
• Assessment and optimization of miRNA extraction techniques; 
• Total RNA and microRNA extraction from CRC cell lines and human samples; 
• miRNA library generation; 
• Analysis of deep sequencing data; 
• Statistical comparison; 
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Abstract 
Lynch syndrome represents the most common, autosomal dominantly inherited 
cancer predisposition worldwide and is characterised by early onset colorectal 
cancer around age 44 years. The syndrome accounts for 3 to 5% of all colorectal 
cancers in Switzerland and is caused by germ line mutations in DNA mismatch 
repair (MMR) genes, predominantly MLH1 and MSH2. MMR deficiency leads to 
genomic instability in the tumor, resulting in the genome-wide accumulation of 
somatic mutations, in particular at short repetitive sequences giving rise to 
microsatellite instability (MSI). To date, little is known on the specific molecular 
genetic alterations, which initiate and promote cancer development in Lynch 
syndrome patients. 
microRNAs (miRNAs) are a family of small non-coding RNAs which are thought to 
control gene expression of about 30% of all protein-coding genes in humans. They 
regulate a variety of cellular processes and are likely to have a causal role in 
carcinogenesis since they are altered in most cancer types, including colon cancer. 
Their diagnostic, prognostic and therapeutic potential has fuelled miRNA research in 
recent years. Despite advances on the role of MSI status and miRNA expression in 
sporadic colorectal cancer, a comprehensive study on miRNA profiles in Lynch 
syndrome-associated colorectal cancers has not been performed to date.  
In a long, painstaking process we evaluated and scrutinized several extraction 
methods and protocols to obtain high-quality miRNA from snap-frozen MMR 
proficient and deficient cancers as well as cancer cell lines. Finally, radiolabelling of 
total RNA with P32 followed by direct excision of the miRNA fraction from a 8-15% 
polyacrylamide gel and extraction with TRI reagent solution proved to yield the best 
miRNA quality. We therefore applied the Truseq sequencing on a HiSeq2000 
platform and investigated the miRNA profiles by unsupervised analysis using 
hierarchical clustering and principal component analysis generating a initial list of 
top/bottom interesting miRNAs. 
 Currently, selected top most differentially expressed miRNAs will be verified / 
validated by quantitative real-time PCR on a total of 100 Lynch syndrome and 50 
sporadic colorectal cancers. Subsequently, tissue expression of verified miRNAs and 
potential target proteins will be assessed by in situ hybridization and 
immunohistochemistry, respectively. Finally, selected miRNAs will be functionally 
characterised by cell transfection experiments.
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Introduction 
 
About 15-20% of all colorectal cancers (CRCs) are thought to arise from an inherited 
genetic susceptibility to colorectal adenomas and carcinomas [1]. Lynch syndrome 
(formerly known as hereditary non-polyposis colorectal cancer, HNPCC), is an 
autosomal dominantly inherited cancer condition with an estimated carrier frequency 
of 1:2000 (up to 1:200) and thus represents the most common inherited cancer 
predisposition worldwide. It is estimated to account for about 2-5% of the total 
colorectal (CRC) cancer burden [2].  
It is characterized by the development of colorectal as well as a distinct spectrum of 
extracolonic cancers (predominantly of the endometrium, ovary, stomach), usually 
diagnosed before age 50 years. The syndrome is caused by germ line mutations in 
the mismatch repair (MMR) genes MLH1, MSH2, MSH6, and PMS2, which 
recognize and correct errors that occur during DNA replication. MSH2 and MLH1 are 
mutated in about 80% to 90% of patients with typical Lynch syndrome whereas germ 
line mutations in MSH6 and PMS2 tend to result in a less severe phenotype [3]. 
Following somatic inactivation of the wild-type allele in the cancer cell MMR 
deficiency leads to genome-wide accumulation of replication errors predominantly at 
microsatellite loci, the hallmark lesion of Lynch syndrome, termed microsatellite 
instability (MSI). In the clinical setting, immunohistochemical assessment of the 
presence / absence of the MMR proteins in the tumor is used as a preliminary tool, 
often in conjunction with microsatellite instability testing, to assess MMR 
proficiency/deficiency and to determine who may benefit from germ line testing [4].  
microRNAs (miRNAs) represent a large family of small non-coding RNAs of about 21 
nucleotides in length that serve as effector molecules of sequence-specific gene 
silencing [5]. It is estimated that the number of miRNAs in the human genome range 
from about 450 to 1000 and that they control gene expression of about 30% of all 
protein-coding genes in mammals. The majority of identified miRNAs, currently 
estimated are highly evolutionary conserved among many distantly related species, 
from worms to human, suggesting that miRNAs have very important roles in 
essential biological processes, including developmental timing, stem-cell 
differentiation, signal transduction, disease and cancer. Their causal role in 
carcinogenesis is further substantiated by the fact that miRNAs are altered in most 
cancer types, including colon cancer [6].  
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In the nucleus, miRNA genes are generally transcribed by RNA polymerase II or III 
to form large primary miRNA transcripts (pri-miRNAs). These are further processed 
by Drosha, a RNase III protein, into 70-nucleotide miRNA precursors (pre-miRNA). 
After transport into the cytoplasm, pre-miRNAs are further processed by another 
RNase III enzyme, Dicer, into miRNA duplexes, typically consisting of 19-25 
nucleotides in length [7, 8]. Subsequently these duplexes can be loaded into the 
miRNA-associated multiprotein RNA-induced silencing complex (miRISC) and the 
mature miRNA strand is preferentially retained. Once bound to the 3’UTR of target 
mRNAs, the mature miRNA induces cleavage, translational repression or 
deadenylation, depending on the degree of complementarity [9]. A single miRNA 
may bind to as many as 200 target genes encoding a broad range of proteins, such 
as transcription factors, receptors and transporters. In recent years, several 
approaches have been used to identify miRNA targets [10].  
With the advent of massively parallel (“next generation”) sequencing technology 
genome-wide miRNA profiling has now become possible allowing global assessment 
of expression-regulating mechanisms in sporadic and hereditary cancer [11, 12]. 
The results of this study will enhance the scarce knowledge available to date on the 
role of miRNAs in Lynch syndrome-associated colorectal cancer development. The 
findings are likely to shed light on intestinal carcinogenesis in general and allow 
further characterisation of the various pathways involved in MSI-related 
tumorigenesis. The identification and characterisation of miRNA expression 
signatures in Lynch syndrome cancer patients may not only improve clinical risk 
assessment and prognosis, but also offer an opportunity to identify novel therapeutic 
strategies for cancer patients. 
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Materials and methods 
 
RNA Isolation 
To isolate genomic total RNA from cell lines Tri-Reagent (Ambion) were used 
according to the manufacturers' guidelines. 
 
Cell lines 
Six colorectal cancer cell lines from the American Type Culture Collection (ATCC, 
Rockville, MD) were used for this study: four repair deficient cell lines (HCT116, 
LoVo, HCT15, DLD-1) and two mismatch repair proficient (SW480 and HT29). 
HCT116, HCT15 and DLD-1 cells (ATCC, Rockville, MD) were cultured in RPMI 
1640 (Invitrogen Basel, Switzerland) supplemented with 10% fetal bovine serum 
FBS, 1% Kanamycin sulphate, 1% GlutaMAX-I, 1% Sodium Pyruvate, 1% non 
Essential Amino Acids (NEAA), 1% HEPES (all from Invitrogen Basel, Switzerland) 
and 0.1% 2-mercapto-ethanol (Sigma-Aldrich Basel, Switzerland). HT29 cells were 
grown in McCoy's 5A Medium (Invitrogen Basel, Switzerland) with 10% fetal bovine 
serum FBS, Kanamycin sulphate and GlutaMAX-I (all from Invitrogen Basel, 
Switzerland). SW480 cells were cultured in L-15 Medium (Sigma-Aldrich Basel, 
Switzerland) with 10% FBS, 1% GlutaMAX-I and 1% Kanamycin sulphate (all from 
Invitrogen Basel, Switzerland). Cells were maintained at 37°C with 5% CO2.  
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Preliminary results 
To yield the best miRNA quality the total RNA (typically 2 µg) marked radioactively 
with P32 from each sample was run on denaturing polyacrylamide-urea gels. The 
approximately 17-25 nucleotide RNAs were excised from the gel, ligated to 
sequencing adaptors on both ends, and reverse-transcribed according to the 
manufacturers' guidelines of Illumina. The resulting cDNA library was PCR-amplified 
for 15 cycles and gel-purified on 6% acrylamide gel. The gel-purified amplicon quality 
and quantity were analyzed on a 6% acrylamide gel relative to oligonucleotides of 
known concentration and size. The library (120 µL 1-4pM) was loaded on an Illumina 
HiSeq 2000 system (Illumina) on a flow cell according to the manufacturer's 
instructions, where DNA molecules were attached to high-density universal adaptors 
in the flow cells and amplified. The DNA clusters generated via this process were 
sequenced with sequencing-by-synthesis technology, where successive high-
resolution images of the 4-color fluorescence excitation dependent on the base 
incorporated during each cycle were captured [13]. Then, nhe data were pre-
processed, including steps of quality check and normalization. miRNA profiles were 
investigated by unsupervised analysis using hierarchical clustering and principal 
component analysis (PCA). For computational prediction of miRNA targets and 
pathway analysis the MirZ web server was used which provides statistical analysis 
and data mining tools operating on up-to-date databases of sequencing-based 
miRNA expression profiles and of predicted miRNA target sites [14] 
In total, we identified 1240 miRNAs differentially expressed in MMR deficient 
compared to proficient cancers cell lines. Among the most downregulated miRNAs 
(Table 1) were hsa-miR-371-5p, involved in Wnt/beta-catenin signaling, a crucial 
pathway for colorectal carcinogenesis [15], and hsa-miR-200a, which has been 
shown to inhibit the epithelial-mesenchymal transition [16] and to be deregulated in 
bladder breast and endometrial cancer (which are, intriguingly, part of the LS-tumor 
spectrum) [17, 18]. Among the most upregulated miRNAs we observed hsa-miR-141 
which is believed to modulate the oxidative stress response [19] and hsa-miR-125b, 
a negative regulator of p53, also referred to as the “guardian of the genome”[20].  
Currently we are analyzing the deep sequencing data of 4 cancer specimens 
matched with their normal counterpart from 2 LS-related, microsatellite-unstable asa 
well as 2 sporadic microsatellite-stable CRCs.  
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Brief discussion 
 
MMR-deficient CRCs exhibit mRNA and miRNA expression profiles distinct from 
their stable, MMR-proficient counterparts. The study by Di Pietro et al. [21], in which 
our research group also took part, analysed gene expression in proximal colon 
cancers and was able to divide them into two groups that almost perfectly 
corresponded with their MMR status. In addition, expression changes in genes 
involved in apoptosis and the immune response were consistent with the better 
prognosis of MMR-deficient cancers. Kruhoffer et al. [22] studied mRNA expression 
in 34 MSI-High (mostly sporadic) and 67 MSS stage II and III colorectal cancers and 
devised a gene expression signature based on nine genes able to distinguish MMR 
status.  
To determine the degree of gene expression differences which could be explained 
by CpG island methylation, we assessed the presence of CpG islands in and 5kb up- 
and down-stream of the top most differentially expressed genes from both studies 
using the UCSC genome database: only about 50-60% of these genes harbour CpG 
islands. Thus, about 40-50% of the gene expression changes in MMR-deficient 
CRCs cannot readily be explained by epigenetic regulation and are likely to be 
caused by other mechanisms, in particular deregulation of miRNA expression.  
The mutator phenotype that results from MMR dysfunction induces the acquisition of 
additional gene mutations that promote cancer progression [23]. In addition to 
germline mutations, various pathogenic events, including promoter methylation [24] 
and reduced histone acetylation [25], result in reduced or absent expression of core 
MMR proteins, as do microenvironmental factors, such as inflammation and hypoxia 
[26]. Our preliminary results suggest that some miRNA such as miR-155, could play 
a role in this multifactorial regulation by causing down-modulation of the core MMR 
heterodimeric proteins MSH2-MSH6 and MLH1-PMS2. The simultaneous inhibition 
of these essential MMR components by some miRNA could well explain the 
observed mutator phenotype. Thus far, only little is known about the role of MSI 
status and miRNA expression in CRC. A study by Lanza et al. [27] established a 
sensitive predictive algorithm to correctly distinguish between sporadic MSS and 
MSI-H CRCs using a 14 miRNA signature in 39 samples. Schepeler et al. [28] used 
microarrays to profile the expression of 315 miRNAs in normal mucosa samples 
(n=10) and stage II colon cancers (n=49) differing with regard to microsatellite status 
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and recurrence of disease. They observed that miR-145 expression was lower in 
cancer relative to normal tissue and that microsatellite status could be correctly 
predicted based on miRNA expression profiles. In conclusion, although largely 
limited to sporadic MMR-deficient CRCs, current data provide evidence that 
perturbed expression of miRNAs in colon cancer may not only have a functional 
effect on tumor cell behaviour, but that some miRNAs with prognostic potential could 
be of clinical importance [29].  
The results of this study will enhance the scarce knowledge available to date on the 
role of miRNAs in Lynch syndrome-associated colorectal cancer development. The 
findings are likely to shed light on intestinal carcinogenesis in general and allow 
further characterisation of the various pathways involved in MSI-related 
tumorigenesis. The identification and characterisation of miRNA expression 
signatures in Lynch syndrome cancer patients may not only improve clinical risk 
assessment and prognosis, but also offer an opportunity to identify novel therapeutic 
strategies for cancer patients. 
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Table1: Top 20 miRNAs differentially expressed in MMR deficient compared to MMR 
proficient colorectal cancers cell lines 
miRNA Name 
Directio
n 
 Pool1 
count 
(MMR-) 
 Pool1 
frequency 
 Pool2 
count 
(MMR+) 
 Pool2  
frequen
cy 
Log(Psame/Pd
iff) 
hsa-miR-499-
5p ↓ 1642 0.0010 119032 0.0090 -150763 
hsa-miR-371-
5p ↓ 18184 0.0010 109922 0.0080 -99962 
hsa-miR-200a ↓ 350694 0.01 342852 0.025 -84781.8 
hsa-miR-373 ↓ 14098 0.0010 81549 0.0060 -73114.1 
hsa-miR-200b ↓ 704912 0.019 479924 0.035 -56962.2 
hsa-miR-372 ↓ 10283 0.0010 59112 0.0050 -52861.9 
hsa-miR-224 ↓ 41743 0.0020 85516 0.0070 -46316.7 
hsa-miR-371-
3p ↓ 6588 0.0010 44572 0.0040 -41790.8 
hsa-miR-429 ↓ 152804 0.0040 156215 0.012 -41021.6 
hsa-miR-141 ↑ 1762050 0.046 401587 0.029 -38202.7 
hsa-miR-10a ↑ 1986950 0.052 467442 0.034 -38149.1 
hsa-miR-31 ↓ 602096 0.016 370715 0.027 -32469.1 
hsa-miR-100 ↑ 164399 0.0050 6491 0.0010 -31483.3 
hsa-miR-125a-
5p ↓ 117214 0.0040 119074 0.0090 -30921.8 
hsa-miR-24 ↓ 566033 0.015 347730 0.026 -30194.2 
hsa-miR-424 ↓ 30682 0.0010 56459 0.0050 -28132.9 
hsa-miR-148a ↑ 303974 0.0080 35600 0.0030 -26735 
hsa-miR-125b ↑ 125963 0.0040 5836 0.0010 -22502 
hsa-miR-499-
3p ↓ 241 0.0010 16837 0.0020 -21238 
hsa-miR-192 ↓ 627758 0.017 348276 0.026 -20761.9 
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8.2 Identification of novel recurrent duplication “hot spots” in 
Lynch syndrome colorectal cancers. 
 
 
 
 
 
My contribution to this work:  
• DNA extraction from Lynch syndrome and sporadic colorectal cancers; 
• Analysis of high resolution chip array; 
• Selection of candidate genes; 
• Validation of selected candidate by qPCR; 
• Statistical comparison; 
• Manuscript preparation; 
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Abstract 
Background 
Lynch syndrome (also Hereditary Non-Polyposis Colon Cancer, HNPCC) represents 
the most common, autosomal dominantly inherited cancer predisposition worldwide 
and accounts for 3-5% of the total colorectal cancer (CRC) burden. It is caused by 
germline mutations in DNA mismatch repair (MMR) genes (mainly MLH1 and 
MSH2). MMR deficiency results in microsatellite instability (MSI), i.e. genome-wide 
accumulation of somatic alterations at repetitive DNA sequence motifs, and present 
in 90% of Lynch syndrome-related cancer. About 80% of MSI tumors have a near-
diploid karyotype which stands in clear contrast to the microsatellite stable (MSS) 
cancers which predominantly are aneuploidy. Thus far, little is known on the type 
and frequency of, microdeletions and microduplications in LS-related CRCs. 
Methods 
Here, we applied a high-density CGH microarray-based method using the Affymetrix 
Whole Genome 2.7 M chip, to study somatic copy number aberrations in CRCs from 
12 unrelated Swiss LS patients, and whose cancers displayed microsatellite 
instability with confirmed germline mutation in MLH1 or MSH2. Next we validated the 
results in 46 LS-related as well as 50 colorectal cancers by quantitative real-time 
PCR using locus specific primer pairs. 
Results 
Copy number assessment by CGH array revealed 2 novel somatic microduplications 
"hot spot" regions containing ERCC2 (19q13.32) and STK40 (1p34.3) gene. The 
frequency of these copy number aberrations were further validate in our cohort of 
Lynch syndrome cancers. CNA were present in 24/46 (60.8%) and in 18/46 (39.1%) 
CRCs for ERCC2.and STK40, respectively. 
Conclusion 
Our study identified novel microduplications in Lynch syndrome related CRC located 
on 1p34.3 and 19q13.32 These genes associated with CN changes in LS-related 
CRCs warrant further investigation to establish their possible clinical implications. 
Currently, to confirm that these CNA are an only present in Lynch syndrome CRC 50 
sporadic CRCs are under investigation. 
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Introduction 
 
Hereditary nonpolyposis colorectal cancer (HNPCC), also referred to as the Lynch 
syndrome (LS), with an estimation between 1:200 and 1:2000 predisposition is the 
most common form of autosomal dominantly inherited cancer predisposition 
worldwide. It is characterized by the occurrence of early onset colorectal carcinoma 
(CRC) as well as a distinct spectrum of extracolonic tumors, such as endometrium, 
stomach, ovarian, breast and renal pelvis cancers [1, 2] and caused by a germline 
mutation in mismatch repair (MMR) genes, MLH1 and MSH2 (90%) and MSH6 
(10%) [1, 2]. Tumors with MMR deficiency exhibited frequent errors in microsatellite 
DNA, short segments of DNA containing tandem repeats of mono-, di-, tri- or 
tetranucleotide [3]. The high-frequency MSI (MSI-H) CRCs have unique 
clinicopathologic features, such as right-sided, mucinous or poorly differentiated, and 
stable chromosomal status in the tumors [4]. 
DNA copy number variation (CNV) and other structural variations in the human 
genome are increasingly recognized as an alternative source of genetic variation that 
may influence cancer risk and are a common occurrence in all forms of cancer [5-9]. 
A typical cancer sample exhibits an average of 17% amplifications and 16% 
deletions within an entire genome [10]. Somatic copy number alterations have been 
shown to significantly affect pathways involving tumor suppressor genes such as 
TP53, APC, BRCA1, BRCA2, PTEN, and RB1 and oncogenes, including HRAS and 
RET [5, 11]. Detection of these alterations and identification of the specific genes 
responsible for cancer proliferation can help to subtype cancers at the molecular 
levels and lead toward more individualized cancer-type specific therapies [12-15]. 
About 80% of MSI tumors have a near-diploid karyotype and a genetic alterations 
different from those of microsatellite stable (MSS) cancers [16-20]. Despite the 
progress of our understanding of CRC genetics, genomic alterations of various 
subtypes of CRC have not been fully characterized. Copy number variations (CNVs) 
can contribute to variable levels of gene expression [21], and thus fine-scale copy 
number (CN) profiling of cancer may further enhance our knowledge about 
tumorigenesis. This study aim to investigate 12 Lynch syndrome-related CRCs with 
high-density CGH microarray-based method in search of somatic microduplications 
and/or microdeletions.  
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Materials and methods 
 
Patient characteristics 
For this study a cohort of 52 Lynch syndrome-related colorectal cancers with 
identified germline mutation (30 MLH1, 16 MSH2, 3 MSH6, 2 PMS2) were analysed 
for CNV. 
In addition, based on the recommendations of the National Cancer Institute 
workshop on MSI, a panel of microsatellite loci (BAT25, BAT26, D2S123, D5S346, 
D17S250) [3] and two additional microsatellite markers (BAT40, MYCL1) were used 
to determine MSI status.  
Patient data including full follow-up were obtained by retrospective analysis of 
medical records, regional tumor registries and/or treating physicians. Tissue samples 
were obtained by surgical or endoscopic excision.  
 
Genomic DNA Isolation 
To isolate genomic DNA from fresh frozen tumor tissue samples the QIAamp DNA 
Mini Kit (Qiagen, Hombrechtikon, Switzerland) and for formalin fixed paraffin 
embedded (FFPE) tumor samples the RecoverAllTM Total Nucleic Acid Isolation Kit 
(Ambion, Invitrogen, Carlsbad, CA, USA) were used according to the manufacturers' 
guidelines. 
 
Cytogenetics Whole-Genome 2.7M Array 
A total of 500 ng of genomic DNA of six LS patients (each of them were matched 
with its normal counterpart),were analyzed using an Affimetrix Cytogenetics Whole-
Genome 2.7M Array, a high resolution array containing approximately 400,000 SNP 
markers and 2.3 million non-polymorphic markers, with high density coverage across 
cytogenetically significant regions according to the manufacturer's instructions. Data 
was collected using either GeneChip® Scanner 3000 Dx and CEL files were 
analyzed using Affymetrix Chromosome Analysis Suite software (ChAS v.1.1). The 
annotation file used in our analysis can be found on the Affymetrix website, listed as 
ArrayNA30.2 (hg18). CNVs detected were compared with the Database of Genomic 
Variants (http://projects.tcag.ca/variation) for overlap with known copy number 
variants using previously described criteria [24].  
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Determination of selected copy number aberrations by Real-time PCR 
Oligonucleotide primers for quantitative PCR (qPCR) were designed for each gene 
using the AlleleID software (PREMIER Biosoft International, Palo Alto, CA) (ERCC2 
for: 5’-TGGGAAATGAACGGGAAACAG-3’; rev: GGGCAAGACGGACTACGG; 
STK40 for: 5’-GTCCTGTTCTCCTGTCTC-3’; rev: GGCTGCGTAATATGATGG-3’; 
CFTR for: 5’- GCATGGGAGGAATAGGTGAA-3’; rev: 5’- 
CACAATCTACACAATAGGACATGG-3’), to assure maximal efficiency and 
sensitivity according to the following parameters: avoidance of the formation of self 
and hetero-dimers, hairpins and self-complementarity, primer length and melting 
temperature. These properties were further verified using different internet-based 
interfaces such as Primer-3 [25]. Melting curve analysis was always performed at the 
end of each PCR assay to control for specificity.  
qPCR was performed using standard protocols with 2X iQ SYBR Green supermix 
(Bio-Rad) on a Bio-Rad iCycler. Briefly, 50 ng DNA was added to 12.5 µl of SYBR-
green PCR master mix (Bio-Rad), with 0.5 µl (600 nM) of each primer, and water to 
a final volume of 25 µl. The reactions were amplified in a single step of 3 min at 95°C 
and then for 40 cycles of 10 s at 95°C, 1 min at 60°C, with final denaturation step for 
10 sec at 95°C. The thermal denaturation protocol was run at the end of the PCR to 
determine the number of products that were present in the reactions. Experiments 
were done in triplicate and included non-template controls for each gene. The 
amount of each gene was normalized to cystic fibrosis transmembrane conductance 
regulator (CFTR) as reference gene. We used a standard analysis to calculate the 
amplification of the genes by the 2-ΔΔCt method as described previously [26]. 
Results for each sample were expressed as the N-fold copy number change [27]. 
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Results 
Initially we investigated six LS-related CRCs from 4 known MLH1 and 2 MSH2 
germline mutation carriers matched with their tumor free counterpart for the 
presence of copy number aberrations (CAN), i.e. micro- deletion/duplication using 
the Affymetrix Whole-Genome 2.7M CGH array  
We observed somatic gains (microduplications) at 1p34.3, 2q24.3, 3p23, 5q23.2, 
5q33.1, 6p23, 8q11.1, 10p15.1, 10q25.1, 12p11.23, 17p13.1, 17q24.3, 19q13.32, 
Xp22.2 and somatic losses (microdeletions) at 19p12, 3p14.2. The overall findings of 
DNA copy number gains and losses across all samples are shown in Table 1. 
Interestingly, we identified 2 recurrent novel somatic microduplicated “hot spots” for 
genomic rearrangements located on 1p34.3 and 19q13.32 containing the ERCC2 
and STK40 gene, respectively (Figure 1 A and 1 B).  
To further assess the frequency at these loci we evaluated 46 LS-related CRCs from 
30 MLH1, 16 MSH2, 3 MSH6 and 3 PMS2 mutation carriers by qPCR. The analysis 
revealed microduplications in ERCC2 were present in 24/46 (60.8%) CRCs and in 
STK40 in 18/46 (39.1%) CRCs (Table 2; Figure 2 A and 2 B). 
In order to assess if these novel recurrent “hot spot” region represent somatic 
alterations typical for LS-related tumorigenesis, a set of 50 sporadic, microsatellite-
stable CRCs is currently under investigation. 
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Brief discussion 
The understanding of chromosomal aneuploidies and their role in tumor 
development is a fundamental problem in cancer biology. Chromosomal aneuploidy, 
the gain or loss of chromosomes is the most common alteration in cancer. The 
majority of cancer cells in sporadic MSS CRCs have numerical and structural 
chromosomal abnormalities with translocations, deletions and other aberrations. In 
contrast, about 80% of MSI tumors display a near-diploid karyotype and a distinct 
genetic alteration distinguishable from those observed in MSS cancers [19]. 
In this study, using the Affymetrix Whole Genome 2.7 M chip array in 6 fresh-frozen 
Lynch syndrome-associated CRCs we identified 2 novel, recurrent microduplication 
“hot spot” regions on chromosomes 1p34.3 and 19q13.32 containing the ERCC2 and 
STK40 genes, respectively, and validated the findings by qPCR in a cohort of 46 
additional LS-related CRCs. To assess if these alterations are specific to LS related 
cancers currently 50 sporadic CRCs is currently under investigation  
ERCC2 is a key component of the nucleotide excision repair pathway. Further, the 
protein is an integral member of the basal transcription factor BTF2/TFIIH complex, 
displays an ATP-dependent DNA helicase activity and belongs to the RAD3/XPD 
subfamily of helicases [28]. Defects in this gene can result in three different 
disorders: the cancer-prone syndrome xeroderma pigmentosum complementation 
group D, trichothiodystrophy, and Cockayne syndrome.  
Little is known concerning the STK40 that may be a negative regulator of NF-kappa-
B and p53-mediated gene transcription. 
To date, it remains to be clarified if and how these microduplications and 
amplifications (up to 6n) may affect cancer cell proliferation and progression in Lynch 
syndrome colorectal cancers.  
Among all somatic mutations, non-germline CNVs found in the cancer genomes, 
also known as copy number alterations/aberrations (CNAs), are frequently observed, 
e.g., gains of oncogene and losses of tumor suppresser gene loci [22]. Furthermore, 
the DNA CN states of CRC cases are related to the response of drug treatments, 
e.g., the degree of CRC-related CNA is associated with response to systemic 
combination chemotherapy with capecitabine and irinotecan [23]. 
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Figures and Tables 
 
 
Figure 1: ChAS analysis of LS-related CRCs 
A  
B  
 
Figure 1: A) Minimal region duplicated on chr19 (19q13.32) including ERCC2 gene 
in 3 different patients. B) Minimal region duplicated on chr1 (1p34.3) including 
STK40 gene in 2 different patients. 
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Figure 2: qPCR results in 46 LS-related CRCs: A) CNAs in ERCC2 gene. B) CNAs 
in STK40 gene. 
 
A  
B  
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Table 2 
Gene name Copy number aberrations  
 2n (diploid) 3n 4n >4n 
ERCC2 22 11 5 8 
STK40 28 8 5 5 
 
Table 2: Degree of copy number aberrations in 46 LS-related CRCs 
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Table 1 
Chromosome Locus Alteration Base Start Base End Del Size (Mb) Patient n. Genes 
 1  
 
1p34.3 
 
Duplication 
 
36583571 36636982 53,4 5 STK40, LSM10 
36567450 36623262 55,8 7 STK40 
2  
  
 
  
2q24.3 
 
Duplication 
 
168993733 169032679 38,9 1 
LASS6 
 168993733 169036109 42,3 7 
 
3p23 
 
 
  
Duplication 
 
 
  
31535493 
  
31557397 21,9  7 
  
STT3B 
 
 31540540 31557397 16,8 16 
3 
 
 
  
3p14.2 
 
 
 
Deletion 
 
 
 
60421679 60439908 18,2 11 
FHIT 
 
 
 
60430695 60450786 20 16 
60530263 60542710 12,4 11 
60497433 60554225 56,7 16 
5 
  
  
  
5q23.2 
 
  
 
Duplication 
122869729 122896827 27 11 CSNK1G3 
 122871101 122896827 25,7 16 
5q33.1 
 
 
151109899 151145327 35,4 5 
 G3BP1 
 151131753 151142191 10,4 16 
6 
 
6p23 
 
Duplication 
 
15406555 15428655 22,1 5 
JARID2 
 15402243 15454282 52 16 
8 
  
8q11.1 
 
Duplication 
 
47134349 47261260 126,9 1 Intragenic 
region 
 47120825 47290072 169,2 7 
10 
 
  
 
10p15.1 
 
Duplication 
 
6168193 6192155 23,9 11 
RBM17 
 6168193 6192694 24,5 16 
  
10q25.1 
 
  
Duplication 
 
 111746435 
  
111756922  10,4    
ADD3 
 111747464 111769074 21,6 1 
12 
 
12p11.23 
 
Duplication 
 
26952817 26993684 40,8 16 
FGFR1OP2 
 26974916 26993684 18,7  
 
17  
 
 
 
 
17p13.1 
 Duplication 
 
 
 
 
10499352 10536740 37,3 7 SCO1, MYH3 
10528556 10566728 38,1 11 SCO1 
  
17q24.3 
 
  
64815529 
  
64839814 24,2  1   
MSI2, ABCA5 
 64827465 64848873 21,4 16 
19 
 
 
 
 
 
19q13.32 
 
 
 
Duplication 
 
 
 
50517505 50549160 31,6 1 
ERCC2, KLC3, 
CKM 
50539800 50550532 10,7 5 ERCC2, KLC3 
 
50540437 
 
50669798 
 
129,3 
 
5 
 
ERCC2, KLC3, 
PPP1R13L, 
CD3EAP, 
ERCC1 
 
 
19p12 
 
 
 
  
Deletion 
 
 
 
  
22987786 
  
 
23041491 53,7 11   
MUC16 
 
 22987786 23041491 53,7 16 
X  
 
Xp22.2 
 
Duplication 
 
9585012 9610052 25 3 
TBL1x 
 9591311 9623919 32,6 16 
Table 1: CGH analysis results for copy number aberration in 6 LS-related CRCs. 
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